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II Abstract
Abdominal aortic aneurysm (AAA) is a progressive weakening of the aortic 
wall commonly associated with vascular calcification. Human AAA tissue 
displays cells undergoing all stages of apoptosis. It is known that aortic medial 
layer thinning, leads to aneurysmal formation through loss of aortic wall tone 
and increased wall stresses. Medial layer thinning is also associated with a 
decrease in smooth muscle cell (SMC) numbers. The cause of this loss of 
SMCs is attributed to apoptosis. Tumour necrosis factor (TNF)-related 
apoptosis-inducing ligand (TRAIL) is capable of inducing apoptosis in 
transgenic cells from various disease states but not in normal cells. An 
inhibitor of TRAIL, osteoprotegerin (OPG), is involved in osteoporosis and 
vascular calcification. We wished to investigate this link between vascular 
calcification and apoptosis by examining TRAIL and its receptors in AAA.
Both qualitative and quantitative analysis of calcification in AAA walls was 
determined using Von Kossa staining and pre-operation computer 
tomography (CT) scans. Apoptosis in human AAA sections was confirmed by 
TUNEL assay and detection of apoptosis cellular marker by histology staining. 
Protein blots and RT-PCR were carried out to investigate the expression of 
TRAIL and its receptors in AAA walls. Comparative analysis was performed 
between normal aortae and AAA. A significant difference was observed 
between normal aortae and AAA for death receptor TRAIL-R2 mRNA 
(decreasing in AAA, p<0.01) and OPG protein (decreasing in AAA, p<0.01). 
Significant differences were also observed between tissues displaying 
different extents of calcification for TRAIL mRNA (increases while the 
calcification level increseas; p<0.05). To mimic the AAA development models, 
AAA specimens were dissected into three different areas according to the 
anatomy structure. This separation is also confirmed by CT scan and 
supported by blood flow diametric theory.




AAA= abdominal aortic aneurysm 
AB= apoptosis body 
ABC= avidin-biotin complex 
AC= aortic calcification
ALPSII= acute lymphoproliferative sydome type II 
Apaf-1= apoptotic protease-activating factor-1 
AMPS = ammonium persulphate 
Al= apoptotic index




Bcl-2= B-cell leukaemia/ lymphoma 2
BMP= bone morphogentic
BIR= baculoviaus IAP repeat
BSA= bovine serum albumin
CABG= coronary artery bypass graph
CAS= carotid artery stenosis
Ca2+ = calcium
CBBG= Coomassie Brilliant Blue G-250
CVC= calcifying vascular cells
cDNA complementary DNA
CHX= cycloheximide
CO2 = carbon dioxide
CT = computer tomography




DEPC = diethyl pyrocarbonate 
DPX= DePeX
DMEM = dulbeccos's modified eagle medium
DNA= deoxyribonucleic acid
DISC= death inducing signalling complex
DTT= dithiothreitol
RNA= ribonucleic acid
EDTA = ethylenediamine tetraacetic acid
ESRD= end stage renal disease
EVAR= endovascular abdominal aortic aneurysm repair
FASL= FAS ligand
FADD= FAS associated death domain 
FADD-DN= negative version of FADD 
FCS = fetal calf serum
FLICE= FADD-like apoptotic cystein protease 
FLIP= FLICE-inhibitory proteins 
FLIPL= long term of FLIP 
FLIPS= short term of FLIP
FITC-dUTP= fluoresecent-deoxyuridine triphosphate nucleotides 
FTIR= transformed infrared spectroscopes 
GAPDH= hlyceraldehyde-3-phosphate dehydrogenase 
GLA= glutamate
GM-CSF= granulocyte/Macrophage colony stimulating factors 
H&E= haematoxylin and Eosin 
H20  = water
HBSS = Hank's balanced salt solution 
HCC= hepatocellular carcinoma 
HCI = hydrochloric acid 
HDL= high density lipoprotein 
H20 2 = hydrogen peroxide 
Hp= haptoglobin phenotype 
HRP= houseradish peroxidase 




IMS = industrial methylated spirits
Kb=kilobase
kD = kilodalton




mg/dL = milligrams per decilitre
mRNA= messenger ribonucleic acid
MRI= magnetic resonance imaging
MGP= matrix glutamate protein
MMP = matrix metalloproteinase
N2= liquid nitrogen
NaCL= sodium chloride
NF-kB = nuclear factor kappa B
NK= natural killer
NO = nitric oxide
N 0 3-= nitrate
N 0 2‘ = nitrite
0 2"* = superoxide
OPG = osteoprotegerin
PAD= peripheral arterial disease
PAGE = polyacrylamide gel electrophoresis
PAP= peroxidase anti-peroxidase
PBS = phosphate buffered saline
PrEC= prostate epithelial cells
PrSC= prostate stromal cells
PT= permeability transition
pmoles = Pico(x10-2).moles
RANK = receptor activator of nuclear factor-xB
RANKL = receptor activator of nuclear factor-xB ligand (TRANCE, OPGL, 
ODF)
rRNA= ribosomal RNA 
RNAse= ribonuclease
RT-PCR= reverse transcription-polymerase chain reaction 
SMAD6= similar to Mothers against decapentaplegic homolog 6 
SDS = sodium dodecylsulphate (lauryl sulphate)
Smac= second mitochondrial activator of caspase
SMCs= smooth muscle cells
SMHC= smooth muscle heavy chain
SIG= small inducible gene
std = standard deviation
TDT= terminal deoxynucleotidyl transferase
TEMED = N.N.N'.N'-Tetramethylethylene diamine
TNF = tumour necrosis factor
TRADD = Tumour necrosis factor receptor-associated death domain 
TRANCE = TNF (tumour necrosis factor).activation-induced cytokine 
TRAIL= TNF-related apoptosis-inducing ligand 
TRAIL-R1= TRAIL receptor 1 (CD4)
TRAIL-R2= TRAIL receptor 2 (CD5)
TRAIL-R3= TRAIL receptor 3 (DcR1)
TRAIL-R4= TRAIL receptor 4 (DcR2)
TRAIL-rTRAIL= TRAIL and its receptors 
tRNA =transfer RNA
Tris-HCI = Tris [hydroxymethyl] amino methane hydrochloride 
TRIR= total RNA isolation reagen 
TIA= transient ischaemic attack
TUNEL= terminal deoxynucleotidyl transfrase biotin-dUTP nick end labelling
Tween 20 = poloxethylene sorbitan monolaurate
XIAP= X-linked inhibitor of apoptosis
VC= vascular calcification
VEGF= vascular endothelia growth factor
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Chapter 1 General Introduction
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1.1 Overview
At autopsy, 75-95% of men and women have coronary artery calcification 
regardless of the cause of their death (Chirgwin et al., 1979). Aortic calcification 
has been found in two 3000 year-old mummies by x-ray analysis, first described 
by Czernak in 1852 (Reginald Magee, 1998). For over a hundred years, 
scientists have tried to find the mechanism of vascular calcification (VC). Recent 
studies have begun to shed light on some aspects of the mechanisms of VC. 
Nowadays it is well established that an unhealthy lifestyle contributes to VC; 
however there are also genetic factors predisposing the disease. Up until about 
20 years ago, the mechanism of VC was thought to be a passive process in 
which calcium deposits on the vessel wall. Somewhat controversially, it has now 
been suggested that calcification is regulated by biological processes similar to 
those in developing bones. Additionally, VC has been found to occur when there 
is either histological or pathological evidence of cell death and a failure of 
clearance of the resulting apoptotic bodies. This might indicate that VC involves 
both positive and negative modulators (Giachelli et al., 2005; Sambrook and 
Fritsch, 1989; Schreurs O. etal., 1997).
Vascular calcification is characteristic of most vascular diseases. Peripheral 
arterial disease (PAD), aneurysm, hypertension, diabetes mellitus, chronic renal 
failure, aortic stenosis and Monckeberg's sclerosis are detailed in brief in the 
following section.
Tumour necrosis factor (TNF) -related apoptosis-inducing ligand (TRAIL) is a 
member of the TNF family which was first found in 1995. It is attracting 
increasing interest from many different scientific fields because it mostly induces 
apoptosis in tumour cells and not in normal cells, giving it great clinical potential. 
Recent studies by Proudfoot etal. (2000-2001) have shown that apoptotic bodies 
(AB) can calcify in the same way as matrix vesicles (often found in bone), and 
that human cultured vascular smooth muscles cells (SMCs) were able to 
undergo apoptosis in vitro. Additionally, osteoprotegerin (OPG) as a decoy 
receptor of TRAIL is also an inhibitor in osteoporosis. TRAIL and its receptors 
appear to be a strong link between apoptosis and the bone related protein OPG.
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The possibility led us to conduct a study of the role of TRAIL and its receptors 
(TRAIL-rTRAIL system) in VC.
1.2 Vascular calcification-related diseases
1.2.1 Peripheral arterial disease
Peripheral arterial disease (PAD) is a narrowing of the arteries that supply the 
legs with blood. The plaque contains calcium and other substances inside the 
arteries will narrow the arteries in the legs. This narrowing of the arteries in the 
legs, leads to inadequate blood flow inducing walking impairment such as 
claudication (Hiatt etal., 2005).
1.2.2 Aneurysm
An aneurysm is defined as a permanent localised dilatation of an artery, with an 
increase in diameter of greater than 1.5 times its normal diameter (Kiernan, 
2001). Abdominal aortic aneurysms may be manifested by catastrophic rupture, 
signs of pressure on other viscera or an embolism originating in the aneurismal 
wall, but most cases are asymptomatic (Crawford et al., 2003). Smaller 
abdominal aortic aneurysms can be detected by regular ultrasound 
measurements or computer tomography (CT) scans.
1.2.3 Hypertension
Hypertension is a common complication in which blood pressure is abnormally 
high, occurring when the blood flows through the vessels at a greater than 
normal force (systolic pressure £140 mmHg, diastolic pressure £90mmHg). The 
most common cause is increased peripheral vascular resistance, although it can 
be caused by prolonged periods of elevated cardiac output (Paul and Smith, 
2005).
Hypertension is commonly associated with VC. It strains the heart, harms the 
arteries causing arteriolosclerosis, and increases the risk of a heart attack, stroke, 
kidney and eye problems, inducing ischaemia or infarction.
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1.2.4 Diabetes mellitus
Diabetes mellitus is a metabolic disorder characterised by a congenital or 
acquired inability to transport sugar from the bloodstream into cells. Patients with 
diabetes mellitus may exhibit arterial calcifications, particularly involving the 
aortae, internal carotid artery, renal artery and the arteries of the pelvis and lower 
extremities. Clinically unsuspected diabetes mellitus may be discovered when 
radiographs reveal calcification of the interdigital arteries of the feet. Subclinical 
atherosclerosis is considered to be one of strongest predictors of this disease 
(Proudfoot etal., 2001).
1.2.5 Chronic renal failure
Chronic renal failure is the progressive loss of kidney function. The kidneys 
attempt to compensate for renal damage by hyperfiltration (excessive straining of 
the blood) within the remaining functional nephrons (filtering units that consist of 
a glomerulus and corresponding tubule). Over time, hyperfiltration causes further 
loss of function. Of deaths in patients with end stage renal disease (ESRD) 40- 
50% are caused by vascular calcification. Arterial calcification presents a high 
risk factor for cardiovascular morbidity and mortality in this population (Raggi, 
2005). Medial calcification of conduit arteries and coronary calcification are very 
common in ESRD. Also, the vascular SMCs of ESRD patients have been shown 
to express osteopontin messenger ribonucleic acid (mRNA) that would normally 
be found in osteoblasts in addition to showing the formation of hydroxyapatite 
(Raggi, 2005).
1.2.6 Aortic stenosis
Stenosis means narrowing. Aortic stenosis is then a narrowing of the aortic valve 
or a narrowing of the aorta directly above (supravalvar) or below (subvalvar) the 
aortic valve. A normal tricuspid aortic valve will undergo calcification, this is 
termed senile calcific aortic stenosis (Otto etal., 1991).
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1.2.7 Monckeberg's sclerosis
Monckeberg's sclerosis is a disease of unknown aetiology characterised by 
dystrophic calcification of the media of arteries. This condition is usually seen in 
the major lower limb arteries of elderly patients, and may also be seen in the 
head, neck and pelvis, especially the uterine arteries. It progresses with age and 
is common in patients with diabetes mellitus and chronic renal failure and it is 
strongly associated with osteoporosis (Schoppet etal., 2004).
1.2.8 Idiopathic infantile arterial calcification
Idiopathic infantile arterial calcification is a rare disease that is characterised by 
calcification in the media and fibroproliferative changes in the intima of larger 
arteries. The vascular elasticity and blood flow is sometimes reduced (Whitehall 
etal., 2003). It is not associated with atherosclerosis.
1.3 Summary
Vascular calcification occurs at two distinct sites in the vessel wall: the intimal 
and medial layers. Intimal calcification is associated with atherosclerosis and can 
be seen at the early second decade of life as well as in elderly patients. Medial 
calcification is completely independent of intimal calcification and atherosclerosis 
and is commonly found in the patients with Monckeberg's sclerosis (Proudfoot 
and Shanahan, 2001). Atherosclerosis is a common disease which can lead to 
other vascular diseases. It affects arteries in two opposing ways; stenosis (a 
narrowing of an artery) or aneurysm (a dilation of an artery). A population-based 
study of asymptomatic patients was performed in which a whole-body CT gave 
access to the carotid, coronary, proximal and distal aortae and iliac vessels. 
Earliest calcification tends to happen in the coronary arteries for those below 50 
years, and the distal aortae for those aged 50 to 60. Additionally, the same study 
identified a significant correlation between the risk factors of age and 
hypertension, and calcified atherosclerosis in different vascular beds (Allison et 
al., 2004).
The death caused by abdominal aortic aneurysms (AAA) rupture is the 13th
leading cause of death in the USA (www.vascularweb.org, 2006). The mortality
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for AAA ruptures in the United Kingdom peaks amongst 65 to 75 year-olds; 
rupture accounts for 1.7% of all deaths in men in this age group. A progressive 
and continuing increase death rate from AAA over the 30-year period to 1988 
was shown in England and Wales. The increased prevalence of aneurysm has 
paralleled the pattern of smoking addiction, which rose during the period 1916 to 
1948; a cohort effect with a 40-year time lag has been suggested to explain this 
observation (Crawford et al., 2003). Taking this information and operable 
accessibility of aneurysm into account, AAA was chosen as a model to study VC.
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2.




Vascular calcification is highly associated with patient morbidity and mortality 
(Raggi, 2005). Wang et al. found a positive correlation between valve 
calcification and cardiovascular disease as well as all-cause mortality in a cohort 
of 192 patients. Cardiovascular mortality was 7 times higher in patients with 
vascular calcification than in those without it. In another study of a cohort of 202 
patients, it was demonstrated that vascular calcification was a predictor of all­
cause as well as cardiovascular mortality regardless of classical risk factor for 
atherosclerosis (Wang et al., 2003). Blacher et al. discovered the presence and 
extent of vascular calcification were strongly associated with an adverse 
outcome in a study of 110 patients (Blacher etal., 2001).
2.2 The anatomy of normal arteries
There are three kinds of vascular structures in the human body; veins, (carrying 
blood into the heart), arteries (carrying blood away from the heart) and capillaries 
(embedded in the tissue connecting arteries and veins (Frederic H.Martini, 2005; 
Kiernan, 2001; Luiz Carlos Junqueira etal., 1998; Shire D. etal., 2003).
In the vast majority of cases, vascular calcification occurs in human arteries and 
rarely in veins (Chirgwin et al., 1979; Demer and Tintut, 2003). The arterial 
system is ramified like a tree; the aorta acts like the trunk, extending to the 
peripheral parts of the body and then to the organs (Gray H., 1918). Most of the 
time, human arteries carry blood rich in oxygen to the organs, the exception 
being the pulmonary artery which carries venous blood from the right ventricle of 
the heart to the lungs. The normal aorta is the main trunk of the series of arteries 
and its maximum diameter is approximately 3cm. It is divided into the right and 
left common iliac arteries which provide blood to the pelvis and legs. The carotid 
artery is the main artery which supplies the blood to the neck and brain. It is 
divided into external and internal carotid arteries (see Figure 2.1). When an 
atherosclerotic plaque forms on the carotid artery wall, it will completely or partly 
block the blood flow to the brain, inducing a transient ischaemic attack (TIA) or 
stroke. The abdominal aorta locates anteriorly in the midline between a point 
2.5cm above the transpyloric plane and a point slightly inferior and a little to the
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left of the umbilicus. The transpyloric plane is an imaginary horizontal plane 
located midway between the xiphisternal joint and the umbilicus. The aortic 
bifurcation into the common iliac arteries occurs just to the left of the midpoint of 
the line joining the highest points of the iliac crests (intercristal line) (Gray H., 
1918).
External carotid artery 
Internal carotid artery





Common iliac artery 
External iliac artery
Figure 2.1 A diagrammatical representation of the human vascular tree
Under the light microscope (LM), it can be clearly seen that artery walls are 
composed of three layers, tunica adventitia, tunica media, and tunica intima 
(from the outer layer to the inner layer, see Figure 2.2). The tunica adventitia 
includes connective tissue, elastic and collagenous fibres. It mainly attaches the 
arteries to the neighbouring tissues. The tunica media consists of smooth muscle 
tissue and elastic connective tissue. Changes in blood vessel diameter depend
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on the encircling smooth muscle tissue. The tunica intima is made of mainly 
endothelium, which effects nutritional absorption and prevents platelet 
aggregation (Frederic H.Martini, 2005; Kiernan, 2001; Luiz Carlos Junqueira et 







Figure 2.2 The three layers of normal artery stained by Haematoxylin and 
Eosin (H&E) under the LM.
2.3 The anatomical changes in calcified arteries
Vascular calcification is not only an end-stage disease but also evident in early 
stage vascular diseases or asymptomatic events which can be detected by 
clinical assessments. It can be observed by CT scan and ultrasound scan, etc 
(Demer and Tintut, 2003). Through the LM the arterioles in the stenosis artery 
are observably thicker than normal lumen and in section exhibit layering like an 
onion-skin (see Figure 2.3 from www.healcenter.org). The word atherosclerosis 
comes from two main components of calcified plaque in the arterial wall which 
are hard collagenous (sclerosis) and soft lipid-rich components (atherosis). 
Collagenous plaques make up the majority of the calcified plaque volume. The 
soft components make up a small part of the volume and are prone to rupture
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(Dixon.K.J. et al., 1997). Under the LM, the hard plaque (fibrous plaque) is 
covered by a cap of multiple layers of SMCs densely packed in the surrounding 
connective tissue. Beneath the cap is a body of SMCs, macrophages and 
occasional lymphocytes. In the centre of the core of plaque there may be areas 
of necrotic debris and cholesterol crystals. The soft plaques (ulcerated plaques) 
may have a disrupted surface with thrombus on top. These atherosclerotic 
plaques may result in the reduction of the vessel lumen when is large enough to 
give rise to clinical signs of ischaemia (Gronholdt, 1999).
200um
Figure 2.3 A coronary artery with atherosclerosis showing build-up of waxy 
deposits inside the vessel. The artery wall is thicker and irregular looking. 
The arrows indicate rupture plaque. (From heal resource, 
www.healcenter.org)
In the arteriograph, the surface of the artery wall is smooth and continuous under 
normal conditions. The surface becomes tortuous and broken in calcified arteries 
as shown in the pictures below (www.bocaradiology.com).
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Figure 2.4 Computer tomography scans demonstrating normal aorta and 





Figure 2.5 Computer tomography scans of a normal aorta (left) and 
calcified aorta (right). The left red circle indicates normal aorta without 
calcification. The right red circle and the arrow indicate calcified aorta. 
(From heal resource, www.healcenter.org)
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2.3.1 The anatomical changes in AAA
Abdominal aortic aneurysm is caused by a progressive weakening of the aortic 
wall that causes dilation, or “ballooning” of the vessel (see Figure 2.6). The 
aneurysm will grow larger and eventually rupture if it is not diagnosed and 
treated (Bostrom, 2001; Sambrook and Fritsch, 1989).
Atherosclerosis is associated strongly with the phenomena of stenosis and 
aneurysm. Stenosis occurs most commonly in the coronary arteries and 
aneurysm occurs in the infrarenal abdominal aortae. In typicai coronary 
atherosclerosis, expansion of the intimal lesion produces stenosis. The tunica 
media underlying the intima is thinned, but the general structure is preserved 
relatively well. In contrast, laminar structure of normal tunica media disappears 
with loss of elastic laminae in aneurysm. Smooth muscle cells in the media layer 
disappear although those in stenosis remain (Crawford et al., 2003; Ernst, 1993).
Normal Aorta Abdominal aortic aneurysm
Figure 2.6 Aorta in normal and AAA conditions (from www.nlm.gov)
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2.4 The histology change of vascular cells
Smooth muscle cells, macrophages and mast cells are believed to be the 
primary cells involved in vascular calcification (Chirgwin et al., 1979). Firstly, 
Schor et al. (1990) showed microvascular pericytes produced vascular 
calcification in nodules in vitro. Since then, Giachelli et al. (1991) found 
expression of osteopontin (bone related protein, always found in calcified bones 
and produced by osteoblasts) in immature SMCs. Bostrom et al. (1999) showed 
a subpopulation of aortic SMCs is responsible for mineralisation by dilutional 
cloning. These findings support the theory that vascular cells are at least partly 
regulated by osteoblastic differentiation (Demer and Tintut, 2003).
However, recent evidence has indicated that all the component cells of the 
atherosclerotic plaque can, at least in culture, undergo apoptosis. Cell death 
occurs after the removal of serum survival factors, with deregulated expression of 
specific gene products, or after exposure to oxidised lipids or drug therapy 
(Proudfoot etal., 2000).
2.4.1 Vascular SMCs
Smooth muscle cells are fusiform. Each cell has a single nuclear located in the
centre of the broadest part of the cell. They are normally located in the tunica
media of the artery wall and engaged in regulation of artery wall tension (Luiz
Carlos Junqueira et al., 1998). Smooth muscle cells become engaged in the
formation of atherosclerotic lesions. They transform into ‘synthetic’ cells with
morphology similar to that of the SMCs characteristic of prenatar developing
arteries. Smooth muscle cells also express a number of bone matrix proteins
BMP-2 and MGPthat regulate or facilitate the vascular calcification process
(Chen and Moe, 2003; Speer et al., 2002). In the early stages of the
atherosclerosis process, medial SMCs are miragrated into the intima. In the
intima SMCs participate in the formation of raised lesions not only by active
proliferation but also by secreting large amounts of connective tissue matrix.
Tumour necrosis factor-a treatment of vascular SMCs results in a partial
differentiation to an osteoblast-like phenotype with alkaline phosphatase
expression and mineralization (Chirgwin et al., 1979; Thorne et al., 1996).
Furthermore, in mice that had matrix r-carboxylated glutamate (GLA) protein
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eliminated (MGP knockout), it was observed that there was a loss of SMCs 
characteristics and that cartilage molecules started to appear in the vessels after 
2 weeks (Speer et al., 2002). Matrix r-carboxylated glutamate is a vitamin K- 
dependent circulating and bone-associated protein that can bind calcium in soft 
tissues.
Calcifying vascular cells (CVC) are a subpopulation of SMCs from cell culture 
medium that exhibit osteoblastic characteristics and form calcified nodules in 
vitro. Calcifying vascular cells have features in common with pericytes including 
a stellate shape and positive staining sharing similarities to osteoblasts (Shin et 
al., 2004).
2.4.2 Macropages
Macropages are amoeboid-like cells. When a foreign body invades, it is ingested 
by the macrophage and destroyed by the action of lysosomal enzymes (Luiz 
Carlos Junqueira et al., 1998). During atherosclerosis, macrophages express a 
variety of bone-related proteins including MGP, osteopontin, alkaline 
phosphatase and bone sialoprotein which are believed to be involved in 
calcification (Chirgwin etal., 1979).
2.4.3 Mast cells
Mast cells contain metachromatic granules which store inflammatory mediators 
(Luiz Carlos Junqueira et al., 1998). When vascular calcification occurs, 
extracelluar mast cells containing tryptase are often seen at sites of early 
calcification and around small calcium deposits, but seldom seen around larger, 
more solid calcifications. This finding suggests that mast cells may have a role in 
the initiation of calcification by an unknown mechanism (Chirgwin etal., 1979).
2.5 The histology changes of AAA
As mentioned before, AAA is comprised of medial and adventitial structure 
degeneration. The most important histological changes of AAA are extensive 
disruption and degeneration of the medial elastic lamellae and accelerated
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turnover of collagen. These two changes are responsible for the decrease in 
tensile strength of the arterial wall, resulting in AAA rupture. Other changes 
include chronic immune and inflammatory cell transmural infiltration, 
immunoglobulin deposition and the decrease in number of medial SMCs 
(Thompson etal., 1997).
Figure 2.7 Aneurysm stained by van Gieson staining. Red staining shows 
collagen, yellow staining shows cytoplasm and black staining shows 
nuclear. It shows the portion of tunica media of aneurysm with thickened 
and disrupted collagen.
2.6 The mechanism of vascular calcification 
and AAA
2.6.1 Passive mechanism of vascular calcification
Up to about 20 years ago vascular calcification was considered to be a passive 
process that occurred as a non-specific response to tissue injury or necrosis 
(Bostrom, 2001; Sambrook and Fritsch, 1989). There have been many popular
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explanations for the hardening of the arterial wall. One of these explanations was 
that lipid deposition resulted as a secondary response to the infection process. 
This was thought to be a protective physical change (Demer and Tintut, 2003). 
Recently, there has been increasingly strong evidence that the phenomenon 
could be biologically controlled, in a similar way to that of bone formation 
(Bostrom, 2001).
2.6.2 Possible active mechanism of vascular 
calcification
Arterial calcification is considered to be an active, cell controlled event, which is 
supported by the expression of mineralisation inhibiting and initiating protein 
(Tintut and Demer, 2006).
2.6.2.1 Similarities between bone formation and vascular 
calcification
The clinical coincidence of osteoporosis (low bone mineral density) and vascular 
disease has been realised (Pennisi etal., 2004; Sattler etal., 2004; Schulz etal.,
2004). Both diseases were thought to be passive, degenerative and inevitable as 
the end-stage processes of ageing, but are now recognised as active, regulated, 
treatable and preventable disorders. Bone tissue forming within the 
atherosclerotic artery wall has been known since at least the 1800s and it was 
reported that red marrow elements were found in bone tissue within 
atherosclerotic plaque in 1908 (Demer, 2002). Epidemiologically, lipid-lowering 
treatments seemed to be inhibiting VC in humans as well as reducing fractures in 
osteoporosis patients in retrospective studies but not confirmed in prospective 
ovariectomy-induced bone loss (Hofbauer and Heufelder, 2001). Severe 
osteoporosis in the hip may indicate advanced atherosclerosis and therefore 
convey an increased risk for not only hip fractures but also for coronary heart 
disease (Tanko et al., 2003). Clinically, in bone-loss studies (Demer and Tintut, 
2003), OPG treatment has been found to increase high mineral density in the hip 
and to decrease VC mortality among the elderly (Schulz et al., 2004). Serum 
osteocalcin (inhibitor of calcification) is used as an early marker of bone turn over 
and is increased in women with aortic atherosclerosis (Dhore et al., 2001). The
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evidence has shown an extremely strong link between cardiovascular 
calcification and bone disease in ESRD patients (Raggi, 2005). It has been found 
that both diseases were caused by at least three different conditions: deficiency 
of OPG, deficiency of essential fatty acids and hyperlipidaemia (Demer, 2002). 
All above findings may suggest that VC has certain unknown genetic links with 
bone formation in humans.
At the cellular level, vascular SMCs and bone cells share similar phenomena 
especially in the atherosclerotic plaque. They both differentiate from the same 
embryonic layer. Vascular calcification has many similarities to embryonic bone 
formation and bone repair (Bostrom, 2001; Speer et al., 2002). Bone formation 
proteins such as osteopontin, osteonectin and osteocalcin (Speer et al., 2002) 
and bone morphogenetic protein 2 (BMP-2) were found in calcified plaques 
(Bostrom, 2001). The major bone components, BMP-2, osteopontin, collagen I, 
MGP, osteonectin, biglycan, osteocalcin, and matrix vesicles, have been found 
not only in calcified bones (Tyson et al., 2003) but also in calcified vascular 
lesions, which means instrumentally these components may contribute to the 
composition of atherosclerotic plaques (Bostrom, 2001). In ESRD patients, 
several mediators of bone mineralisation are believed to contribute to VC though 
an unidentified mechanism (Raggi, 2005). Osteoclast cells were present in the 
artery wall in calcified human atherosclerotic lesions (Demer and Tintut, 2003). 
Interestingly, the calcium deposits in some of the arteries did not only contain 
complete bone tissue but also bone marrow and fat tissue in autopsy tissue 
(Demer and Tintut, 2003). This strongly supports that VC is not a simple calcium 
depositing process, but that it is actually an active process like bone formation 
(Chen and Moe, 2003; Fitzpatrick etal., 2003; Raggi, 2005).
Vascular calcification also has been seen in animal models where bone related 
proteins had been knocked out. Medial calcification occurred in a number of mice 
which were deficient in MGP, similar to Mothers against decapentaplegic 
homolog 6 (SMAD6, an intracellular mediator of bone morphogenetic protein 
signalling) and Klotho (a gene associated with aging) (Schoppet et al., 2004). It 
also occurred in mice treated with supraphysiological doses of vitamin D or 
warfarin. Additionally, medial calcification in the treated mice can be prevented 
by inhibitors of osteoclasts, including OPG, bisphosphonates, and a selective
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inhibitor of the osteoclastic V-H+-adenosine triphosphatase, providing further 
evidence for a mechanistic link between vascular calcification and bone 
metabolism (Schoppet etal., 2004).
2.6.2.1.1 OPG-RANK-RANKL system in VC
Osteoprotegerin, a receptor activator of nuclear factor- kB ligand (RANKL) and a 
receptor activator of nuclear factor-KB (RANK) system is produced by and targets 
vascular cells (endothelial cells and vascular SMCs) in vivo. Osteoprotegerin is a 
neutralising soluble decoy receptor for RANKL and TRAIL (Hofbauer and 
Heufelder, 2001; Sattler et al., 2004). It has been found in bone related cells, 
such as bone marrow stromal cells, osteoblast-like cells, osteosarcoma cells and 
pulp cells in teeth as well as in endothelial cells (Dhore etal., 2001). Osteoblastic 
cells, T cells and tumour cells produce RANKL, and in vitro studies have 
identified that RANKL is expressed in endothelial and SMCs. The receptor RANK 
is stimulated by its RANKL and is expressed on the surface of osteoclasts. 
Ligation of the receptor stimulates all aspects of osteoclast function, such as 
differentiation, maturation, fusion, survival, and activity (Van etal., 2006).
The RANKL-OPG system has been shown to be involved in the progress of VC. 
Firstly, RANKL and OPG were localised in normal and atherosclerotic human 
vessels by immunohistochemical analyses, and were found in normal vascular 
walls and early atherosclerotic lesions by immunoreactivty. In particular, OPG 
was found in the borders of calcified structures and was expressed most 
abundantly in the media of large arteries among the tissue, where RANKL was 
found adjacent to calcium deposits (Sattler etal., 2004). In addition, the vascular 
phenotype of OPG-/- mice can be completely rescued by prenatal activation of 
an OPG transgene. Targeted deletion of OPG has been shown to result in both 
osteoporosis and calcifications of the medial layers of the aortae and renal 
arteries, affecting two thirds of OPG-/- mice (Collin-Osdoby, 2004). Of note, 
dexamethasone enhances differentiation of vascular SMCs toward an 
osteoblastic phenotype in vitro and concurrently inhibits OPG expression by 
osteoblasts (Schoppet et al., 2004). Above all, OPG might be a protective factor 
to inhibit the vascular calcification in mice.
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However, the use of OPG in vascular disease is controversial. Serum OPG 
levels were independently associated with vascular calcification by aortic 
calcification index research in Tokyo. The serum levels of OPG and RANKL were 
also measured in patients with PAD indicating that OPG and RANKL serum 
levels are similar in patients and controls (Pennisi et al., 2004). Hence, there is 
insufficient evidence to support that the RANKL-OPG system was activated in 
PAD. Nevertheless, Nitta et al. documented that rapid progression of vascular 
calcification was associated with serum OPG concentration on long-term 
haemodialysis (Nitta et al., 2003). Increased OPG serum levels also have been 
found to be associated with the presence and severity of coronary artery disease, 
which may indicate an insufficient regulatory mechanism in the protective role of 
OPG in the vascular system (Jono et al., 2002). The elevated levels of serum 
OPG have been found to be associated with intima-medial thickness of carotid 
artery and may play a role in the pathogenesis of atherosclerotic disease 
(Erdogan etal., 2004). Finally, single nucleotide polymorphisms in the OPG gene 
were found associated with cardiovascular morphology and function (Brandstrom 
etal., 2004).
2.6.2.2 Intimal Calcification
Intimal calcification only occurs within atherosclerotic plaques and can be seen in 
the second decade of life. It can be used as a surrogate marker for 
atherosclerosis because calcium mineral deposits are frequently found in the 
atherosclerotic plaque (Proudfoot and Shanahan, 2001). Atherosclerosis can 
severely narrow and block arteries. This deposition which is comprised of fatty 
substances, cholesterol, cellular waste products, calcium and other substances, 
is called plaque. It has a diffuse, punctate morphology and appears as 
aggregates of calcium crystals. These deposits can coalesce to form large solid 
crystals, occasionally with the characteristics of true bone (Frederic H.Martini, 
2005; Raggi, 2005). Atherosclerosis usually affects large and medium-sized 
arteries. The atherosclerotic plaques that rupture cause blood clots to form that 
can block blood flow or break off and travel to another part of the body. If either 
happens and blocks a blood vessel that feeds the heart, it causes a myocardial 
infarction; if it blocks a blood vessel that feeds the brain, it causes a stroke; if 
blood supply to the arms or legs is reduced, it can cause claudication and
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eventually gangrene. Therefore atherosclerosis can induce ischaemia and 
infarction in end stage of organs (Doherty etal., 2004).
In summary, it is believed that atherosclerosis begins with damage to the 
innermost layer of the artery, the endothelium. The damage to the endothelium 
causes deposition of fats, cholesterol, platelets, cellular waste products, calcium 
and other substances in the artery wall. These may stimulate artery wall cells to 
produce other substances that result in further build-up of cells. These cells and 
surrounding material thicken the endothelium significantly. The artery's diameter 
shrinks and blood flow decreases, reducing the oxygen supply. Often a blood 
clot forms near this plaque and blocks the artery, stopping the blood flow 
(Schinke and Karsenty, 2000). However, numerous studies demonstrated that 
intimal calcification is not a passive progress requiring active inhibitors, but is 
more like biological net with active initiating and inhibiting components. Taken 
together, the mechanism responsible for this has not yet been illustrated (Demer 
and Tintut, 2003).
2.6.2.2.1 Potential mechanisms of intimal calcification
In a review by Proudfoot and Shanahan in 2001, it is suggested that there are 
four possible classes of mechanisms of intimal calcification. These are involving 
apoptotic bodies/ matrix vesicles, bone-associated proteins, lipids and calcium 
and phosphate ions.
2.6.2.2.1.1 Apoptotic bodies (AB)/ matrix vesicles
It has been found through electron microscopic and histological studies that 
calcification occurs in association with matrix vesicles which are most commonly 
found in cartilage, bone and organelle-remnants which are shed from intima 
vascular SMCs (Upchurch, Jr. and Schaub, 2006). Chondrocyte ABs, like matrix 
vesicles can act as a nidus for calcium crystal formation in vitro. In addition, ABs 
derived from human vascular SMCs can also undergo calcification in vitro 
(Upchurch, Jr. and Schaub, 2006). This suggested that AB is crucial in initiating 
VC. Matrix vesicles or AB should be cleared by phagocytic macrophages rapidly, 
but the presence of either of them suggests a deficiency of phagocytes. This
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might be due to the competing presence of oxidised lipids (Proudfoot and 
Shanahan, 2001).
2.6.2.2.1.2 Bone-associated proteins
Human SMCs express many bone calcifying regulation proteins such as 
osteopontin, BMP-2 and MGP which were found accumulated in the area of 
calcification. However, the function of these proteins in vascular walls is not clear. 
This could be due to phenotypic change in SMCs leading to VC, or could be only 
secondary to calcification (Proudfoot and Shanahan, 2001).
2.6.2.2.1.3 Lipids, calcium and phosphate ions
It is well known that a diet high in lipids and cholesterol carries with it a high risk 
of atherosclerosis. Lipids and cholesterol were also found in the atherotic 
plaques. Lipid filled SMCs were found in human carotid atherosclerotic plaques. 
Of interest, spontaneous lipid accumulation was found in cultured human SMCs 
before calcification. It could be a potential nidus for calcification. Also oxidised 
lipids were shown to induce osteoblastic differentiation in CVCs and to compete 
with macrophages in clearing ABs. Another possible mechanism is an increase 
of calcium and phosphate ion concentration will attract calcium deposition. 
Smooth muscle cells respond by increasing calcium uptake, and a higher 
concentration of phosphate ions was found to be able to induce osteogenic 
differentiation in human SMCs, resulting in calcification (Proudfoot and 
Shanahan, 2001).
2.6.2.3 Medial Calcification
Medial calcification occurs independently of intimal calcification and 
atherosclerosis. It commonly occurs in the peripheral arteries of the lower limbs 
in otherwise healthy elderly patients (Monckeberg’s sclerosis) or ESRD patients. 
It also occurs in younger patients with diabetes and chronic renal failure (Labat- 
Moleur et al., 1998). Severe medial calcification is also seen in calcific uremic 
arteriolopathy (calciphylaxis), a relatively rare and often fatal syndrome of 
ischaemic necrosis of skin, muscles, and subcutaneous fat occurring almost 
exclusively in uremic patients. Finally, there are a number of genetic disorders
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with unknown aetiology which result in medial calcification. These include 
idiopathic calcification of infancy and Singleton-Merton syndrome (Schreurs O. et 
al., 1997). The arteries of both diabetic and non-diabetic patients were free of 
atherosclerosis, and no difference was observed between two groups of intimal 
thickness and intima-to-media thickness ratio. It was noticed that calcification 
was found in tunica media, but not in tunica intima, obviously greater in diabetic 
than in non-diabetic patients, and independent of known risk factors such as 
hypertension, hyperlipidemia, obesity and history of old myocardial infarction 
(Sakata etal., 2003).
Medial calcification morphology differs from intimal calcification, appearing in its 
earliest form as linear deposits along elastic lamellae. It is responsible for arterial 
stiffening and a decrease in arterial compliance, leading to systolic hypertension, 
left ventricular hypertrophy and ultimately left ventricular failure (Labat-Moleur et 
al., 1998; Proudfoot and Shanahan, 2001; Raggi, 2005). Medial calcification 
progresses with age and at its most severe, it forms a dense circumferential 
sheet of calcium crystals in the centre of the media, bounded on both sides by 
vascular SMCs and often contains bone trabeculae and osteocytes (Labat- 
Moleur etal., 1998).
2.6.2.3.1 Potential mechanisms of medial calcification
In the review by Proudfoot and Shanahan in 2001, it is suggested that there are 
two possible classes of mechanisms of intimal calcification. These are involving 
apoptosis/elastin and bone-associated genes.
2.6.2.3.1.1 Apoptosis/ elastin
Medial calcification is absent of lipid and inflammatory cells and occurs along the 
elastic lamellae between layers of vascular SMCs and elastin (Schreurs O. etal., 
1997). Apoptotic bodies have been shown to be calcified in a similar way to 
matrix vesicles. This is possibly because when medial vascular SMCs undergo 
apoptosis, ABs are released and are not efficiently cleared. When crystals are 
formed on these matrix vesicles in the media of artery wall, it is likely that crystal 
growth occurs along elastin fibres due to its suitability as a substrate. It is also 
possible that elastic lamellae create a physical barrier between vascular SMCs,
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preventing ABs of vascular SMCs to be phagocytosed, which could explain the 
location of calcification in the vessel media (Schreurs O. etal., 1997). In addition, 
apoptosis has not been found in medial calcification but if it does occur within the 
media, lack of clearance of apoptotic cells would cause higher extracellular 
concentrations of calcium and phosphate ions. This could lead to deposition of 
calcium crystals (Proudfoot and Shanahan, 2001).
2.6.2.3.1.2 Bone-associated genes
Mice lacking MGP developed extensive medial calcification. When medial 
calcification occurs, MGP decreased, and there was an increase in some bone- 
related proteins secreted by SMCs which act as nucleators of calcium. This could 
result in VC by absence or inactivity of calcification inhibitor proteins (Proudfoot 
and Shanahan, 2001).
2.6.2.3.1.3 Summary
Intimal calcification and medial calcification both are strongly associated with 
high morbidity and mortality. Increasing amounts of evidence suggest that a 
regulating process of calcification, including initiating and inhibiting proteins is 
involved. Taken together, the above conditions all have potential to induce VC. 
The failure of clearance of AB, the lack of bone-related calcification inhibitors and 
the expression of the initiating proteins for calcification all provide a favourable 
environment for the generation of VC.
2.6.2.4 The possible mechanism of AAA formation
Atherosclerosis produces both stenosis (narrowing) and aneurysms (dilation) 
which are directly opposite in nature (see picture below for the concept of 
stenosis and aneurysm). Also atherosclerosis and AAA frequently coexist 
(Jorgensen et al., 2004). A strong association exists between cardiovascular risk 
factors and measures of clinical and subclinical atherosclerosis, cardiovascular 










Figure 2.8 Diagram of carotid aneurysm (right) and stenosis (left).
Abdominal aortic aneurysms are characterised by destruction of elastin and 
collagen in the media and adventitia, loss of medial SMCs with thinning of the 
vessel wall, and transmural infiltration of lymphocytes and macrophages 
(Crawford etal., 2003; Ernst, 1993).
Like stenosis, aneurysm formation is not well understood. The National Heart, 
Lung, and Blood Institute has described aneurysm formation in 4 different ways, 
a combination of these 4 multiple factors is more likely to reflect the truth 
(Crawford etal., 2003).
2.6.2.4.1 Potential m echanism s of AAA
• Proteolytic degradation of aortic wall connective tissue
• Inflammation and immune responses
• Biomechanical wall stress
• Molecular genetics
Aneurysm formation involves a complex process of destruction of the aortic 
media and supporting lamina through degradation of elastin and collagen. The 
degradation of elastin, collagen, and other constituents might be a reason for the 
widespread destruction of elastic laminae. Matrix metalloproteinases (MMPs) 
and their inhibitors have been found to be expressed in vessel walls favouring 
elastin and collagen degradation, which has attracted a lot of interest in AAA
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studies. However, the biological mechanism for initiation of AAAs is still uncertain 
(Crawford etal., 2003).
The tunica media of abdominal aorta is lacking of vasa vasorum ( the vessel of 
the blood vessel wall) causes relative less blood supply in this particular portion 
than the rest of arteries (Libby Peter, 2002). This could explain that aneurysm 
often occur in the abdominal aorta. Additionally, 3-blockers which could reduce 
wall stress have been suggested to be used as protection against continued 
aneurysm dilation and rupture in animal models. Also, once AAA has developed, 
the increased vessel wall stress affects the dilation of the aneurysm and the 
outcome of AAA such as AAA rupture. Increased shear and tension on the aortic 
wall results in collagen remodelling; furthermore, a decrease in the elastin to 
collagen ratio from the proximal to the distal aortae may be clinically relevant 
(Upchurch, Jr. and Schaub, 2006). In addition, AAA was shown to be affected by 
inflammation. Smooth muscle cell destruction might be due to apoptosis 
triggered by inflammatory mediators and induce AAA formation (Plutzky, 2003).
Currently, no single genetic polymorphism or defect has been identified as a 
common denominator for AAAs. Some phenotypes have been found to be 
associated with AAAs, such as the haptoglobin phenotype (Hp)-21 and 
deficiencies in a1-antitrypsin. Additionally, there is a decreased frequency of 
AAAs in patients with a Rh-negative blood group, and an increased frequency in 
patients with MN (in humans, the MN blood group is characterised by the 
presence of molecules called glycoproteins on the surface of red blood cells) or 
Kell-positive blood groups (a family of antigens found in erythrocytes and 
designated K, k, Kpa, Kpb, and Ku; antibodies to the K antigen, which occurs in 
about 10% of the population of England, have been associated with haemolytic 
transfusion reactions and with haemolytic disease) (Upchurch, Jr. and Schaub, 
2006).
2.6.2.5 Animal models
The clinical significance of arterial calcification is continually growing with 
population age. Study of human samples is very frustrating because only 
established-stage samples can be obtained. Thus, appropriate animal models to
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imitate VC in vitro will lead to new insights into the pathogenesis of arterial 
calcification.
The mouse models lack specific calcification inhibitors which has been 
demonstrated by developing a complex regulation of the calcification process 
(Chirgwin et a!., 1979). Osteocalcin-deficient mice developed increased bone 
formation, but retained normal blood vessel formation (Dhore etai., 2001). Matrix 
GLA protein knockout mice have been found to develop vascular calcification in 
vivo (Dhore et al., 2001). Osteoprotegerin knockout mice develop medial and 
subintimal calcification apparent at 2 weeks and marked by 2 months. These 
animals also develop severe osteoporosis, and exhibit the same relationship 
between VC and osteoporosis as that shown in humans (Collin-Osdoby, 2004; 
Kiernan, 2001). Therefore, MGP is considered as an inhibitor of mineralisation in 
arteries and cartilages in mice. Of note, patients with Keutel syndrome (a disease 
caused by functional MGP absence) showed calcification of cartilage but not in 
the arteries. This finding shows human arterial calcification does not depend on 
MGP, but may rely on some other proteins acting in a similar fashion participate 
in the inhibition of mineralisation (Schinke and Karsenty, 2000). Dystrophic 
calcification is not observed in smaller arteries, capillaries or veins, suggesting 
that these vessels express additional unknown inhibitors of calcification (Demer 
and Tintut, 2003).
A rat model of aortic allografts was built up to analyse the arteriosclerotic 
progress. Endothelial cells were reported firstly to gradually disappear at the graft 
lumen. Subsequently, SMCs, lymphocyte and macrophages proliferated in the 
tunica intima of the vascular wall. After 4-8 weeks, progressive apoptosis was 
found in the media. Finally, accumulation of macrophages and calcification were 
observed in the media and endothelial cells reappeared at the graft surface 
(Religa et al., 2003). These findings show that proliferation and apoptosis of 
SMCs is a major change.
2.6.2.5.1 Animal models with OPG
The arteries of the OPG knockout mice that exhibited calcification are also sites
of endogenous OPG expression, suggesting that OPG may have a specific role
in protecting these arteries from calcification. The OPG knockout mice also
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developed partial aortic dissection and SMC proliferation in the intima and media 
suggesting additional regulatory roles for OPG (Dhore et al., 2001; Jono et al., 
2002; Kiernan, 2001). In addition, OPG injection in OPG knockout mice cannot 
reduce the calcification but can reverse bone loss in OPG knockout mice. This 
implied that OPG cannot reverse the calcification once it has occurred (Collin- 
Osdoby, 2004). Thus, administration of OPG in arterial calcification might be 
associated with some other molecules. Interestingly, OPG administration can 
prevent arterial calcification caused by warfarin or high vitamin D in rats (Collin- 
Osdoby, 2004). In some animal models, cell death appears to be the principal 
stimulus for calcification. Arterial calcification in the balloon-injured rabbit aorta 
occurred early (at 2-4 days) in areas of the media where cells had been killed by 
necrosis or apoptosis. Calcification occurred before the matrix protein 
osteocalcin was detected, indicating that the early calcification process in this 
model was more closely associated with cell death than to the expression or 
deposition of bone- associated proteins (Luiz Carlos Junqueira etal., 1998).
Hence, a question needs to be addressed. Do vascular calcification animal 







Cell death occurs in two main ways: necrosis and apoptosis. Necrosis is usually 
referred to as traumatic cell death caused by overheating, toxin or hypoxia. 
When damaged cells undergo necrotic cell death, they swell and the membranes 
spilt resulting in the intrinsic chemical substances exuding and infecting the cells 
around them. Briefly, apoptosis is described as a cell suicide or programmed cell 
death. It does not affect the surrounding cells, and is characterised by various 
biological and morphological changes of affected cells. The biological changes 
include an alteration of mitochondrial membrane potential, activation of caspases, 
DNA fragmentation and formation of apoptotic bodies (AB). The morphological 
changes include loss of cell surface structures, cell shrinkage and shape 
modification, condensation of cytoplasm and nuclei, nuclear envelope alterations, 
nuclear fragmentation and membrane blebbing. The blebbing phenomenon of 
apoptotic cells lasts for only few minutes and is impossible to detect by light 
microscopy, but the formation of AB remains visible for 1 to 2 hours and can be 
observed if the size is over 0.5pm (Anna-Kaisa Eerola, 2000). Differences 
between necrosis and apoptosis are detailed in appendix B.
Figure 3.1 Apoptotic vascular SMCs were photographed by 
videomicrograph. The white arrow indicates an apoptotic body. It appears 





The Nobel Prize in physiology or medicine in 2002 was awarded for fundamental 
discoveries concerning the genetic regulation of organ development and 
programmed cell death in the model organism (Fadeel and Orrenius, 2005). 
Apoptosis is defined as a type of programmed cell death which plays an 
important role in many physiological and pathological conditions. Approximately 
5% of the cells of an organism undergo apoptosis each day.
Originally, the word apoptosis comes from the Greek, meaning ‘falling off’ 
(Michael Quinion, 1996). The principles of apoptosis were first described by Carl 
Vogt in 1842. It has become a hot topic since 1972, when an Australian scientist, 
John Kerr, published his finding “Apoptosis; a basic biological phenomenon with 
wide ranging implication in tissue kinetics” in the British Journal of Cancer (Kerr 
et al., 1972). The cellular mechanisms that regulate and initiate apoptosis were 
first elucidated by genetic studies of the roundworm, Caenorhabditis elegans 
(Ellis and Horvitz, 1986).
3.2.2 Apoptosis related disorders
Many of the proteins that control apoptosis that were initially identified in the 
study of Caenorhabditis elegans have also been found in mammals. These 
include proteins such as ced-3, ced-4, ced-9 and egl-1 in Caenorhabditis 
elegans. The protein of ced-3 encodes a protease of the caspase family in 
mammals. The protein of ced-4 is an adaptor protein that is similar to apoptotic 
protease-activating factor-1. Both of them oligomerize to form an apoptosome 
like complex to induce apoptosis. Proteins of ced-9 and egl-1 encode members 
of the Bel family: ced-9 is an anti-apoptotic protein with four Bcl-2 homology 
domains, whereas egl-1 is a pro-apoptotic BH3-only-domain protein. Molecular 
model of apoptosis activation (Caspase family and Bel family are detailed in the 
next section) (Lettre and Hengartner, 2006). Subsequently, these genes were 
found to be mutated in tumours of cancer patients. Many other mutated genes 
found in tumours are associated with cell cycle regulation. These findings appear
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to indicate the uncontrolled cell proliferation of cancer results from either excess 
cell division or insufficient apoptosis (Finley, 2003; Sedghizadeh et al., 2004).
Caenorhabditis elegans 
Inhibitor CED-9 -| EGL-1
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Adaptor CED-4 










Figure 3.2 Proteins in the Caenorhabditis elegans encodes the proteins in 
mammal.
Derangement of apoptosis contributes to many human diseases directly or 
indirectly, resulting in either cell accumulation or cell loss (Fadeel and Orrenius,
2005). Apoptosis deficiency is suggested to be associated with cancer. 
Conversely, excess apoptosis is associated with numerous diseases, such as 
acquired immune deficiency syndrome (AIDS), neurodegenerative disorders 
(Alzheimer's Disease, Parkinson's Disease), blood diseases (aplastic anaemia), 
low-oxygen injury (heart attacks or stroke), or even toxin-induced liver disease 
(such as that caused by alcohol) (Fadeel and Orrenius, 2005).
3.2.3 Apoptosis pathways
There are two main pathways initiating apoptosis in cells: one is through the 
cellular death receptor-mediated activation i.e. Fas and TNFR’s; the other is 
mediated by changes in the mitochondrial permeability. Simply, they were 
described as the extrinsic pathway and the intrinsic pathway respectively. These 
two pathways have different mechanisms, but both of them result in the cellular
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morphological and biochemical alterations that are characteristic of apoptosis 
(Lesauskaite et al., 2003).
3.2.3.1 Extrinsic pathway
The extrinsic pathway is important in the maintenance of tissue homeostasis, 
(Ballou et al., 1996). External signals activate the Fas ligand (FasL or CD95L) 
which then binds to the Fas receptor (CD95). This allows the assembly of a 
death-inducing signalling complex (DISC); active Fas-associated death domain 
protein (FADD). This complex then recruits pro-caspase 8. Pro-caspase 8 can 
autocatalyse releasing the active enzyme which then cleaves the inhibitory pro­
section of caspase 3. The active caspase 3 is an effector caspase of apoptosis, 
resulting in the eventual death of the cell. The TNF family of proteins, including 
TRAIL, follow a similar method of inducing apoptosis. The TNF ligands bind to 
their receptors; triggering the assembly of the TNF receptor associated death 
domain (TRADD). The initiator caspases (8 etc) activate the effector caspapse 
(3, 7 etc) to induce apoptosis (Fadeel and Orrenius, 2005). Caspases are subject 
to inhibitions by a family of inhibitor of apoptosis proteins (lAPs) and FLIP (FLICE 
(FADD-like apoptotic cysteine protease)-inhibitory proteins). This inhibitor, IAP, 
binds to the substrate groove of caspase 3 and 7, thus blocking access of protein 
substrate to the active caspase (Chai etal., 2001; Huang eta!., 2001; Riedl et al., 
2001; Shi, 2004). This inhibitory protein, FLIP, shares significant homology with 
caspase-8 (also called FLICE) with an additional death effector domain, but lacks 
the catalytic active site of the caspases and has no protease activity (Boatright et 





Figure 3.3 Extrinsic apoptosis pathway. FAS ligand and TRAIL bind to their 
death receptors and results in the activation of effector caspases within 
cell. Affected cell finally undergoes apoptosis. FLIP and IAP are inhibitors 
of apoptosis.
3.2.3.2 Intrinsic pathway
The intrinsic pathway is also called mitochondrial pathway. This is because
mitochondria are crucial for the execution of cell death during this pathway,
although the endoplasmic reticulum has been implicated (Parone et al., 2002).
The intrinsic pathway plays an essential role in response to foreign body invasion 
or internal insults such as desoxyribonucleic acid (DNA) damage (Fadeel and 
Orrenius, 2005;Hay and Kannourakis, 2002). This pathway in instigated by pro- 
apoptotic signals which are suicide signal originating from inside the cell. Pro- 
apoptotic signals activate the mitochondria. Apoptotic proteins are 
compartmentalised within and are release from functional mitochondria. They 
have been placed in close proximity to their apoptotic sites of action, and 
consequently apoptosis occurs.
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Cytochrome c is normally localised in the intermembrane space of the 
mitochondria. It interacts with apoptotic protease-activating factor-1 (Apaf-1), 
adenosine triphosphate (ATP)/ deoxyadenosine triphosphate (dATP), and 
caspase 9 to form the apoptosome. Cytochrome c and ATP/dATP, Apaf-1 
undergoes a conformational change permitting self-aggregation. Caspase 9 
binds to Apaf-1 forming a complex while cytochrome C and dATP are present. 
This complex leads to cleavage of caspase-9, converting it to effector caspase 9. 
Caspase 9 can then directly activate the effector caspases 3 and 7, which results 
in the orderly death of the cell through controlled proteolytic processing of 
various downstream targets. Cytochrome C, Apaf-1, ATP/dATP and caspase are 
all essential in activation of caspase 3 and 7 (Anna-Kaisa Eerola, 2000; Li et al., 
1997).
The second mitochondria-derived activator of caspase (Smac) is also located in 
the mitochondria and released into the cytosol in response to apoptotic stimuli. 
Smac removes lAPs inhibitory effect on caspase activity by binding to 
baculovirus IAP repeat (BIR) domains to promote procaspase-9 activation (Du et 
al., 2000).
The apoptosis-inducing factor (AIF) is a mitochondrial flavoprotein that 
translocates to the nucleus following apoptotic stimulation. Desoxyribonucleic 
acid (DNA) fragmentation was triggered by AIF and chromatin condensation in 
the nucleus-independent from caspases. However it promotes apoptosis 
cooperating with other factors such as endonuclease G (Cregan etaI., 2004).
The p53 tumour suppressor gene is a 53kDa phosphoprotein. This gene arrests 
cells in the G0/G1 phase whenever DNA is damaged in order to allow the cell's 
DNA repair mechanism to function. If DNA repair is unsuccessful, p53 induces 
apoptosis by upregulating the apoptosis-inducer bax and down-regulating the 
anti-apoptotic bcl-2, leading cells to apoptotic death. It resides primarily in the 
nucleus and functions as a transcriptional regulator. The gene p53 promotes 
apoptosis when cells become hypoxic or are exposed to UV irradiation. It also 
triggers apoptosis when DNA damage occurs, growth factors are withdrawn or in 
the presence of mitogenic oncogene expression in cells (Semenza, 2006).
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Human bcl-2 family is very important in the initiation and the inhibition of 
apoptosis. Members of the inhibitory bcl family of proteins include bcl-2, bcl-xL, 
mcl-1, bcl-w, A1 and Boo; members of initiatory family of bcl proteins include bax, 
bak, bok/mtd, bcl-xS, bik/nbk, hrk/dp5, bim/bod, blk, bad, bid. Inhibitory group 
(the Bcl-2 proteins) proteins reside on the outer mitochondrial membrane while 
initiatory group proteins (the bax proteins) reside in the cytosol. High expression 
of the bcl-2 proteins inhibits apoptosis and high expression of the bax proteins 
induces apoptosis. The ratio of bcl-2 to bax determines the susceptibility of a cell 
to apoptosis and p53 probably regulates this ratio. When overexpressed, bax 
forms homodimers, thereby accelerating apoptosis. In contrast, when bcl-2 is 
expressed in excess, it heterodimerises with bax and apoptosis is suppressed 
(Israels and Israels, 1999).
The bax proteins receive apoptotic signals and then migrate and bind to the 
mitochondrial membrane inducing membrane changes. These changes result in 
cytochrome c and AIF being released from mitochondria to induce apoptosis 
(Israels and Israels, 1999).
| Membrane
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Figure 3.4 Intrinsic apoptosis pathway. Pro-apoptotic signals actives 
caspase 3 by a number of different proteins released from mitochondria, 
resulting in apoptosis.
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3.2.3.3 Other apoptosis pathways
There are other apoptosis pathways excluding the intrinsic and the extrinsic 
pathways described. For example, cytotoxic T cells and natural killer cells trigger 
apoptosis either by FAS ligand pathway or perforin/ granzyme B-dependent 
pathway. Perforin/ granzyme B-dependent pathway involves a pore-forming 
protein, perforin and a serine protease, granzyme B. Granzyme B can directly 
cleave and activate pro-caspase 3 to initiate apoptosis. This pathway mainly 
operates in viral defence and immune surveillance against cancer. It also works 
to protect immune homeostasis. In addition, granzymes A and C also play roles 
in the apoptosis pathway (Israels and Israels, 1999). Granzyme A is independent 
from granzyme B but still synergistically induce apoptosis in a perforin-dependent 
manner (Israels and Israels, 1999; Lieberman, 2003). Whereas granzyme C acts 
through another independent apoptotic pathway from perforin-dependent manner 
(Anna-Kaisa Eerola, 2000; Lieberman, 2003).
3.3 Apoptosis correlated with vascular 
calcification
The link between cell death and VC has been noted in pathological studies.
Vascular cells that undergo apoptosis or necrosis may provide membrane
fragments that play a role in initiating calcification. Apoptosis has been shown to
precede calcification in vitro, and has been identified in normal cultured animal
and human vascular SMCs and in the remodelling of new born animal’s arterial
walls. The formation of ABs may act as a nucleation site for calcium crystal
formation in the vessel wall (Proudfoot and Shanahan, 2001). Lynch et al. have
shown that apoptosis is an integral part of osteoblast differentiation and
calcification in foetal rat calvarial osteoblast cultures (Lynch et al., 1992).
Proudfoot et al. provided experimental evidence of a role for apoptosis in the
initiation of VC (Proudfoot et al., 2000). Under the electron microscope, the ABs
have a similar structure to the matrix vesicle, membrane-bound vesicles that are
produced by osteoblasts, chondrocytes and odontoblasts, containing the
necessary calcium-binding proteins and phosphatases for nucleation of
hydroxyapatite (Proudfoot et al., 2001). These proteins were found in forming
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bones and mineralising cartilages as well as calcified arteries and heart valves. 
Furthermore, bax proteins were found in SMCs which were derived from 
advanced carotid atherosclerotic plaques. It is a sign of remnants of apoptotic 
cells. Cytoplasmic vesiculation is a recognised feature here, and the formation of 
matrix vesicles may therefore represent a manifestation of programmed cell 
death. It backs up the evidence of apoptosis in VC occurring via an extracellular 
pathway (Proudfoot etal., 2000).
Although calcification in atherosclerosis has been detected mainly in association 
with extracellular structures, intracellular calcification has also been detected, 
such as calcified cell organelles or calcified structures that have been engulfed 
by SMCs. Consequently, apoptosis appears to be a relatively common event in 
atherosclerotic arteries and after arterial injury.
3.4 The events of apoptosis in the formation of 
vascular calcification
Women tend to have more calcified vascular diseases after menopause. It is 
known that oestrogen deficiency occurs after menopause and it also results in 
osteoporosis in humans. Additionally, it has been proven that oestrogen prevents 
glucocorticoid-induced apoptosis in osteoblasts (Gohel etal., 1999). Proudfoot et 
al. (2000) found apoptosis occurred in the early stages of VC before calcium 
crystal deposition in the SMC nodules. Kondo et al. found the frequency of 
apoptosis was significantly higher in the earlier stage of VC. In progressive 
saccular aneurysms, medial SMCs had almost disappeared at the dome; 
apoptosis of SMCs took place in the neck portion. Thus, the aneurysmal wall 
expands and the aneurysm becomes larger (Kondo et al., 1998). These 
observations showed that apoptosis precedes the onset of VC. However, the 
mechanism of regulation the VC by apoptosis remains unknown.
Studies have been carried out to investigate whether inhibitors of apoptosis also
inhibit VC and conversely if initiators of apoptosis initiate VC (Jian et al., 2003;
Proudfoot et al., 2000). However, there are few studies that focus on whether
inhibiting VC will inhibit apoptosis and vice versa. To test whether apoptosis was
actually required for calcification to occur, apoptosis was inhibited in nodules by
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the caspase inhibitor ZVAD.fmk. A decrease in calcification was found after the 
treatment. Conversely, when apoptosis was initiated by anti-Fas IgM and 
cyclohexamide in the SMC nodules this resulted in a 10-fold increase in 
calcification (Proudfoot et al., 2000). In addition, when cultured SMCs underwent 
TNF-initiated apoptosis they presented with calcific aortic stenosis cusps (Jian et 
al., 2003). Taken together, all the evidence strongly supports the role of 
apoptosis in calcification.
Another possibility is that ABs are the initiators of calcification. This concept was 
tested experimentally in rat aortic segments by Religa et al. (Religa et al., 2003). 
Calcification was minimal when the segments were grafted and contained 
inflammatory cells and then placed in Millipore chambers in the peritoneal cavity. 
As phagocytes are the professional scavengers in the human body, they should 
recognise and phagocytose ABs in the early stages of apoptosis. However, ABs 
were still capable of stimulating calcium crystal growth because phagocytes 
become less efficient which might due to the presence of oxidised lipids. 
Oxidised lipids are known to compete with ABs for phagocytes binding. 
Therefore, a potential mechanism of induction of calcification was assumed as 
the absence of efficient phagocytic cells in atherosclerotic lesions or a lack of 
clearance of ABs (Proudfoot etal., 2000).
Smooth muscle cell AB and chondrocyte matrix vesicles both initiate VC but in a 
different manner. Apoptotic bodies could induce VC independent of ATP while 
matrix vesicles only induce VC in the presence of ATP. As a matter of fact, ATP 
was not necessary for matrix vesicle calcification according to different studies 
(Hashimoto etal., 1998). When SMC-derived AB were permeabilised with NP-40, 
no calcium accumulation was observed indicating that calcium accumulation 
occurs via a mechanism requiring an intact AB membrane (Proudfoot et al., 
2000). Proudfoot et al. suggested that calcium is taken up into SMC AB by an ion 
channel or calcium-binding protein that does not require ATP for its activity. This 
suggests that AB may contain sufficient ATP to accumulate calcium. Furthermore, 
when adding exogenous ATP to vascular SMCs, there is no additive effect in VC. 
This implies that vascular SMC AB may not contain the necessary enzymes for 
ATP hydrolysis, which is present in matrix vesicles (Proudfoot etal., 2000).
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Confocal imaging revealed that calcium was concentrated in calcein-loaded AB. 
Calcium was seen throughout the AB, rather than being localised at the 
membrane. This was supported by elemental analysis of the ABs in calcifying 
solutions containing abundant calcium but very low phosphate. Additionally, AB 
contain calcium carbonate as the preferred form of calcium. These observations 
implied that SMC-derived ABs can concentrate and crystallise calcium in a form 
that is found in vivo (Proudfoot etal., 2000).
Apoptotic bodies derived from SMC in atherosclerotic plaques are similar to 
matrix vesicles derived from chondrocytes (Proudfoot et al., 2001). It seems that 
these two components may share the same pathways to initiate calcification. 
However, it appears that SMC AB and chondrocyte-derived matrix vesicles 
produce a different type of calcium crystal in vitro and use a different method to 
accumulate calcium. This may be attributable to differences in in vitro culture 
conditions or perhaps to intrinsic differences in protein expression (Proudfoot et 
al., 2000). It is also worthy of note that not all chondrocyte matrix vesicles calcify, 
this only occurs at specific sites in the cartilage matrix. Only tissues normally 
engaged in mineralisation produce mineralisation-competent vesicles. Matrix 
vesicles only calcify in vitro if they are preincubated in ascorbate- and phosphate- 
rich medium, which generates matrix vesicles enriched with annexin V (which 
can act as a Ca2+ channel) and alkaline phosphatase. Above all, it suggests that 
not all matrix vesicles encourage VC. However, it is also possible that non­
mineralising tissues produce inhibitors of matrix vesicle function to block 
mineralisation. Therefore, a lack of production of inhibitors of matrix vesicle 
calcification may lead to the development of pathological calcification (Proudfoot 
etal., 2001).
Apoptosis occurs not only in SMCs but also in other vascular cells such as 
endothelial cells and macrophages. Endothelial cells that are undergoing 
apoptosis have exposed phosphatidylserine on their cell membrane increasing 
the likelihood of arterial thrombosis. Macrophages that are undergoing apoptosis 
contribute to the formation and progression of the lipid core and promote 
thrombosis of atherosclerosis in disordered arteries (Lesauskaite et al., 2003). 
Additionally, TRAIL, which is a member of TNF family, is expressed by vascular 
SMCs and may promote cell death in an autocrine or paracrine fashion when
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induced in conditions such as diabetes, hyperlipidemia, chronic renal failure, or 
atherosclerosis (Wang and El-Deiry, 2003). Nevertheless, no evidence shows 
that apoptosis is the only mechanism of VC.
3.4.1 Apoptosis in AAA
Smooth muscle cells in the medial layer of AAA have been proven to contribute 
to the formation of AAA. Some researchers found that the number of SMCs in 
the medial layer of AAA decreases (He and Roach, 1994; Lopez-Candales etal., 
1997). Furthermore, SMCs in the medial layer of AAA appear intact and are 
thinner than is usually seen, lying between the layers of the degraded lamellae 
(Lopez-Candales et al., 1997). Medial layer SMCs have been observed to 
display characteristic apoptotic morphological and biological changes at the 
ultrastructural level in addition to DNA fragmentation being detected by agarose 
gel electrophoresis (Thompson etal., 1997).
Further investigations have been performed to test AAA apoptosis in vivo. 
Apoptotic cells were observed in intimal and medial layers of AAA vessel walls 
and the majority of apoptotic cells in the media were SMCs. The tumour 
suppressor gene p53 was also found in AAA in vivo. It has been shown that p53 
protein expression was much higher in the AAA than in normal aorta and 
atherosclerotic occlusive disease. Another important finding was that the p53 
accumulated in the medial of AAA but not in the medial of normal aorta and 
atherosclerotic occlusive disease. Additionally, p53 positive cells co-expressed 
a-actin which is a typical stain for vascular SMCs. It is worthy of note that FAS 
was also detected in medial SMCs in human AAA tissues (Thompson et al., 
1997).
All the above evidence implicates apoptosis to be involved in AAA but it is still 
unclear whether apoptosis is a key mechanism of AAA. Three suggestions have 
been taken together to discuss the potential impact of apoptosis in the 
mechanism of AAA formation. Firstly, high local concentrations of oxidants 
produced in atherosclerotic tissue including nitric oxide, oxygen free radicals and 
oxidised low-density lipoproteins (LDL) induce apoptosis in the medial SMCs in 
AAA. Secondly, apoptosis in AAA medial SMCs might be subject to ischaemic
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injury of the arterial wall. Finally, extensive matrix degradation might be 
responsible for apoptosis in AAA (Thompson etal., 1997).
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4.
Chapter 4 Tumour Necrosis Factor 
(TNF). - Related Apoptosis- Inducing 
Ligand (TRAIL).
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4.1 The TRAIL Apoptosis System
Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a type II 
transmembrane protein with a trimeric structure (Hymowitz et al., 2000). It is an 
important apoptosis-inducing member of the TNF family whose main role is to 
induce programmed cell death in tumour cells from various tissue origins (Griffith 
and Lynch, 1998). It was firstly cloned from human heart and lymphocyte DNA 
libraries initially with 32 kDa molecular weight in 1995 (Wiley et al., 1995) then 
discovered by an independent lab in 1996 (Pitti et al., 1996). Human TRAIL is 
281 amino acid (aa) residues long, with 17aa residue cytoplasmic tail, a 21 aa 
residue transmembrane segment, and 243 aa residue extracelluar region. It 
shares highest sequence homology with FASL which is also a member of TNF  
family (Gruss, 1996). Like the other members of the TNF family, TRAIL is 
capable of inducing apoptosis in many tumour cells, but, interestingly, not in 
normal cells. TRAIL and its five receptors are expressed in the almost all normal 
and abnormal human tissues. They are predominantly localised in germ cells 
(Grataroli et al., 2004) and cells of the immune system (Wang and El-Deiry,
2003). The system plays a role in both T-cell- and natural killer cell-mediated 
tumour surveillance and the suppression of tumour metastasis (Wang and El- 
Deiry, 2003).
TRAIL’S 5 receptors are divided into two groups: death receptors and decoy 
receptors. Death receptors include TRAIL receptor 1 (TRAIL-R1, CD4) and 
TRAIL receptor 2 (TRAIL-R2, CD5, killer) which both initiate apoptosis 
(Schneider and Tschopp, 2000). Decoy receptors include TRAIL receptor 3 
(TRAIL-R3, DcR1), TRAIL receptor 4 (TRAIL-R4, DcR2) and OPG which are all 
inhibiting receptors (LeBlanc and Ashkenazi, 2003). Additionally, it has been 
reported that two novels splice variants of human TRAIL, TRAIL-beta and TRAIL- 
gamma exist that do not show apoptotic potential (Krieg et al., 2003).
The receptor 1 of TRAIL (TRAIL-R1) is 468 aa residues long, with 220 aa residue 
cytoplasmic domain, a 19 aa residue transmembrane segment, and 226 aa 
residue extracelluar region. It is a type I transmembrane protein with extracelluar 
N-terminus and intracellular C-terminus death domain (Schneider and Tschopp, 
2000). The receptor 2 of TRAIL (TRAIL-R2) is 411 aa residues long, with 206 aa
45
residue cytoplasmic domain, a 22 aa residue transmembrane segment, 132 aa 
residue extracelluar region and 51 aa residue signal sequence (LeBlanc and 
Ashkenazi, 2003). Both death receptors contain 2 cysteine-rich motifs in 
extracelluar region and C- terminus death domains which are independent of
Figure 4.1 The molecular structure of TRAIL and interaction of TRAIL with 
its death receptors (TRAIL-R1 and TRAII-R2). Red ribbons indicate the 
receptors, and blue ribbons indicate TRAIL. Residues in DR5 complexes 
are in dark green, and residues in DR4 complexes are in light green.
(Hymowitz et al., 2000)
In contrast to these death-inducing receptors, TRAIL-R3, which shares homology 
with TRAIL death receptors, is devoid of a cytoplasmic domain and exists as a 
glycophospholipid-anchored protein on the cell surface. It is 259 aa residues long, 
with a 19 aa residue transmembrane segment, 217 aa residue extracelluar 
region and 23 aa residue signal sequence (Schneider et al., 1997a). Since 
TRAIL-R3 mRNA was preferentially found in normal cells but not in transformed 
cells, it is thought that TRAIL-R3 might be responsible for the cellular resistance 
of some normal cells to TRAIL-mediated cytotoxicity (gli-Esposti et al., 1997). It 
has been suggested that TRAIL-R3 can protect cells from TRAIL-induced
FADD.




apoptosis by competing with the death-inducing TRAIL receptors for TRAIL 
binding. The receptor 4 of TRAIL (TRAIL-R4) is 386 aa residues long, with 154 
aa residue cytoplasmic domain, a 21 aa residue transmembrane segment, 125 
aa residue extracelluar region and 31 aa residue signal sequence. The 
cytoplasmic domain containing a truncated death domain lacking 4 out 6 aa 
essential for recruiting adapter proteins that cannot transmit a death signal but 
can weakly activate necrosis factor (NF)-kB. It has been shown that NF-kB 
activation may increase the anti-apoptotic threshold of cells and tissues exposed 
to cytotoxic cytokines such the TNF family to inhibit TRAIL-induced apoptosis. 
Also TRAIL-R4 may protect the cells from apoptosis by competing with TRAIL 
death receptors using a similar inhibiting mechanism as TRAIL-R3 (gli-Esposti et 
al., 1997; Marsters etal., 1997). Osteoprotegerin is the last decoy receptor, but is 
unlike the other two decoy receptors. It is a soluble receptor. It is a secretory 
glycoprotein consisting of 401 aa residues with a molecular weight of 60 kDa as 
a monomer and 120 kDa (Blair et al., 2006) as a disulfide-linked dimer which is 
produced in different tissues including the cardiovascular system e.g. heart, 
arteries and veins and is found in particularly high levels in aortic and renal 
arteries (Collin-Osdoby, 2004; Miyashita et al., 2004). In addition, OPG inhibits 
the binding of RANK to RANKL (TRANCE, osteoprotegerin ligand, OPGL, 
osteoclast differentiation factor, ODF) and thus inhibits the recruitment, 
proliferation and activation of osteoclasts (bone cells associated with bone 
removal and absorption). Since OPG exhibits an inhibitory effect on osteoclasts, 
it acts as a soluble factor in the regulation of bone mass. Osteoclast formation 
activity may be monitored principally by determination of concentration ratio of 
RANKL /OPG. Alteration of this ratio may be the cause of bone loss in many 
imbalances in bone metabolism such as osteoporosis (bone mass decrease), 
osteopetrosis (bone mass increase), hypercalcemia (high level of calcium in the 
blood), metastatic osteolytic lesions and rheumatic bone degradation. The 
protein RANKL is expressed by osteoblastic lineage cells and T lymphocytes and 
acts by binding to its physiological receptor RANK, which is expressed on 
osteoclasts. As mentioned in chapter 2, ligation of RANK stimulates all aspects of 
osteoclast function including differentiation, maturation, fusion, survival, and 
activity (Blair et al., 2006). By contrast, OPG is produced by a variety of tissues, 
including the cardiovascular system, and acts as a soluble decoy receptor by 
neutralising RANKL (Schoppet et al., 2004). In summary, OPG is a decoy
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receptor of TRAIL and RANKL. For the above reasons, it appears to be a genetic 
factor that has influence in both arterial and bone systems.
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Figure 4.2 Representative diagram represents TRAIL and its five receptors. 
Transmembrane protein TRAIL-R1 and TRAIL-R2 bind to TRAIL to induce 
apoptosis. Transmembrane receptor TRAIL-R4 and non-transmembrane 
receptors TRAIL-R3 and soluble receptor OPG bind to TRAIL to inhibit 
apoptosis. DD represents death domain.
4.2 Biochemistry of TRAIL-induced Apoptosis
The fact that TRAIL has five receptors, all slightly differing in their mode of action 
with TRAIL, indicates that a complex regulation of cellular susceptibility to TRAIL- 
mediated apoptosis exists at the level of receptor expression.
The roles of TRAIL in health and disease have not been identified since it was 
first discovered in 1995 (Song et al., 2000). Recently, increasing evidence 
suggests that TRAIL not only is a potential anticancer therapeutic agent both in
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vitro and in vivo, but also, because of its ubiquitous expression in many normal 
tissues may also have other important physiological and biochemical roles. Song 
et al suggested that TRAIL is a potent inhibitor of autoimmune arthritis. The 
inhibitory effect of TRAIL on arthritis may be a result of inhibition of cell cycle 
progression and/or cytokine production (Song et al., 2000). Lee et al showed 
TRAIL may specifically protect the visual axis from tumour growth and 
metastasis. This is consistent with the fact that tumours rarely occur in the eye 
compared with other organs. Both TRAIL and FASL have been found to be 
expressed in the eye and are capable of inducing apoptosis of tumour cells in 
vivo. However, it has been indicated that the mechanism of TRAIL action is 
different from that of FASL. Whereas FASL induces apoptosis of activated T cells, 
TRAIL appears to inhibit their proliferation without eliminating them through 
apoptosis (Lee et al., 2002). This finding is consistent with the unique trait of 
TRAIL in inducing apoptosis of tumour cells but not normal cells.
Although very little is known about possible non-apoptotic functions induced by 
TRAIL, it has been shown that endothelial cells express the mRNA for all TRAIL 
receptors and that TRAIL protein is expressed by the medial smooth cell layer of 
aortae and pulmonary artery (Gochuico et al., 2000). It is also noteworthy that 
cleavage of membrane TRAIL from the cell surface requires the action of 
cysteine proteases (Muzio, 1998), which are abundantly present in the vessel 
wall (Garcia-Touchard et al., 2005). The magnitude of the TRAIL-induced 
proliferative response is similar to that of more thoroughly characterised 
angiogenic factors, such as vascular endothelial growth factor (VEGF). An 
interesting parallel between VEGF and TRAIL is that both are produced by the 
vascular SMCs of the human vascular wall and most likely modulate endothelial 
cell functions in a paracrine pathway (Mitsiades et al., 2002). Thus, TRAIL may 
also be implicated in the homeostatic control of endothelial biology and possibly 
in angiogenesis. These data demonstrated that TRAIL has a direct effect on 
endothelial cell survival and proliferation without inducing inflammatory markers 
and proposes its potential role in SMCs (Secchiero etal., 2003).
The mechanism of TRAIL triggering apoptosis in vivo is unclear. Similar to the 
other TNF members, TRAIL induces apoptosis by both the intrinsic pathway and 
the extrinsic pathway (Qian and Chen, 2002). The intrinsic pathways of TRAIL
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involve late dissipation of the mitochondrial membrane potential and cytochrome 
c release that follows activation of caspase-8 and caspase-3 and inducing DNA 
fragmentation. However, inhibition of caspase-8 but not caspase-3 can prevent 
mitochondrial permeability transition (PT) and apoptosis. Various cells that are 
overexpressing the anti-apoptotic proteins bcl-2 or bcl-XL are not or are only 
marginally protected against TRAIL-induced apoptosis. In contrast, apoptosis 
induced by the chemotherapeutic drug etoposide was severely impaired in these 
cells. In addition, in other ceil types this invokes a different phenomenon e.g. 
pancreatic tumour cell lines which are primarily TRAIL-resistant can be rendered 
TRAIL-sensitive by bcl-xL antisense treatment (Thomas etal., 2000). Additionally, 
high levels of cellular FLIP (c-FLIP) often correlated with resistance of cells to 
TRAIL-induced apoptosis (Sayers and Murphy, 2006). The external apoptosis 
pathway of TRAIL is similar to the extrinsic apoptosis pathway of FASL. It is to be 
noted that NF-kB activation occurs in collagen-induced arthritis, and that 
inhibition of NF-kB activation in T cells prevents this disease. This indicates that 
TRAIL also induces apoptosis by activating NF-kB. Different use of FADD or 
TRADD as the molecular switch might contribute to whether proximal caspase or 
NF-kB be activated (Sayers and Murphy, 2006). The connection and crosslink 
between two main pathways (will be detailed in 4.3) might contribute into TRAIL 
systems behaviour such as it inducing apoptosis in tumour cells but not in normal 
cells. However, various signal transduction pathways of TRAIL receptors are yet 
to be defined. Unidentified pathways may be responsible for the inhibitory effect 
of TRAIL in inflammation and cell cycle progression (Song et al., 2000). 
Therefore, it is necessary to determine whether these pathways also occur in 
normal cells, and if so, whether this is responsible for the cell cycle-arresting 
effect.
4.3 Analysis of TRAIL apoptosis pathways
Under native conditions, which molecules transmit the TRAIL death signal has 
not been fully determined. Further studies of the cloned TRAIL-rTRAIL system 
were carried out to illustrate this remaining question.
As detailed in chapter 3, a great number of proteins known to be involved in 
various aspects of apoptosis signalling have been suggested to also play a role
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in TRAIL-induced apoptosis. It has been documented that TRAIL receptors can 
activate both caspase (through FADD/ TRADD) and NF-kB pathways in tumour 
cells (Song etal., 2000).
Firstly, FADD as a death domain for TRAIL death receptors and caspase-8 are 
revealed. The death-inducing signalling complex (DISC) of TRAIL and FASL is 
quite similar. FADD and caspase-8 recruited to the TRAIL DISC have been 
identified in cell lines, such as hepatocellular carcinoma (HCC) cell lines that 
exhibit differential sensitivity to TRAIL. Pre-treatment with chemotherapeutic 
drugs, e.g. 5-fluorouracil (5-FU) rendered the TRAIL-resistant HCC cell lines 
sensitive to TRAIL-induced apoptosis. Analysis of the TRAIL DISC revealed 
substantially increased caspase-8 recruitment and activation after sensitisation 
with unchanged FADD. At the same time marked downregulation of c-FLIPL and 
c-FLIPS or upregulation of TRAIL-R1 and -R2 was noted after 5-FU treatment. In 
summary, the results suggest that TRAIL-mediated apoptosis in this cell line is 
controlled at the DISC level through the ratio of caspase 8 and cFLIP (Ganten et 
al., 2004).
The role of FADD in TRAIL mediating apoptosis pathway is controversial. When 
cells express FADD-DN (negative version of FADD, lacking of death receptor 
domain), these cells showed an insensitivity to both TRAIL and FASL mediated 
killing (Ou et al., 2005). It also has been implicated in TRAIL death receptors. 
However, it is reported that cells were still capable of undergoing apoptosis upon 
stimulation of TRAIL death receptors in mice lacking of FADD by Yeh et al (Yeh 
Wen-Chen et al., 1998). It indicated that there was some adapter protein like 
FADD involved. However, most researchers concluded that FADD is required for 
TRAIL death receptors to mediate apoptosis (Berger and Kretzler, 2002).
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Figure 4.3 Linking TRAIL and its death receptors through the the DISC of 
FADD, caspase 8. FLIP inhibits the process pro-caspase 8 activation.
Secondly, the involvement of another protein, namely caspase-10, in DISC 
formation and apoptosis induction by death receptors has been controversial. 
Caspase-10 is the only other caspase besides caspase-8 that contains a death 
effector domain, the domain necessary to dock to adaptor proteins like FADD 
(Cohen, 1997). Interestingly, mutations in caspase-10 have been identified in 
patients with autoimmune lymphoproliferative syndrome type II (ALPS II). 
Resulting defects in TRAIL-induced apoptosis were suggested to be causative 
for ALPS II. Caspase-10 is found further to be cleaved during FASL-induced 
apoptosis of activated T cells. These two findings suggested that the observed 
caspase-10 mutations in ALPS II patients may be causative for this disease by 
inhibiting proper DISC formation and caspase activation not only at the TRAIL 
DISC, but also at the FASL DISC (Jackson and Puck, 1999; Wang et al., 1999). 
However, as it has been controversial whether caspase-10 is a constituent of the 
apoptosis initiating DISC protein complex it was tested whether or not this 
caspase forms part of the native TRAIL and/or the native FASL DISC. It has 
been shown that caspase-10 is recruited to both, the native TRAIL DISC and the 
native FASL DISC (Choi and Benveniste, 2004). It has also been shown that 
FADD is necessary for recruitment of caspase-10 and its activation at these two 





The role of Caspase 10 in the TRAIL DISC is 
still controversial.
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Figure 4.4 Linking TRAIL and its death receptors through the the DISC of 
FADD, caspase-10. The role of caspase 10 activation in the DISC is still 
controversial.
Binding of TRAIL to its receptors TRAIL-R1 or TRAIL-R2 triggers rapid apoptosis 
in many cells, however unlike FASL; its expression has been shown to be 
constitutive in many tissues (Wang and El-Deiry, 2003). No essential adapter 
molecule has been identified that associates with the TRAIL death receptors to 
initiate apoptosis. A study in FADD- deficient mice has indicated that FADD is not 
necessary for triggering apoptosis via these receptors. FADD and caspase-8 
constitute integral components of the TRAIL-R2-DISC. FADD and caspase-8 are 
necessary for the TRAIL-R2 DISC to be functional in Jurkat cells that lack either 
FADD or caspase-8 and that are completely resistant to apoptosis induced either 
by TRAIL-R2-specific agonistic antibodies or by TRAIL itself (Jin et al., 2004; 
Marini et al., 2003). One question that remains to be solved is whether TRAIL- 
R1 or heteromeric TRAIL-R1/R2-DISCs also uses these signalling molecules or 
whether the various possible complexes use different pathways to signal cell 
death (Schneider et al., 1997).
TRAIL has been shown to induce a rapid activation of NF-kB. TRAIL was shown 
to exert potent cytotoxic activity against transformed keratinocytes, whereas 
primary cells are relatively resistant against TRAIL. Moreover, upon inhibition of 
TRAIL-induced NF-kB activation, primary keratinocytes were dramatically 
sensitised to TRAIL-induced apoptosis. At the molecular level, sensitisation to 
TRAIL-induced apoptosis was independent of the activation of caspase 8 or its 
receptors, but correlated with full caspase 3 maturation and the release of
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cytochrome c and Smac from the mitochondrion. These data suggest that 
modulation of proteasomal function sensitises keratinocytes to TRAIL-induced 
apoptosis at or upstream of the mitochondrion, but downstream of caspase 8 
activation at the DISC, leading to cytochrome c and Smac release from the 
mitochondrion and concomitant full caspase 3 maturation (Leverkus etal., 2003).
It has been reported that TRAIL-R1 acts as an essential receptor in apoptosis in 
some cells. Normal prostate epithelial cell (PrEC) and prostate stromal cells 
(PrSC) were compared to test the cytotoxicity of the combination of doxorubicin 
and TRAIL. Although PrSC were more resistant than PrEC, all cells undergo 
apoptosis by this combination. There was no correlation between TRAIL 
phenotype and expression of c-FLIP, caspases or TRAIL decoy receptors, but 
PrSC failed to express TRAIL-R1. Additionally, a TRAIL-R1-specific antibody, 
which behaved as an agonist in combination with doxorubicin, was also used in 
this comparison, and found to selectively induce cell death in malignant but not 
normal prostate cells. Although normal PrEC expressed TRAIL-R1 protein as 
determined by western blot, flow cytometry revealed that only malignant prostate 
cancer cells and not PrECs exhibited TRAIL-R1 surface expression. Therefore, 
effective TRAIL-R1 seems crucial to inducing apoptosis in malignant prostate 
cells (Voelkel-Johnson, 2003).
It was also reported that TRAIL-R2 plays an important role in transducing 
apoptosis signals. TRAIL-R2 was internalised into the cytoplasm where it recruits 
FADD under TRAIL stimulation in both sensitive and resistant cells. TRAIL- 
induced apoptosis through TRAIL-R2 and was mediated by caspase-8-initiated 
extrinsic and intrinsic mitochondrial pathways in sensitive glioma cell lines. In 
addition, TRAIL also triggered apoptosis in resistant glioma cell lines through the 
same pathways, but only if the cells were pretreated with chemotherapeutic 
agents, such as cisplatin, camptothecin and etoposide. A more general effect of 
these agents is to downregulate caspase-8 inhibitor, c-FLIP and up-regulate Bak. 
However, the active form of caspase-8 was recruited to FADD and only sensitive 
cells showed increased caspase-8 activity upon TRAIL stimulation. The caspase- 
8 specific inhibitor, Z-IETD, impaired caspase-8 activation and completely 
abrogated TRAIL-induced apoptosis. TRAIL resistant cells are due to negative 
regulation at the level of caspase-8 activation and that caspase-8 activation is an
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indispensable process in TRAIL-induced apoptosis (Song et al., 2000). 
Interestingly, in some cell lines, TRAIL sensitivity and caspase-8 activity was 
enhanced or restored with the treatment of cycloheximide (CHX). In addition, X- 
linked inhibitor of apoptosis (XIAP) levels decreased significantly and rapidly 
following treatment with CHX. Down-regulation of XIAP may be responsible for 
enhancement or restoration of TRAIL sensitivity after CHX treatment in B- 
lymphocytic leukaemia cells (Kang etal., 2003).
In summary these studies show TRAIL-induced apoptosis can be regulated at 
several steps in the signalling cascade. Further studies will be aimed at defining 
the nature of the molecules involved and their mechanisms of regulation.
4.4 Physiological Role of the TRAIL Apoptosis 
System
The physiological function of TRAIL and its receptors remains unknown (Wang 
and El-Deiry, 2003). A number of studies has been carried out focusing on the 
functional expression of TRAIL-rTRAIL system to discover its expression on 
different cell surfaces. Amongst them are type II interferon (IFN-)-stimulated 
monocytes (Nakayama et al., 2000), type I IFN (Chou et al., 2001) or T cells 
(Kayagaki etal., 1999), non-stimulated TRAIL-R1 positive T cells (Kayagaki etal., 
1999), IFN stimulated as well measles virus-infected dendritic cells (DC) (Fanger 
et al., 1999), and natural killer cells (Ochi et al., 2004). Interestingly, functional 
surface expression of TRAIL was often associated with stimulation by interferon 
in these studies. Therefore, it is likely that the anti-tumour effect of IFN may at 
least be partially mediated by TRAIL-induced direct killing of TRAIL-sensitive 
tumour cells. Yet, the main physiological function attributed to IFN resides in their 
anti-viral activity.
In fact, it has been shown that TRAIL induced apoptosis specifically in virally-
infected cells while sparing non-infected normal cells. Thus, the TRAIL system
might have evolved in order to control viral transformation (Matsuda etal., 2005).
The fact that many oncogenically transformed cells are also sensitive to TRAIL
might be a beneficial side effect of the function of TRAIL to kill virally transformed
cells. On the other hand, death receptors for TRAIL have to be involved on the
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target side of the newly discovered physiological activities of TRAIL. However, it 
is still unknown which one of the two death receptors or combination is a crucial 
transducer of the apoptotic signal in different physiological and 
pathophysiological situations either. As detailed in 4.3, TRAIL-R1 or TRAIL-R2 
tends to works differently in individual types of cells. In addition, the desired 
experiments with mice deficient for one or a combination of the TRAIL death 
receptors will be crucial in the determination of the function of each individual 
receptor.
It is still unclear which decoy receptors or the combination thereof serves as 
inhibitors of apoptosis induced by TRAIL. Moreover, there may be other 
mechanisms that reduce TRAIL-induced apoptosis (Gochuico etal., 2000). Since 
TRAIL induces apoptosis mostly in transformed cells not in normal cells, it 
seemed as if the existence of these functional decoy receptors might provide an 
answer to the differential sensitivity to TRAIL observed between normal and 
transformed cells. In addition, it has recently been shown for various cellular 
systems that TRAIL resistance is controlled intracellularly rather than at the 
simple level of TRAIL-R3 and/or TRAIL-R4, the putative “decoy receptors” by 
using monoclonal antibodies specific for each one of the individual surface- 
bound TRAIL receptors (Leverkus et al., 2000). Expression of TRAIL-R3 and R4 
was more prevalent in normal tissue than in most cancer cells. Nevertheless, no 
good correlations were found between these two decoy receptors and TRAIL 
sensitivity (Sayers and Murphy, 2006). As a hypothesis, the difference of TRAIL 
death receptors and decoy receptors and the ratio of receptors/TRAIL might be 
more interesting to examine in apoptosis associated vascular calcification.
Some studies in different cell lines showed that the TRAIL system has various 
roles in inducing or inhibiting apoptosis. In melanoma cells rTRAIL expression 
levels did not significantly correlate with sensitivity towards all TRAIL receptors. 
The cell death is determined by the level of surface expression of TRAIL death 
receptors especially TRAIL-R2 (Chawla-Sarkar et al., 2002). TRAIL-R2 is also 
markedly increased in bile-ligated mouse atherefore inducing apoptosis resulting 
in liver hepatotoxicity (Higuchi et al., 2002). TRAIL and TRAIL-R2 are expressed 
in megakaryocytes and platelets and regulate megakaryocytopoiesis whereas 
the other receptors are rarely seen (Crist etal., 2004; Melloni etal., 2005).
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Decoy receptors appear to play a very minor role in determining cells 
susceptibility to TRAIL. In endothelial cells, decoy receptors appear to play an 
important role in protection against TRAIL-induced apoptosis (Zhang etal., 2000). 
Conversely, they were not correlated with the sensitivity to TRAIL. In the Primary 
versus transformed keratinocytes the levels of cFLIP are inversely correlated 
with sensitivity to TRAIL and TRAIL-R1/R2-specific antibodies whereas TRAIL- 
R3 and -R4 were not involved. When human blood-derived DC were examined, 
immature DC was susceptible to TRAIL whereas mature DC was not. Also, while 
the TRAIL-R surface expression pattern did not change upon DC maturation 
cFLIP levels increased over time in DC. The increase in cFLIP expression may, 
thus, be responsible for TRAIL resistance of fully mature DC. Human peripheral 
blood T cells were not efficiently killed by TRAIL (always less than 5%) when 
stimulated by conventional means. In conclusion, the decoy concept awaits 
confirmation in non-overexpression systems and the biochemical function of the 
non-apoptosis-inducing receptors, TRAIL-R3, TRAIL-R4, and OPG, remains 
unsolved. Taken together, cFLIP seems to be one of the prime candidates as an 
intracellular regulator of TRAIL sensitivity versus resistance in a number of 
different cell types. Yet, other intracellular inhibitors of apoptosis are likely to be 
involved in resistance to TRAIL. TRAIL-induced apoptosis is enhanced by the 
level of HBV replication in human hepatocytes, in part, by HBxAg-dependent 
upregulation of TRAIL-R1/DR4 (Janssen et al., 2003; Krieg et al., 2003). TRAIL 
treatment in combination with chemo- or radiotherapy enhances TRAIL 
sensitivity or reverses TRAIL resistance by regulating the downstream effectors. 
Efforts to identify agents that activate death receptors or block specific effectors 
may improve therapeutic design (Wang and El-Deiry, 2003). Finally, in support of 
the role of apoptosis in calcification in vivo, mice lacking matrix Gla protein or 
osteoprotegerin develop medial vascular calcification and both proteins have 
potential roles in apoptosis (Proudfoot et al., 2000). However, there is no 
sufficient evidence in the study of the role of TRAIL-rTRAIL system in arterial 
systems.
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4.5 Treatment Potential of TRAIL
The property of TRAIL to kill tumour cells more efficiently than normal cells 
implies a clinical treatment potential of TRAIL in vivo. TRAIL treatment might be 
combined with chemo- or radio-therapy, improving TRAIL efficacy (Wu et al.,
2004). Because recombinant forms of TRAIL can successfully eradicate human 
tumours in mice, without unwanted toxicity (Wu et al., 2004), TRAIL has been 
hypothesised to be a key component of anti-tumour immunity in vivo. For 
example, in the study of prostate cancer, combination of doxorubicin and an 
antibody to TRAIL-R1 were found to have therapeutic potential for the treatment 
of prostate cancer by selectively targeting malignant prostate cells (Voelkel- 
Johnson, 2003). TRAIL was also found to be capable of inhibiting tumour growth 
in the absence of any overt toxicity in mice. These suggest TRAIL anti-tumour 
potential.
Most chemotherapeutic drugs and radiation therapy used in the treatment of 
malignancies lead to apoptosis primarily by engagement of the mitochondrial 
pro-apoptotic machinery (Russo et al., 2006). Since TRAIL leading apoptosis by 
both pathways, it combined with different chemotherapeutic drugs have been 
seen synergistic induction of apoptosis. Systemic administration of recombinant 
TRAIL, but not FASL, selectively kills tumour cells while sparing normal host cells. 
Additionally, it is supported by a observation that TRAIL can inhibit DNA 
synthesis and provides direct evidence that TRAIL can prevent G1 to S phase 
progression of lymphocytes (Song etal., 2000). Also in many cases Bcl-2 or Bcl- 
xL overexpression is the reason for therapy resistance. TRAIL can bypass the 
anti-apoptotic effect of Bcl-2 or Bcl-xL overexpression in some tumour systems 
(Sinicrope and Penington, 2005). Thus, it could be an alternative therapy for 
tumour treatment.
Two major biochemical pathways lead to the induction of apoptosis under 
physiological conditions: the death receptor pathway and the mitochondrial 
pathway as mentioned in the last section. In many cancer cells one of these 
pathways or both pathways are blocked due to mutations in genes encoding 
proteins that are part of the apoptotic cascade or due to over expression of 
genes that code for anti-apoptotic proteins (Wajant, 2006). This results in the 
incapability of the cancer cell to die when triggered by physiological means.
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Consequently, the equilibrium between cell growth and cell death is unbalanced. 
In recent years the most currently used post-operative cancer therapies - i.e. 
radiation and chemotherapy - achieved therapeutic effect by killing tumour cells 
via induction of apoptosis (Toloza etal., 2006). Both chemotherapy and radiation 
mainly trigger the mitochondrial apoptotic machinery of cancer cells (Watson and 
Fitzpatrick, 2005). These therapeutic measurements often fail in the long run 
because the tumour develops therapy-resistance by generating variants of the 
original tumour cell which are resistant to apoptosis induction via the 
mitochondrial pathway.
4.6 Summary and Formulation of hypothesis
Abdominal aortic aneurysm (AAA) rupture accounts for 10,000 death annually in 
UK (Dawson et al., 2006). It is possible to detect AAA occurrence at a very early 
stage by the modern diagnosis methods including X-ray, CT scan and ultrasound 
(Cates, 1997). However, surgical repair is the only treatment to reduce the 
chance of AAA rupture (Dawson et al., 2006). The Nature Medicine of 11th, 
December, 2005 issued a new possibility in medical treatment of AAA regression 
(Yoshimura et al., 2005). This inspires the other potential of pharmacotherapy 
studies.
Abdominal aortic aneurysm is associated with Atherosclerosis (Prisant and 
Mondy, III, 2004). It has been suggested that atherosclerosis or VC are events 
which are similar to osteogenesis. Osteogenesis involves four possible 
phenomena: activation of osteogenesis, loss of inhibitory factors, enhanced bone 
turnover and abnormalities in mineral metabolism. A number of proteins have 
also been suggested to be concerned. They are OPG, RANKL and RANK 
(Dellegrottaglie etal., 2006).
Apoptosis was found in human and animal AAA (Thompson et al., 1997). A role 
for apoptotic bodies has also been implicated in AAA. Apoptosis might result in 
the SMC layer of AAA becoming thinner (Dellegrottaglie etal., 2006), resulting in 
AAA dilation or rupture (Prisant and Mondy, III, 2004). TRAIL is a member of 
TNF family which has five known receptors. Osteoprotegerin is one of its decoy 
receptors to inhibit the apoptosis induced by TRAIL. Hence, TRAIL and its
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receptors appear to be a strong link between apoptosis and osteogensis. The 
possibility shed a light for us to study of the role of TRAIL and its receptors 
(TRAIL-rTRAIL system) in the AAA.
Human lung cancer cells (immortal in normal medium) were observed to die in 
half an hour when human breastmilk was included in the medium. The same 
study also showed that breastmilk can kill immature cancer cells but not mature 
ones by the very common milk protein called alphalactalbumin through apoptosis 
(Hakansson et al., 1995). Osteoprotegerin has been found to be in the human 
breast milk (Vidalk etal., 2004). Also OPG has been used in the clinical trials for 
bone disease treatment. Thus, it is great potential to use OPG as a medical 
treatment.
It is hypothesised whether TRAIL can be a novel treatment for vascular 
calcification cause of TRAIL inducing apoptosis by both apoptotic pathways but 
mainly by direct caspase pathway, also of TRAIL having two different types of 
receptors while decoy receptors to be induced into human to prevent the 
apoptosis. However, the physiological role of the TRAIL system is still unclear. 
Above all, every single clinical treatment about TRAIL should all base on the 
truth which is vascular calcification is initiated by apoptosis induced by TRAIL at 
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5.1.1 TRAIL-rTRAIL system expression in calcified 
vessels
Increased aortic calcification has been shown to be associated with bone density 
loss in humans (Schulz et al., 2004). As OPG deficiency is known to result in 
human osteoporosis, it is important to investigate OPG in VC. Firstly, serum 
OPG levels were reported to be associated with human vascular diseases 
(Brandstrom et al., 2002) and are positively correlated with the progression of 
coronary artery disease (Jono et al., 2002). Secondly, OPG can be produced by 
various tissues, including the cardiovascular system where it is released by 
vascular endothelial cells. In addition, mice lacking OPG developed not only 
bone density loss (osteoporosis) but also showed extensive calcification in the 
medial and subintimal regions of the ascending aorta, and intimal calcification in 
the renal arteries (Bucay et al., 1998). Furthermore, both of these clinical 
manifestations in OPG-treated mice are completely prevented by the restoration 
of OPG (Min et al., 2000). Taken together, it has been proven that OPG is 
involved in osteoporosis and VC. However, the mechanism of the OPG effect in 
VC is still uncertain.
Osteoprotegerin is a decoy receptor of TRAIL which acts as an inhibitor of 
apoptosis induced by the latter. TRAIL induces apoptosis in vascular SMCs and 
endothelial cells in culture and increases TRAIL decoy receptors in vivo and in 
vitro (Gochuico et al., 2000). Smooth muscle cells and endothelial cells have 
been found in atherosclerotic plaques and express calcification-related proteins 
that are commonly found in bones, e.g. MGP, osteocalcin (often acts in the bone 
formation), osteonectin (may acts in the tissue mineralisation) (Giachelli et al.,
2005). As discussed in chapter 2, these proteins contain calcium and apatite 
properties and accumulate in the areas of calcification (Geng et al., 1996). 
Additionally, the number of SMCs in the intimal layer increases during 
atherogenesis, and apoptotic SMC and endothelial cells have been discovered in 
vascular injuries and areas of inflammation (Gochuico et al., 2000). A soluble 
form of TRAIL is required in cells in these processes. The generation of TRAIL 
involves the action of cysteine protease (Mariani and Krammer, 1998) which is
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enriched in the human vessel wall (Chapman et al., 1997). Thus, there is a 
strong possibility that TRAIL-induced apoptosis participates in VC.
5.1.2 Abdominal aortic aneurysm, osteoporosis and 
vascular calcification
Atherosclerosis and abdominal aortic aneurysms (AAA) have been found to be 
positively correlated (Matsushita et al., 2000) and calcified plaques are often 
found in the walls of aneurysms (Jorgensen et al., 2004). Predisposing risk 
factors for AAA and atherosclerosis are similar to those for osteoporosis, such as 
smoking, low serum levels of high density lipoprotein (HDL), cholesterol, high 
serum levels of low density lipoprotein (LDL), and hypertension (Blanchard, 1999; 
Singh etal., 2001). These all suggest that there might be some link between the 
three clinical manifestations. Atherosclerosis has been proven to be associated 
with osteoporosis (Schulz et al., 2004). However, bone mineral density has not 
been found to have any relation to the prevalence of AAA in a majority of elderly 
men and women. There may be a possible association in younger men and 
women, but this needs further confirmation (Jorgensen etal., 2004).
All this strongly suggests that the interaction of TRAIL and its receptors, including 
OPG, might play a role in the calcifying process during the formation of AAA.
5.1.3 Computer tomography (CT) scan
A number of non-invasive imagining techniques are available for assessing the 
presence of vascular calcification. Plain X-ray, echocardiography and ultrasound 
can be used to identify the presence of vascular calcification but not to quantify 
its extent. In contrast, CT scan can be used to quantify calcification as well as 
being a highly effective way of detecting and accurately localising plaques 
anywhere in the body. This is due to its ability to differentiate calcium from 
adjacent soft tissues (Stanford and Thompson, 1999).
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5.1.4 Reverse transcription-polymerase chain reaction 
(RT-PCR)
Numerous procedures have been used for detecting and determining the 
abundance of a particular mRNA in a total RNA sample. The most popular 
methods are: Northern blot analysis, Nuclease Protection Assays, in situ 
hybridisation, and reverse transcription-polymerase chain reaction (RT-PCR). 
Among those techniques, RT-PCR is a very sensitive method for qualifying and 
quantifying of mRNA from very small amounts of tissue and cells. The AAA 
samples obtained from elective surgeries were largely calcified tissue and of 
small amounts. Since RT-PCR is inexpensive, rapid, simple and sensitive for 
small amount samples, it was used for mRNA analysis in this project.
Figure 5.1 This diagrammatic picture mimics that the process in the PCR 
tube. DNA double helix is separated in the denaturation step. Then primers 
bind to single DNA strand which is called annealing. Finally, the process of 
DNA copy completes.
Specific sequence primers of TRAIL-rTRAIL system were applied (see Table 5.1 
Sequence of primers used.). An internal control that was multiplexed in the same 
RT-PCR reaction with the gene specific primers was used. The human house­
keeping gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and p- 
actin were used as internal positive controls and placenta was used as an 
external positive control. The signal from the internal positive controls was used
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to normalise sample data to account for tube-to-tube differences caused by 
variable RNA quality or RT efficiency, inaccurate quantitation or pipetting. For 
RT-PCR data to be meaningful, the PCR reaction was terminated when the 
products from both the internal control and the gene of TRAIL-rTRAIL system are 
detectable. Because housekeeping genes are highly abundant, their 
amplification only needs very few PCR cycles.
The same PCR program works slightly different on different thermocyclers (PCR 
machine) because the temperature and time profiles vary depending on the 
manufacture construction, therefore it is necessary to test the best PCR 
programme for each primer pairs for optimal results. The same volumes of cDNA 
from same sample were tested by using different annealing temperature. The 
PCR products were then tested for the band density. Eventually, the most 
suitable PCR programme was decided.
5.2 Aims and Objective
•  To determine whether TRAIL and its receptors are expressed in normal
control tissues
•  To determine whether TRAIL and its receptors are expressed in calcified
AAA tissues
•  To determine whether there are gene expression differences of TRAIL and
its receptors’ expression between normal control samples and AAA
samples
•  To determine whether there are variations among TRAIL and its receptors
in tissues with different level of calcification
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5.3 Materials and methods
5.3.1 Computer tomography (CT) scan material and 
methods
5.3.1.1 Samples
The CT Scans used in this analysis were from patients who had undergone AAA 
repair and had supplied samples for the other parts of this study. This study 
group included 5 females and 20 males with an age range from 59 to 96 years 
(mean age 76±7 years). More than half of the patients (55%) had hypertension, 
17% had hypercholesterolemia, and 78% were ex-smokers or current smokers. 
None of them had diabetes mellitus, hypocalcaemia or chronic renal failure. Most 
patients (78%) had various other vascular diseases. The maximum diameters of 
these 25 patients AAA were from 5cm to 8.3cm (mean diameter 6.5 ±1 cm).
5.3.1.2 Methods
A CT scanner is a special type of X-ray machine that is used to produce images 
of the inside of the body. Images can be produced through many different levels 
(termed slices) of the area of interest. The image slices are black, white and grey 
providing detailed information and can be built up by computer software to give a 
three dimensional view. Patients are scanned while awake and without the need 
for any anaesthetic. They simply lie on a table which slides through the scanning 
machine. The table is positioned to make sure the part of the body being 
examined within the machine. Also it moves backwards or forwards when each 
new image slices were taken. The scanner can rotate around the target body 
parts. Each image was obtained with 100-millisecond scan time and 10-20 mm 
slice thickness. Twenty slices were required to include the entire abdominal aorta 
area (Raggi, 2005; Stanford and Thompson, 1999).
Professional radiologists use an aortic calcification score (AC score), which is
calculated as the product of calcified area by its density, to reflect the amount of
calcium deposition of the calcified plaque. In this study the AC score was semi-
quantitatively derived by averaging the scores of 2 individual experienced
investigators. In the AC score scoring system used here, 0 represents no
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calcification; 1 represents speckled calcification (figure 5.3-1 a); 2 represents 
plaques of calcification (figure 5.3-1 b) and 3 represents continuous calcification 
(figure 5.3-1 c). Therefore the larger the score refers the more severe the 
calcification.
Figure 5.2 Representative CT scans of AC scores. Calcified tissue 
(normally appearing in bone or teeth in human), is depicted as bright areas 
on a CT scan. The representative CT scans shown are of AAA 
demonstrating enlarged aortic artery and thinned aortic wall. The white 
condensed area, indicated by the red arrows, on the aortic wall are 
considered as calcium deposition on a standard CT scan. Panel a shows 
speckled calcification (Score 1). Panel b shows plaqued calcification (score 
2) and panel c shows continuous calcification (score 3), note this scan was 
done with an intravenous contrast medium to also highlight blood filled 
organs.
Score 1: speckled calcification
Score 2: plaque calcification
k- Score 3: continuous calcification
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Calcification scores were obtained form the proximal outer layer, proximal inner 
layer, body outer layer, body inner layer, distal out layer and distal inner layer of 
each AAA examined. Proximal AAA represents the nearest point of the AAA to 
the heart. Body AAA represents the centre of the enlarged or swollen aorta at the 
point of the aneurysm. Distal AAA represents the farthest point of AAA from the 
heart close to the iliac artery. Inner layer stands for intimal and medial layer of 
vascular wall and the outer layer stand for adventitial layer of vascular wall.
5.3.1.3 Statistical analysis
The AC scores of all the areas examined were analysed by ANOVA for multiple
comparisons. Paired analysis between two groups (e.g., between proximal and 
body AAA) was performed by paired t test when ANOVA indicated significance 
for the multiple comparison.
All analyses were performed using the GraphPad Prism Instat package, Version
3.02, GraphPad Software Inc., San Diego USA. Differences were considered at 
*P <0.05 levels and confidence >95%. All error bars are ± standard error of the 
mean (SEM). One star refers to *P< 0.05 and two stars refers to **P< 0.01. 
Three stars refers to ***p< 0.001.
5.3.2 Gene expression
5.3.2.1 Samples
Vascular calcification occurs frequently in advanced atherosclerotic lesions. 
However it has been documented that there are different genetic mechanisms 
involved in the pathology of VC and atherosclerosis(Schinke and Karsenty, 
2000). All samples used were obtained from AAA repair surgery from end-stage 




As described in section 2.2, the abdominal aorta begins at the aortic hiatus of the 
diaphragm, in front of the lower border of the body of the last thoracic vertebra, 
and, descending in front of the vertebral column. It ends at the body of the fourth 
lumbar vertebra, commonly a little to the left of the middle line, by dividing into 
the two common iliac arteries (Gray H., 1918). It carries the blood and oxygen 
from the heart to the lower portion of the body. Surplus aorta tissue distal to the 
infra-renal artery on donor kidneys was considered as normal controls for AAA. 
Because most of the samples were frozen for transport and storage they are the 
best to be used for extracting mRNA and protein and not for histological analysis. 
Paraffin embedding for histology and cell culturing were performed occasionally 
when fresh normal aorta was obtained.
Umbilical artery obtained from donated umbilical cords was also used as normal 
control in early studies for this project. The umbilical arteries follow the 
hypogastric arteries where are along side the bladder and embed in the umbilical 





Figure 5.3 Anatomic structures of umbilical arteries and normal aorta. 
Umbilical arteries as red arrow indicated in the left picture, (from Henry
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Gray on-line resource). Normal aorta sample as red circle indicated in the 
right picture, (from www.wiheart.cardiolohydomain.com)
5.3.2.3 Abdominal aortic aneurysms
Abdominal aortic aneurysm is defined as a focal dilation of the aorta which is 1.5 
times greater than normal aorta diameter. It appears a bulging or ballooning out 
in the arterial wall which is characterised as atherosclerosis (Upchurch, Jr. and 
Schaub, 2006). Smoking, hypertension or family history (especially in male (Salo 
et al., 1999)) are the risk factors for AAA (Alcorn et al., 1996). A Swedish study 
conducted from 1958-1986 documented AAA rising rapidly in men from the age 
of 55 and in woman from the age of 70 (Ernst, 1993). The mechanism 
responsible for AAA still needs to be elucidated.
Normally, AAA has no obvious clinical symptoms. It can be detected by X-ray or 
by imaging techniques such as echocardiography, magnetic resonance imaging 
(MRI) and CT scan. When AAAs rupture, massive internal bleeding will occur 
that is fatal without immediate intervention (Upchurch, Jr. and Schaub, 2006).
To date, surgery is the only effective treatment for AAA (www.surgical- 
tutor.org.uk, 2006). An artificial piece of blood vessel is used to replace the 
diseased tissue in the open aneurysm repair. Aneurysms for this project were 
taken from elective open surgeries (n=25) or emergency aneurysm rupture repair 
(n=6) as calcified samples. The fresh samples were dissected into the proximal 
(2cm from aneurysm body and close to the heart, referred to as the neck of AAA), 
the body (the biggest dilation in the AAA) and the distal regions (2cm from 
aneurysm body and away from the heart, often this was iliac artery). The 
aneurysm sample was also separated into outer (tunica adventitia and outer 
tunica media of aortae) and inner (tunica intima and tunica neointima of aortae). 
The intimal layer is thicker which is called tunica neointima and the tunica media 
is thinner in the AAA (Crawford etal., 2003; Ernst, 1993).
The aneurysms are divided into two classed based on their shape: fusiform and 
saccular aneurysm. Fusiform aneurysm is enlarged evenly in all directions and
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saccular aneurysm only occurred in one side of aortic wall. Among all samples 
obtained, there are 29 fusiform aneurysms and 2 saccular aneurysms.
Fusiform Aneurysm U trJer Aneurysm
Figure 5.4 The diagrams of fusiform aneurysm (left) and saccular aneurysm 
(from www.csmc.edu)
Samples were snap frozen in liquid nitrogen (N2) for total RNA and total protein 
isolation, or stored in specimen pots with 10% formol saline for paraffin bedding. 
Cultured SMCs were extracted from the medial layer of the aneurysms.
Figure 5.5 Computer tomography scans of AAA. The diameter of the aorta 




Figure 5.6 A diagramtic picture and a photo of AAA speciment. Panel a 
shows a diagrammatic picture shows that dissection of AAA as performed 
in this project. (From www.stanfordhospital.com) Panel b shows a 
representative photo of the AAA specimens. Black arrow indicates the 
inner later of the AAA displaying yellow atherosclerosis plaque. The black 
arrow heads indicate the proximal, body and distal region of the AAA in the 
order from top to bottom.
5.3.2.4 Gene expression materials and methods
5.3.2.4.1 Total RNA extraction
• Chloroform, Sigma-Aldrich Co Ltd, Poole, UK
• Diethyl pyrocarbonate (DEPC), Sigma-Aldrich Co Ltd, Poole, UK
• Ethanol, Sigma-Aldrich Co Ltd, Poole, UK
• RNAse free tubes, Abgene Inc., Rochester, NY
• RNAse free water, Gibco, Life Tech, Paisley, UK
• Isopropanol, Sigma-Aldrich Co Ltd, Poole, UK
• Total RNA isolation reagent, Abgene Inc., Rochester, NY
Freshly obtained AAA specimens were stored in sterile tubes at 4°C before
homogenisation. Two methods for RNA extraction were evaluated because the
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method of mRNA extraction affects the outcome of PCR (Boom et al., 
1990;Villahermosa etal., 2000). These methods were the liquid nitrogen method 
and the homogeniser machine (Ultr-Turrax T25 Homogeniser, IKA, Germany) 
methods prior to RT. Results obtained by the both methods or their combination 
were compared in three aspects: the proportion of amplified samples, RNA purity, 
and band intensity.
When the tissue is removed from the human body, the rapid onset of action of 
degradative enzymes occurs which starts the process of autolysis. Thus, fresh 
samples were fast frozen in the liquid nitrogen and cut into small pieces in order 
to extract RNA. Then these samples were ground thoroughly at cryogenic 
temperature prior to homogenisation in the total RNA isolation reagent (TRIR). 
The first method is based on a lysis-centrifugation process followed by a column 
filtration through a silica membrane in an RNase-free glass tube starting with 50 
pi of TRIR. In detail, tiny specimens were ground with mortar and pestle into fine 
power and then transferred into the glass tube with 50 pi TRIR. Press the handle 
of the glass tube to squeeze the solution. Gradually add 50 pi TRIR each time 
until samples were entirely homogenised. The second method is based on the 
manual instruction of STAT-60. The TRIR solution was added into the samples 
before machine homogenisation on ice. RNA extracts obtained by these two 
methods were tested in parallel for RNA purity and RNA band intensity after RT.
In conclusion, the second method is more reliable. It could be because its high 
efficiency to breakdown the cells and homogenise samples more quickly. In 
summary, total RNA was extracted from freshly frozen sample in DEPC treated 
tubes (see appendix A). Samples were added about 1ml total RNA isolation 
reagent/ 0.1g sample. The mixture was then homogenised thoroughly and 
transferred to Eppendorf tubes (about 1.0ml/ per tube). These Eppendorf tubes 
were incubated on ice for 5 minutes followed by addition of 0.2ml chloroform /  
1ml RNA Isolation reagent, shaking well for 15 seconds by hand. They were 
returned to ice for 5 minutes and then centrifuged at 12,000 rpm for 15 minutes 
at 4°C. The aqueous phase was transferred to fresh tubes (approximately 1ml 
each). Isopropanol (0.5ml) was added to each sample then samples were stored 
on ice for 10 minutes. They were centrifuged at 12,000 rpm for 10 minutes at 4°C. 
Supernatant was removed and 1ml 75% ethanol was added to each tube,
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shaking well by hand. These tubes were centrifuged at 7,500 for 5 minutes at 
4°C. Repeat above two steps. The tubes were air-dried for approximately 10 
minutes. Eventually, RNA were added with 10-20pl RNase free water and stored 
in -80°C freezer for future study.
5.3.2.4.2 RT-PCR materials and methods
•  Agarose, Fisher Scientific UK Ltd
• Ethidium bromide, Fisher Scientific UK Ltd
• RNAse free PCR tube, Abgene Inc., Rochester, NY
• RNAse free water, Gibco, Life Tech, Paisley, UK
• RT-PCR reaction kits, including oligo-dT, 5X strand synthesis buffer, MgCI2,
RNAse inhibitor, dNTP-mixer, RT, RCR mixer, Promega, UK
• Human p-actin primes, R&D system, UK
• Human GAPDH, TRAIL, TRAIL-R1, TRAIL-R2, TRAIL-R3, TRAIL-R4 , OPG,
RANK, RANKL primers, Invitrogen, UK
Total RNA was quantified by using spectrophotometric absorption at 260nm 
(UV1101 Biotech Photometer). Total RNA sample (2pl) was mixed with 198 pi 
RNAse-free water. The reading of photometric absorption at 260nm (A260), 280 
nm (A280) and the ratio of A260/A280 were recorded. The concentration of RNA 
was calculated according to the equations below. The purity of RNA was 
assessed by the ratio of A260/ A280. A high purity of RNA has the ratio of 1.8- 
2.0 (Wilfinger etal., 1997).
RNA concentration = 40pg/ml x A260 X  dilution factor (2pl RNA in 200 pi liquid).
Total RNA pg/ml = concentration x volume of sample (ml).
RNA was reverse transcribed to cDNA by RT according to the Promega kit 
instruction manual. Total RNA (1pg) was added with 1pl oligo-dT with enough 
RNase free water to make up the total volume to 5pl. The mixture was heated 
briefly at 70°C for 5 minutes for denaturation. Then 4pl 5X strand synthesis 
buffer, 2 pi MgCI2, 1 pi RNase inhibitor, 1 pi dNTP-mixer and 0.5pl RT and 6.5pl 
RNase-free water were added to the mixture. The tubes were incubated at 25°C
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for 5 minutes then 42°C for 1 hour, final extension were processed at 75°C for 10 
minutes in the thermal cycler (Peltier Thermal Cycler PTC-200). Final products 
were stored at -80°C for future use or in ice for subsequent PCR.
PCR was carried out to elucidate the clear picture of mRNA expression. GAPDH 
or B-actin was used as internal positive control. The primer pairs used for PCR 
amplification of the cloned sequence that were eventually used for cDNA probe 
preparation are shown in Table 3. PCR was performed in a final volume of 50 pi 
containing 1pl cDNA of a defined specimen, 1pl of each primer for housekeeping 
gene and OPG, RANK, RANKL or 5pl of each primers for TRAIL and its other 
four receptors, 25pl PCR mixer and RNase water. Individual PCR programme 
were employed for every PCR target (see table 3). PCR products were loaded, 
10pl per well, alongside a 100bp DNA ladder and electrophoresed in 1.2% 
agarose gels (see appendix A for recipe for gel). Specific products were 



















Table 5.1 Sequence of primers used.
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Target gene Denaturation Annealing Extension cycles
TRAIL 95°C for 45 Sec 55°C45Sec 72°C60Sec 35
TRAIL-R1 95°C for 45Sec 60°C45Sec 72°C60Sec 35
TRAIL-R2 95°C for 45Sec 60°C45Sec 72°C60Sec 35
TRAIL-R3 95°C for 45Sec 58°C45Sec 72°C45Sec 35
TRAIL-R4 95°C for 45Sec 58°C45Sec 72°C60Sec 35
OPG 94°C for 45Sec 55°C45Sec 72°C45Sec 35
GAPDH 94°C for 45Sec 55°C45Sec 72°C45Sec 35
RANK 94°C for 45Sec 65°C45Sec 72°C45Sec 30
RANKL 94°C for 45Sec 55°C45Sec 72°C45Sec 35
B-actin 94°C for 45Sec 55°C45Sec 72°C45Sec 35
Table 5.2 PCR programs for target gene.
5.3.2.4.2 O ptim isation and sem i-quantitation
Final PCR gel image was exposed to UV light and then captured by digital 
camera within the Syngene machine. The equipment allows for adjustment of 
exposure time to produce an optimal best image on the screen.
The images then saved as .TFT file for digital analysis by an image densitometry 
system (Scion image software, http://www.scioncorp.com accessed, see 
appendix A for more details). The image was first inverted and then a 
measurement area mask was selected of sufficient size to include the largest 
band to be analysed. The mask was applied to all the bands and the software 
gave a calculation of the band density. The software gives final results according 
to the volume (density x area). The amount of cDNA was normalised to the 
internal positive control (GAPDH).
5.3.2.4.3 Statistical analysis
All mRNA data were presented normalised to GAPDH mRNA. The analyses 
were carried out in duplicate. Comparisons between groups for study variables 
were made using the unpaired t test for normal distributions and Mann-Whitney 
u-test for non-normal distributions. The differences of mRNA expressions were 
analysed by ANOVA for multiple comparisons. Paired analysis between two
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groups (e.g., between proximal and body AAA mRNA expression) was 
performed by paired t test when ANOVA indicated significance for the multiple 
comparison. The linear regression test (Pearson test) was used to determine the 
correlation between mRNA expression in the TRAIL-rTRAIL system. Differences 
were considered at *P <0.05 levels and confidence >95%. All error bars are ± 
standard error of the mean (SEM). One star refers to *P< 0.05 and two stars 
refers to **P< 0.01. Three stars refers to ***p< 0.001.
All analyses were performed using the GraphPad Prism Instat package, Version
3.02, GraphPad Software Inc., San Diego USA.
5.4 Results
5.4.1 Calcification level of CT Scan
The calcification level by preoperational CT scan was quantified by two 
independent consultant vascular surgeons. Out of 31 AAA donors, 27 CT scans 
were examined the remaining 3 patients, who underwent emergency repair after 
rupture did not have a preoperational CT scan. Proximal, body and distal regions
of each AAA were given AC score respectively.
Proximal Body Distal Proximal Body Distal
1 1 1 2 2 3
0 1 0 1 2 3
1 1 1 1 2 3
0 1 0 0 1 2
0 1 1 1 1 2
1 1 0 1 1 2
1 2 1 1 1 2
1 2 1 1 1 3
1 2 1 1 2 2
0 _ u 0 2 1 3
1 2 1 1 2 1
0 1 0 0 2 1
0 1 1 1 1 2
2 1 2
Table 5.3 shows the semi-quantitative AC scores of all examined AAA 
areas of 27 patients. As discussed in the methods, O is equal to non­
calcification. 1 is equal to speckled calcification. 2 is equal to plaqued 
calcification. 3 is equal to continuous calcification.
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proximal Body distal
Figure 5.7 AC score of proximal, body and distal lesions of AAAs. Distal is 
the most calcified areas and proximal is the least calcified areas according 
to CT scan. Proximal calcification level is significantly less than distal area 
(*p< 0.05, one way ANOVA test, confidence > 95%); so does body area (*p< 
0.05, one way ANOVA test, confidence > 95%).
5.4.2 Assay development
Following representative pictures are RNA isolated by different isolation methods 
running on the 1.2% argarose gel as described in the methods.
An efficient and accurate method for isolation of RNA from AAA tissue is very 
important. It is the first step for the entire RT-PCR procedure and the good 
quality mRNA is necessary for PCR results.
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NIsolated mRNA from AAAs
P1 P 2 H 1  H2 H3 H4 H5 H6 H7 H8 H9 H10H11 H12
Figure 5.8 Comparsion of isolated RNA from AAA by two isolation methods. 
They were run on the 1.2% agarose gel. Total RNA was isolated by two 
methods as described in the methods section. P1 and P2 represent good 
quality RNA which was isolated by homogeniser on ice. H1 to H12 
represent bad quality RNA which was isolated by unsuccessful extraction 
methods. The RNA has broken down and shows a much lower band 
density than that of P1 and P2 because the original gel has been exposed 
maximally. The red arrows indicate that 18sRNA (top arrow) and 28sRNA 
( bottom arrow) running in the gel.
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Comparison of normalised gene controls
GAPDH (3-actin
Figure 5.9 The comparison of GAPDH (600bp) and 13-actin (500bp) 
expression. Two 1.2% electrophoretic gels of cDNA isolated from AAA. 
Four PCR amplified cDNA were shown in each gel. GAPDH was used as 
primers in the gel a, and 13-actin was used as primers in the gel b. Red 
arrows indicated the size of PCR products. It is clearly shown that gene 
expression for GAPDH in all four AAA samples and two of samples 
expressions for 13-actin were absent. Thus, GAPDH is better to be used in 
the AAA studies.
5.4.3 Messenger RNA expression in normal controls
The abdominal aorta is that part of aorta that passes from the diaphragm and 
continues down the abdomen. It ends where it divides to form the two iliac 
arteries that go to the legs (Gray H., 1918). Normal aorta samples obtained from 
kidney donors are mainly iliac lesions of the aorta. Thus, they are a most suitable 
normal control sample for the study of AAA.
The umbilical artery is comparatively much easier to access than the normal 
aorta. For that reason, the mRNA expression for TRAIL and its receptors were 
compared in an umbilical artery and a normal aorta. The placenta was regarded 
as an external positive control and GAPDH was applied as the internal positive
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control. GAPDH was expressed in all three samples, confirming the presence of 
cDNA. TRAIL and all its five receptors were expressed in the placenta and 
umbilical artery, but in contrast, TRAIL and TRAIL-R1 were not detected in the 
normal aorta. Thus, the umbilical artery is not the best normal control sample for 
the study of the TRAIL-rTRAIL system in AAA samples. The normal aortic 
samples as positive controls are better than umbilical arteries. Consequently 
normal aortae were used as a normal control.
It is well known that the placental circulation is cut off immediately at birth and 
umbilical arteries actually carry venous blood. These two facts could be reasons 
of the mRNA differences between normal aorta and umbilical artery but there is 
no evidence.
Figure 5.10 The relative abundance of mRNA expression (normalised to the 
level of GAPDH mRNA expression, semi-quantitative) in the umbilical 
artery, placenta and normal aorta. It shows clearly that this normal aorta 
lacks TRAIL and TRAIL-R1 mRNA, and there is a visible difference between 
the umbilical artery and the normal aorta.
mRNA expression for TRAIL-rTRAIL system 
(comparison among normal control samples)
0> 0
TRAIL TRAIL-R1 TRAIL-R2 TRAIL-R3 TRAIL-R4 OPG 
TRAIL & its receptors
■  umbilical artery ■ the medial layer of normal aortaB placenta
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TRAIL-R4 OPG
GAPDH TRAIL TRAIL-R1 TRAIL-R2
TRAIL-R3 
V  -
Figure 5.11 These gel images demonstrate the mRNA expression of 
umbilical artery and normal aorta. UA represents umbilical artery; PL 
represents placenta and NA represents medial normal aorta. These PCR 
products were loaded and run on 1.2% agarose/TBE analytical gels and 
stained with ethidium bromide. The PCR products were then compared 
with the standard, loaded in the same gel. The red arrows indicate the size 
of the samples on the DNA ladder. Panel a indicates the PCR products for 
GAPDH (600bp); the normal aorta showed a lower expression level than 
the other two products. Panel b indicates the PCR products for TRAIL 
(443 bp) and there was a missing band for the normal aorta. Panel c 
indicates the PCR products for TRAIL-R1 (506 bp); panel d indicates the 
PCR products for TRAIL-R2 (502 bp); panel e indicates PCR products for 
TRAIL-R3 (512bp); panel f indicates PCR products for TRAIL-R4 (453 bp); 
and panel g indicates PCR products for OPG (371 bp).
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5.4.4 Messenger RNA expression for TRAIL-rTRAIL
system in normal aortae
Messenger RNA expressions for TRAIL-rTRAIL system by RT-PCR were carried 
out in eight normal aortic vessel walls. According to the level of their TRAIL 
mRNA expression, they were separated into two groups for analysis. Group 1 
includes five normal aortic samples whose GAPDH mRNA was expressed at a 
lower level than that of the placenta samples. Group 2 includes three normal 
aortae whose GAPDH mRNA was expressed at a similar level to that of the 
placenta.




CC TRAIL R1 R2 R3 R4 OPG
■  normal aorta 1 ■  normal aorta 2 ■  normal aorta 3
■  normal aorta 4 ■  normal aorta 5
Figure 5.12 This graph illustrates the mRNA expression of TRAIL 
(normalised to GAPDH) and its receptors in group 1 normal aortae. A 
similar trend is found in individual normal aorta in the group 1 although big 
differences were observed between one and another. The highest bar of 
each sample symbolises the mRNA expression of TRAIL-R2 and the lowest 
point of each one symbolises the mRNA expression of TRAIL-R1. Decoy 
receptors are expressed higher than death receptors and TRAIL.
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Group 1 norm alaortae
a TRAIL-rTRAIL in a normal aorta GAPDH
TRAIL R1 R2 R3 R4 OPG
Figure 5.13 This representative gel image shows eight PCR reactions for 
group 1 normal aortae. The reactions amplified TRAIL, TRAIL-R1, TRAIL- 
R2, TRAIL-R3, TRAIL-R4 and OPG gene as shown in graph a. An aliquot of 
each product was loaded and run in the same 1.2% agarose/ TBE gel and 
stained with ethidium bromide. The PCR products were then compared 
with the standard and loaded in the same gel. The normal aortic sample’s 
GAPDH (G) was compared to normal standard GAPDH (st) as shown in 
panel b. Negative control (N) of GAPDH (RNase free water) was loaded in 
the lane 1. Positive control of GAPDH was loaded in the lane 2 and normal 
aortic sample was loaded in the lane 3. The normal aortic GAPDH is 
barely observable. The red arrows indicate the size of the samples on the 
DNA ladder. This represents a very low level of expression for TRAIL 
mRNA, whereas TRAIL decoy receptors had much higher expressions 
which were found consistently in group 1 normal aortae.
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Group 2 Normal aortae
Figure 5.14 This representative gel image shows seven PCR reactions that 
were set up on the isolated RNA in group 2 normal aortae. One PCR 
reaction was GAPDH-controlled PCR on the same normal aortic sample. 
The rest of the reactions amplified TRAIL, TRAIL-R1, TRAIL-R2, TRAIL-R3, 
TRAIL-R4, OPG gene as shown here. An aliquot of each product was 
loaded and run in the same 1.2% agarose/ TBE gel and stained with 
ethidium bromide. The PCR products were then compared with the DNA 
ladder and loaded in the same gel. The red arrows indicate the size of the 
samples. This represents a higher TRAIL mRNA expression than in group 
1. TRAIL-R3 was expressed at a very low level that was only detectable on 
the original image. The level of the mRNA expression of TRAIL decoy 
receptors was lower than in group 1 (shown in Figure 5.13).
8 6
mRNA expression for TRAIL-rTRAIL system 
(group 2)
h hit
TRAIL R3 R4 OPG
normal aorta 6 ■ normal aorta 7 □ normal aorta 8
Figure 5.15 This graph shows that a different trend is found in group 2 to 
that found in group 1 (shown in Figure 5.12). The values of mRNA 
expression are normalised to GAPDH. The highest point of each sample 
symbolises the mRNA expression for TRAIL-R2 and the lowest point of 
each symbolises the mRNA expression for TRAIL-R3. The death receptors 
and TRAIL are expressed higher than decoy receptors.
Two completely different trends in mRNA expression in normal aortae were 
found (see Figure 5.12 and Figure 5.15). Among group 1 normal aortae, TRAIL- 
R1 tends to express in a similar way to TRAIL, and the decoy receptors 
appeared highly expressed. In contrast, the decoy receptors in group 2 normal 
aortae showed relatively lower expression than TRAIL and TRAIL-R1. 
Interestingly, TRAIL-R2 retains the highest level of expression among eight 
normal aortae.
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5.4.5 Messenger RNA expression for TRAIL-rTRAIL
system in AAA
Expression of TRAIL and its receptors at mRNA levels was examined by RT- 
PCR in 33 freshly-isolated human AAA specimens. Messenger RNA expressions 
for TRAIL-rTRAIL systems were found in the normal aortae constantly, though 




GAPDH TRAIL R1 R2 R3 R4 OPG
600bp
GAPDH TRAIL R1 R2 R3 R4 OPG
8 8
Distal AAA
Figure 5.16 The representative gel image here shows seven PCR reactions 
that were set up on the isolated RNA for proximal, body and distal AAAs 
as described in methods. One PCR reaction was GAPDH-controlled PCR 
on each AAA sample. The rest of the reactions amplified TRAIL, TRAIL-R1, 
TRAIL-R2, TRAIL-R3, TRAIL-R4 and the OPG gene, as shown here. A 10pl 
aliquot of each product was loaded and run in the same 1.2% agarose/ 
TBE gel and stained with ethidium bromide. The PCR products were then 
compared with the standard, loaded in the same gel. The red arrows 
indicate the size of the samples on the DNA ladder. Panel a indicates gene 
expression on proximal AAA; panel b indicates gene expression on body 
AAA; and panel c indicates gene expression on distal AAA. These three 
gel images show clearly the variable pattern of the mRNA expression for 
TRAIL-rTRAIL systems.
The messenger RNA of TRAIL (76%) was widely expressed on AAA vessel walls 
and the mRNA for decoy receptors was also extensively expressed (OPG 82%, 
TRAIL-R4 75% and TRAIL-R3 70%). Surprisingly, TRAIL death receptors were 
expressed much less frequently on the AAA wall than were decoy receptors. 





■ TRAIL ■ R1 □ R2 □ R3 ■ R4 ■ OPG
Figure 5.17 The summary graph of TRAIL and its receptors in AAA. It 
clearly shows the variable expression in each AAA wall.
5.4.5.1 Correlation of TRAIL and its all receptors in AAA
To explore the relationship between TRAIL and its receptor, correlation tests 
were carried out. In the correlation, the value r represents correlation coefficient 
and r2 represents correlation r squared. A correlation coefficient is a number 
between -1 and +1 which measures the degree to which two variables are 
linearly related. When a positively perfect linear relationship exists between two 
variables, r equals 1. If there is a positive correlation (both variations increase 
and decrease together), then r is greater than 0. Correspondingly, r equals -1 
when a negatively perfect linear relationship between two variables exists. If 
there is a negative correlation (whenever one variation increases another one 
decreases), then r is less than 0 and greater than -1. Value r equals 0, which 


















r 0.79 0.78 0.75 0.67 0.55 0.52 0.28 0.10
r 0.63 0.61 0.57 0.45 0.31 0.27 0.08 0.01
Table 5.4 This table shows positive correlations among TRAIL and TRAIL 
receptors. All decoy receptors share positive correlations. TRAIL-R2 
positively correlates with all decoy receptors. TRAIL positively correlates 









r -0.10 -0.20 -0.24 -0.33
r 0.01 0.04 0.06 0.11
Table 5.5 Negative correlations among TRAIL and its receptors. TRAIL-R1 
has negative correlation with TRAIL and all the receptors apart from TRAIL- 
R3. (n=33)











Coefficients Standard Error tStat
P-
value
0.31 0.11 2.75 0.01
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Coefficients Standard Error tStat P-value
0.46 0.11 4.17 0.003





















Coefficients Standard Error tStat P-value
0.56 0.13 4.34 0.0001
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Correlation of mRNA expression between TRAIL &
TRAIL-R2
* *











Coefficients Standard Error t Stat P-value
0.56 0.11 4.91 4.17
Correlation of mRNA expression between TRAIL &
OPG* *






Coefficients Standard Error t Stat P-value
0.57 0.18 3.05 0.005
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Figure 5.18 These graphs show correlations of mRNA expression among 
TRAIL, TRAIL-R2 and decoy receptors in the AAAs (n=28). Each pair of 
different colour dots on the same X axis refers to the mRNA expression of 
different genes but from the same AAA sample. Panel a represents a 
positive correlation of mRNA expression between TRAIL-R2 and TRAIL-R3 
(significant difference, *P< 0.05). Panel b represents a positive correlation 
of mRNA expression between TRAIL-R2 and TRAIL-R4 (significant 
difference, *P< 0.05). Panel c represents a positive correlation of mRNA 
expression between TRAIL-R2  and OPG (significant difference, *P< 0.05).
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Panel d represents a positive correlation of mRNA expression between 
TRAIL-R2 and TRAIL (significant difference, *P< 0.01). Panel e represents a 
positive correlation of mRNA expression between TRAIL and OPG 
(significant difference, *P< 0.01). All results were tested by linear 
regression (confidence > 95%). Panel f represents a negative correlation of 
mRNA expression between TRAIL and TRAIL-R1. Panel g represents a 
negative correlation of mRNA expression between TRAIL-R1 and OPG.
5.4.6 Comparison between normal aortae mRNA and 
AAA mRNA
5.4.6.1 Frequency of TRAIL-rTRAIL mRNA existence
In comparison, there is no certain pattern of mRNA expression in individual AAA 
samples (see Figure 5.19). TRAIL and its receptors were missing from AAA 
vessel walls. However, mRNA fragments of appropriate size were detected in the 
placenta, which was an external control. Compared with the frequency of mRNA 
expression in normal aortae, TRAIL death receptors were significantly lower in 
AAA. This indicates that TRAIL death receptors might be involved in AAA 
formation.
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Figure 5.19 The graph illustrates the frequency of mRNA expression in 8  
normal aortae and in 33 AAA vessel walls. There is a significant difference
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between the frequency of mRNA TRAIL-R2 & R3 expression in normal 
aortae and in AAAs (**P<0.01, t test, two tails, confidence > 95%).
5.4.6.2 Relative abundance of mRNA for TRAIL-rTRAIL 
system expression
There are big differences in the percentage of vessel walls expressing mRNA 
between normal aorta and AAA. This indicates that TRAIL and its receptors are 
expressed in the normal and abnormal aortae. To compare the mRNA level in 
the normal aortae and AAA, semi-quantitative PCR results were shown.
Since TRAIL was expressed similarly in human normal aortae and AAAs (Figure 
5.20a) and the ratio of TRAIL to death receptors is higher in AAA than normal 
aortae it follows that death receptors are higher in normal aortae. Similarly, 
because the ratio of TRAIL to decoy receptors is higher in AAA compared to 
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Figure 5.20 The comparison of TRAIL-rTRAIL mRNA expression in normal 
aortae and AAAs. Panel a shows mRNA expression for TRAIL in normal 
aortae and AAAs. TRAIL is expressed at similar levels on both tissues. 
Figure b shows the ratios of TRAIL to death receptors and TRAIL to decoy 
receptors in normal aortae and AAAs. DR-NA indicates that the ratios of 
TRAIL to death receptors in normal aorta. DcR-NA indicates that the ratios 
of TRAIL to decoy receptors in AAAs. DR-AAA indicates that the ratios of 
TRAIL to death receptors in AAAs. DcR-AAA indicates that the ratios of 
TRAIL/decoy receptors in AAAs. DR-AAA is significantly increased (* p<0.5) 
in AAAs. DcR-AAA was expressed significantly lower than DR-AAA(* p<0.5). 
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Figure 5.21 This figure shows the ratios of the mRNA expressions of 
TRAIL/death receptors and TRAIL/decoy receptors in AAAs (normalised to 
GAPDH). There is a significant difference between the ratio of TRAIL/death 
receptors and TRAIL/decoy receptors (***p<0.0001, paired t test, two tailed, 
confidence > 95%). Where TRAIL was expressed more often than death 
receptors, the value is greater than 1. Where the ratio is less than 1, it 
means that TRAIL was expressed less often than death receptors. Where 
the ratio equal to 1, it means that TRAIL and death receptors were absent in 
AAA walls (n=3). In conclusion, in the AAAs, more decoy receptors were 
expressed than TRAIL, and fewer death receptors were expressed than 
TRAIL. The top of the bar represents standard error.
When no good correlation was found, one-way ANOVA was the best statistical 
method for further tests to test whether there is significant difference. In addition, 
more analysis was carried out on different areas of AAAs according to the level 
of their calcification.
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5.4.7 The correlation of CT scan results and mRNA 
expression results
5.4.7.1 Frequency of mRNA expression in different areas 
of AAA
In an attempt to determine the involvement of the TRAIL system in the 
progression of aneurysmal disease, we used a mode! of aneurysm stages (early 
stage, developing stage and late stage) that involved taking samples from three 
different areas of the aneurysm wall to correlate with these stages (proximal, 
body and distal respectively). This approach was taken because most 
aneurysms available to us from surgery were of medium size developing stage 
(> 50mm and smaller than 69mm); early and late stage availability was extremely 
limited.
Calcification levels of different AAA lesions were determined by CT scan. Clearly, 
proximal area is the least calcified area and distal is the most calcified area 
(Figure 5.7, *p<0.05).
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75 Frequency of mRNA expression in different areas of AAA walls
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Figure 5.22 This graph shows that TRAIL and all its five receptors were 
expressed widely in different areas of AAA vessel walls. Each bar 
represents the frequency of mRNA expression for TRAIL or its receptors 
in proximal, body and distal AAAs (proximal, n=8 ; body n=15; distal n=7). 
There is no significant differences among TRAIL and its receptors in 
these three areas of vessel wall (one-way ANOVA test, confidence>95%). 
According to results from CT scan, body AAA refers to severe 
calcification, proximal AAA refers to calcification in progress and distal 
AAA refers to end-stage calcification. In the distal area where calcification 
level increased, more vessels express TRAIL. In contrast, while 
calcification level increase; less vessels express TRAIL death receptors 
(TRAIL-R1 and TRAIL-R2). Regardless the calcification level, all areas of 
aorta express similar level of TRAIL decoy receptors with the one 
exception being a low expression rate of TRAIL-R4 (43%) in the proximal 
region.
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5.4.7.2 Relative abundance of mRNA expression in
different areas of AAA
The previous results show that more calcified vessels express more TRAIL and 
less TRAIL-death receptors, while the decoy receptors stay relatively level in all 
AAA areas. To express the results in a different way, comparisons were made 
between the expressions of TRAIL system components (TRAIL, death receptors 
and decoy receptors) by semi-quantitative PCR.
Proximal Body Distal
TRAIL
Figure 5.23 The graph shows the mRNA expression for TRAIL in proximal, 
body and distal AAA (normalised to GAPDH). Proximal, n=8 ; body n=15; 
distal n=7. TRAIL increased while calcification level increased. Significant 
difference was found between proximal and distal AAA (*p<0.05). This is 
compatible with the findings in the frequency comparison. More vessels 
expressed TRAIL in the more calcified region. The top of the bar represents 
standard error.
Since TRAIL is not expressed constantly in these three AAA regions, the ratios of 
TRAIL to its receptors are not meaningful as mentioned in the chapter 4. The 
graphs below show the mRNA expression for TRAIL death receptors (TRAIL-R1 
and TRAIL-R2) and TRAIL decoy receptors (TRAIL-R3, TRAIL-R4 and OPG). As 
it is shown in the frequency results, decoy receptors were expressed similar in all 
three regions. Interestingly, TRAIL death receptors were expressed the most in
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the body AAA while only half of vessels express them. This shows that TRAIL 





Figure 5.24 These graphs show the TRAIL decoy receptors (TRAIL-R3, 
TRAIL-R4 and OPG) and TRAIL death receptors (TRAIL-R1 and TRAIL-R2) 
in proximal, body and distal AAA. Panel a illustrates the mRNA expression 
for TRAIL death receptors and panel b illustrates the mRNA expression for 
TRAIL decoy receptors. TRAIL decoy receptors were expressed 
consistently in all three regions and death receptors were expressed 
variably from one region to the other. Their expression was expressed 
mostly in the body AAA and the least in the distal AAA. However, this is 
only a tendency, with no significant difference observed (by ANOVA test, 
confidence > 95%). The top of the bar represents standard error.
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Figure 5.24b demonstrates TRAIL decoy receptors are expressed similar from 
one region to another in the AAA. Thus, the ratio of TRAIL death receptors to 
TRAIL decoy receptors is comparative.
mRNA expression for death 
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Figure 5.25 The graph shows the ratios of the mRNA expression for death 
receptors / decoy receptors in proximal, body and distal AAAs (normalised 
to GAPDH). Overall, the ratios are less than 1, which means that decoy 
receptors were expressed more often than death receptors in all three 
types of AAA (proximal n=8 ; body n=15; distal n=7). The ratios decreased 
while calcification level increased. However, this is only a tendency, with 
no significant difference observed (by ANOVA test, confidence > 95%). The 
top of the bar represents standard error.
5.4.7.3 The correlations of TRAIL and its receptors in 
different areas of AAA
As mentioned before, the correlation test for TRAIL and its receptors is also 
carried out in three AAA regions. Some almost perfect positive correlations were
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observed in mRNA expression among TRAIL, TRAIL-R1, TRAIL-R2 and OPG in 
the different types of AAAs (see Table 5.4-5.6).
proximal
TRAIL TRAILR1 TRAIL-R2 OPG
TRAIL 1 0.99 -0.22 0.99
TRAIL-R1 1 -0.23 0.99
TRAIL-R2 1 -0.22
OPG 1
Body TRAIL TRAILR1 TRAIL-R2 OPG
TRAIL 1 -0.46 -0.25 0.10
TRAIL-R1 1 -0.35 -0.20
TRAIL-R2 1 -0.20
OPG 1
distal TRAIL TRAILR1 TRAIL-R2 OPG
TRAIL 1 -0.23 -0.20 0.99
TRAIL-R1 1 0.14 -0.20
TRAIL-R2 1 -0.20
OPG 1
Table 5.6 This table shows correlations value r (correlation co-efficient, 
see 5.4.5.1 for details) among TRAIL, TRAIL-R1, TRAIL-R2  and OPG in the 
proximal, body and distal AAA (proximal n=8 ; body n=15; distal n=7). The 
red highlights clearly indicate an almost perfect correlation between 
TRAIL and TRAIL-R1, TRAIL and OPG, and TRAIL R1 & OPG in proximal 
AAA. TRAIL and OPG are also perfectly correlated in the distal AAA. 
TRAIL, TRAIL-R1 and OPG were expressed least often in proximal AAA 
(less calcified). TRAIL and OPG were expressed most often in distal AAA 
(most calcified).
The positive correlations between TRAIL and OPG may imply that OPG is 
compensated for TRAIL activation in AAA formation. Of note, the entire three 
decoy receptors were expressed similarly irrespective of AAA area. This may 




5.5.1 Messenger RNA expression for TRAIL and its
receptors in normal aortae
All normal aortic specimens were obtained with informed consent from pulseless 
kidney donors from Bristol Southmead Hospital; unfortunately complete 
information on these specimens is missing. Firstly, two different trends of mRNA 
expression in normal aortae were found. This could be explained by the age 
difference of the specimen donors. Osteoprotegerin is known to be expressed 
more in the old than in the young because OPG functions as an inhibitor of bone 
loss in vivo and osteoporosis occurs more frequently in the old than in the young 
ones (Hak et al., 2 0 0 0 ;Jono et at., 2 0 0 2 ). Since OPG appeared to be expressed 
more in group 1 normal aortae than group 2 , it suggests that group 1 normal 
aortae might be obtained from an older age group.
Secondly, GAPDH in normal aortae was shown to have inconsistent expression. 
As mentioned in the methodology section, hypoxia and post-mortem delay could 
affect GAPDH expression severely (Zhong and Simons, 1999). All normal aorta 
specimens were obtained from open surgeries in normoxic conditions thus post­
mortem delay would be an explanation for inconsistent GAPDH expression. 
Taken together, normal aortae were divided into 2 groups according to the 
mRNA level of TRAIL expression for accurate analysis.
Additionally, RANK mRNA was not detected while RANKL was detected 
consistently in the normal aortae and AAA (n=5, data not shown), which is 
different from the finding of Min at al., (2000) and (Hofbauer etal., 2001). It might 
suggest that RANK and RANKL are not involved in AAA formation.
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5.5.2 The correlation of the TRAIL-rTRAIL system mRNA 
expression in AAA
The physiological function of TRAIL and its receptors in different cell types is still 
not certain (Wang and El-Deiry, 2003). As detailed in 4.3, another question that 
has not been addressed is whether TRAIL-R1 or TRAIL-R2 is dominant in the 
initiation of apoptosis in certain cell types or whether the possible complexes of 
these two work together to signal cell death (Schneider et al., 1997). To 
investigate this, analysis was carried out in pairs of TRAIL and its receptors. 
TRAIL-R2 positively correlated with TRAIL, TRAIL-R3, TRAIL-R4 and OPG. 
TRAIL-R1 negatively correlated with TRAIL, TRAIL-R2, TRAIL-R4 and OPG 
(refer to table 5.4-5.5). These results combined with the findings of a decrease in 
the compensatory responses of decoy receptors to death receptors suggest that 
TRAIL-R1 might have the dominant influence in the AAA.
5.5.3 TRAIL and its receptors mRNA expression in 
normal aortae and AAAs
5.5.3.1 The frequency of mRNA expression
TRAIL and its receptors are expressed extensively in miscellaneous tissues such 
as brain, heart and lung in human (Spierings et al., 2004). For example, TRAIL- 
R1, TRAIL-R2 and TRAIL-R3 but not TRAIL are expressed in the human brain. 
TRAIL and all its receptors are expressed in the human heart and in this study 
TRAIL and its receptors were found in human normal aortae and AAA tissue. 
This is a novel finding since, to date, no other report of the TRAIL-rTRAIL system 
in aorta or AAA has been published.
Significant differences between normal aortae and AAA of TRAIL death 
receptors’ frequency were found (see Figure 5.19). This strongly suggests the 
participation of TRAIL death receptors in the AAA formation. It is interesting to 
note that significantly fewer AAAs express death receptors than normal aortae. 
This suggests that the TRAIL-rTRAIL system may be involved in the initiation of 
abdominal aneurysm formation. There is considerable variability in TRAIL 
receptor expression in human AAA tissues. This could be because of two factors.
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The first factor is the loss of gene coding for the receptors. Significantly, there 
are only 42% of AAA vessel walls expressing TRAIL-R2 mRNA but 100% normal 
aortae expressing TRAIL-R2 mRNA. The AAA vessel walls expressed less 
TRAIL and the other receptors than normal aortae. The possibility is that more 
diseased cells in the AAA samples explain the lower level of gene expression 
encoding the subunits of TRAIL and it receptors. Of note, greater differences 
were found for TRAIL death receptors than decoy receptors between human 
normal and abnormal aortic samples. This would support the association of dead 
cells with loss of encoding genes. Also, the significant difference between TRAIL 
death receptors and decoy receptors in AAA may indicate an imbalance between 
these receptors with respect to the normal situation. The second reason could be 
that death receptor mRNA was possibly lost from the AAA because the of the 
survival pressure exerted by TRAIL.
5.5.3.2 Relative abundance of mRNA expression
Messenger RNA for death receptors was expressed much more abundantly than 
the decoy receptors but on fewer normal aortic vessel walls. However, the 
opposite pattern of expression was seen in the AAA. Decoy receptors were 
expressed much more abundantly than death receptors (statistically significant 
difference) in AAA, and this is consistent with their protein expression (see next 
chapter). This might suggest that decoy receptors mRNA are raised in response 
to the disease state, and may act as protective agents against AAA progression. 
The increased decoy receptors in AAA might be a compensatory response to the 
change of death receptors.
TRAIL was expressed similarly in the normal aortae and AAA. Thus, any 
difference between the ratio of TRAIL to death receptors and the ratio of TRAIL 
to decoy receptors might suggest how the balance is tipped with respect to 
TRAIL in its capacity to induce or inhibit apoptosis. The former ratio is 
significantly greater than the latter in AAA (see Figure 5.20). This indicates that 
TRAIL death receptor expression is less than that of decoy receptors in AAA. 
This finding is consistent with the results of the expression frequency. In 
summary, the loss of encoding gene might be associated with the disease cells 
in the AAA samples and the survival pressure exerted by TRAIL.
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5.5.4 The TRAIL and rTRAIL system mRNA expression 
in different areas of AAA
5.5.4.1 The frequency of the TRAIL-rTRAIL system 
expression in the different areas of AAA
The criteria attached to elective AAA open repair surgery restricted the size of 
AAA specimens that could be obtained from selective surgeries (occasionally 
obtained from emergency AAA rupture repair). The size and calcification level of 
AAA specimens are quite similar and at the end stage of disease (all diameters 
of AAA >50mm). For a better understanding of the contribution of TRAIL and its 
receptors to AAA formation, AAA specimens were separated into three groups 
according to different calcification levels to imitate the developing progression of 
AAA. The expression of TRAIL mRNA increased while calcification levels 
increased. The mRNA of TRAIL death receptors was significantly decreased as 
the calcification level increased. TRAIL decoy receptors maintained a similar 
expression in all stages of AAA (see Figure 5.24). This might suggest a 
continuous inhibition of calcification by decoy receptors and TRAIL death 
receptors initiation at an earlier stage of calcification.
5.5.4.2 The relative abundance of the mRNA expression 
for TRAIL-rTRAIL system in the different areas of 
AAA
TRAIL was expressed more abundantly in the more calcified area. This supports 
the proposition that TRAIL capacity for triggering apoptosis increases and 
prevention of apoptosis diminishes in the more calcified AAA regions. TRAIL 
decoy receptors were expressed similarly in the three AAA regions examined. 
This is consistent with the findings of bone calcification-inhibiting proteins (MGP, 
osteocalcin and bone sialoprotien) being found to be expressed at all stages of 
human atherosclerosis (Dhore et al., 2001). This correlation may imply a 
functional association between TRAIL decoy receptors and bone calcification- 
inhibiting proteins.
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Interestingly, the fact that TRAIL death receptors were expressed highest in the 
AAA body suggests that the general situation of a developing aneurysm (body 
area) is where apoptosis might be upregulated. The lowest level of death 
receptors were found in the distal region that would consist of damaged 
apoptotic cells incapable of expressing mRNA or new protein. This is also 
coherent with previously published results of bone related activators of 
calcification (BMP-2, BMP-4, osteopontin and osteonectin) which were restricted 
to advanced, calcified lesions (Dhore et al., 2001). All these findings suggest that 
AAA formation similar to the vascular calcification process is the result of time 
and plaque-stage-restricted activation and continuous inhibition. The TRAIL- 
rTRAIL system may play a role in this developing process.
5.5.4.3 The correlation of mRNA expression for the 
TRAIL-rTRAIL system in the different areas of 
AAAs
TRAIL and OPG are positively associated in the proximal and distal AAA. Thus, 
OPG was increasingly expressed while calcification level increased. This feature 
might be representative of a counter-regulatory mechanism of OPG limiting 
apoptosis in the less calcified areas and therefore the restricting the initiation of 
calcification. Since OPG has been found to play a role in the process of vascular 
calcification in an animal model, there is a strong implication that OPG also plays 
a role in AAA pathogenesis.
Atherosclerosis is associated with the AAA. It is possible that the different 
calcification level of aneurysm could be a result of unsteady three-dimensional 
blood flow that might also simulate atherosclerosis in abdominal aortic aneurysm. 
A Japanese research group successfully produced a model of such three 
dimensional blood flow using a graphics workstation (Taylor and Yamaguchi, 
1994). This aneurysm flow stimulation model predicts that a single asymmetric 
blood flow occurs in the proximal (neck) region of the AAA which coincides with 
the area of least calcification found in this study. In the aneurysm body, two 
symmetric vortices were formed which might lead to more calcification than 
found in the proximal area. In a similar way, the model proposes that as the
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blood passes through the wide body of the AAA into the narrower distal region, a 
greatly increased stress is exerted on the vessel wall. This correlates with the 
region identified here as being the most calcified and may indicate that this distal 





Figure 5.26 Blood flows in the calcified AAA as red arrows indicated. The 
no.1 vortices where is proximal AAA becomes no.2 vortices where is body 
AAA. The no.2 blood flow forms a small circulation inside the enlargement 
of AAA increasing the burden of the vessel wall then causing the more 
sever calcification. While no.2 blood flow stream arrives at narrow distal 
area, the extra stress of the vessel wall suddenly increases. This could be a 




Chapter 6 TRAIL, TRAIL-R1 and OPG 
protein expression in human normal 
and calcified aortic samples
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6.1 Introduction
6.1.1 The role of OPG in vascular calcification
The role of OPG in vascular calcification is still uncertain. Osteoprotegerin is 
present in heart, arteries, and veins of the cardiovascular system, where it is 
particularly high in the aorta and the renal arteries (Collin-Osdoby, 2004). The 
protein OPG was found in the borders of calcified structures and areas 
surrounding calcified regions in arterial medial calcification (Collin-Osdoby, 2004).
Osteoprotegerin was found in human aortic fibrocalcific plaque without 
immunoactivity (Dhore et a /., 2001). It was also found in the calcified aorta and 
renal arteries in mice (Min et al., 2000). Injection of OPG can prevent the onset 
of vascular calcification in these mice but cannot change the incidence of VC in 
adult mice even on high dose (Min et al., 2000). Additionally, it has been 
demonstrated that serum OPG levels are often associated in vascular 
calcification diseases, such as carotid stenosis in postmenopausal woman, 
coronary artery disease and vascular calcification in patients with long term 
haemodialysis (Erdogan et al., 2004; Jono et al., 2002; Nitta et al., 2003). The 
role of the circulating levels of OPG still needs further investigation. It may reflect 
the correction of over-mineralisation processes and possibly demonstrates a 
protective role at the biological level. It is believed to inhibit directly vascular 
calcification and provides an indicator of vascular pathology (Collin-Osdoby, 
2004).
The physiological roles of OPG that may influence vascular SMC and endothelial 
cells are also not certain, especially in the SMC (Collin-Osdoby, 2004). In the rat 
endothelial cells undergoing apoptosis, OPG binds to TRAIL and prevents TRAIL 
interaction with its receptors (Malyankar et al., 2000). Rats treated with warfarin 
or Vitamin D3 develop vascular calcification which can be suppressed by OPG 
serving as a protective agent in the vasculature (Bucay et al., 1998; Min et al., 
2000). Osteoprotegerin and TRAIL have been found to be expressed in human 
atherosclerotic or calcified vessels (Schoppet et al., 2004). Also human OPG 
promotes polymorphisms that protective against coronary artery disease or 
atherosclerotic-like vascular changes (Brandstrom et al., 2 0 0 2 ). Osteoprotegerin
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may be an important autocrine/ paracrine factor protecting against arterial 
calcification and the vascular-damaging effects of inflammatory cytokines 
through enhancing endothelial cell survival. This could be via two possible 
mechanisms; first by conveying NF-KB-induced survival signals and secondly by 
directly binding and neutralising the pro-apoptotic actions of TRAIL released from 
vascular SMCs (Collin-Osdoby, 2004; Pritzker etal., 2004; Scatena and Giachelli, 
2 0 0 2 ; Schoppet etal., 2004).
Consequently, further research is needed to learn if and how OPG might 
interface with TRAIL in regulating mineralisation within the vascular systems.
6.1.2 Western Blot introduction
Western blotting is a commonly used method for identifying a specific protein 
from a protein mixture. It detects the target protein by its specific reaction with an 
antibody and determination of its size relative to standard proteins of known size.
Total protein is separated on the gel that includes molecular weight markers. 
Molecules are separated on the gel according to their charge, size and shape. 
More highly charged species move more rapidly in an electric field; larger 
molecules, and those less spherical in shape, are retarded by the gel to a greater 
extent. Small polynucleotide fragments (up to 1 kilo base (Kb)) are separated on 
polyacrylamide gels; larger nucleic acids, such as restriction fragments are 
separated on agarose gel. Hence, the choice of gel and gel size is critical for 
optimal results.
When only the molecular size is relevant, the proteins are denatured with sodium 
dodecylsulphate (SDS). Sodium dodecylsulphate is an anionic detergent-which 
denatures proteins by wrapping around the polypeptide backbone. In so doing, 
SDS confers a net negative charge to the polypeptide which is in proportion to its 
length. When treated with SDS and a reducing agent, the polypeptides become 
rods of negative charges with even "charge densities" or charge per unit length. 
Since the charge per unit length of the SDS-polypeptide complex is constant, the 
electrical force exerted on the complex per unit length is also constant. Thus the 
migration velocity is totally determined by the sieving effect of the acrylamide
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matrix so that proteins are separated according to their molecular weight (Swank 
et al., 2006). The proteins to be examined here are TRAIL, TRAIL-R1 and OPG 
which are 20 kDa, 55 kDa and 16kDa respectively, therefore SDS-PAGE gels 
were used for Western blot for separation of total protein in this project.
The upper layer, through which the sample passes first, is known as the 
"stacking gel". It is a large-pore gel, which is non-restrictive to the protein sample. 
The buffer in which the stacking gel is made contains an ion (usually an anion) 
whose electrophoretic mobility is greater than that of the protein, while the tank 
buffer, or electrode buffer, contains an ion whose mobility is less than that of the 
protein. As electrophoresis begins, the "leading ion" in the stacking gel moves 
faster than the protein and leaves behind it a zone of lower conductivity. The 
higher voltage gradient of this zone causes the protein to move faster and to 
"stack" at the boundary between the leading and trailing ions (Swank et al., 
2006).
Below the stacking gel is a deeper layer of gel with a smaller pore size, known as 
the resolving gel. This gel is prepared in a buffer of higher concentration and pH 
in an anionic system. In this environment, the mobility of the trailing ion increases 
so that its boundary moves ahead of the protein. The protein is resolved into 
individual bands according to size (Riederer and Goodman, 1987). For the 
purpose of this study, 12% resolving gel was used when OPG and TRAIL were 
the target protein and 9% resolving gel was used when TRAIL-R1 was the target 
protein. This is because the size difference. For good final detection results,
target protein is ideally suited in the middle of the gel.
Antibodies react with specific protein which is based on enhanced
chemiluminescence (Swank et al., 2006). This is achieved by performing
oxidation of luminol by the Horseradish peroxidase (HRP) in the presence of 
hydrogen peroxide (H2O2). The excited intermediate that is formed emits light 
which is detected by a photo-sensitive film. This light emission can be enhanced 
by chemical enhancers such as phenols. This increases the output of light by 















Figure 6.1 Principles of enhanced chemiluminescence detection method 
used for visualisation of Western blots.
6.1.3 Bradford assay introduction
The Bradford assay is one of the most commonly used protein assay methods. It 
works by the action of Coomassie Brilliant Blue G-250 (CBBG). This dye 
specifically binds to proteins at arginine, tryptophan, tyrosine, histidine and 
phenylalanine residues, especially at arginine (da Silva and Arruda, 2006). The 
assay is very sensitive and suitable for detecting protein isolated from vessel 
walls. The CBBG solution is mostly anionic and binds to those residues at 
absorbance maximum at 595 nm (blue). It also contains some free dye in the 
cationic form, which has an absorbance maximum at 470 nm (red). The assay is 
monitored at 595 nm in a spectrophotometer to measures the protein complexed 
with CBBG.
6.1.4 Dot blots introduction
Dot blotting is another technique similar to Western blot for detecting, analysing, 
and identifying proteins. The protein loaded on the nitrocellulose membrane are 
not separated electrophoretically but are only observed through circular
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templates of the membrane. Dot blots can only be used when both the primary 
and secondary antibodies are specific for the antigen as can be assessed by 
Western blotting first.
Western blotting is a time-consuming technique and is restricted by a limited 
number of samples per gel (usually only 8 ). Comparatively, Dot blot has the 
advantages of being rapid and allowing large numbers of samples to be 
analysed simultaneously (maximum 96 protein samples can be loaded each 
time). This also gives the opportunity to automate or semi-automate analysis of 
multiple samples. Moreover, Dot blot has been documented to be approximately 
10- to 1000-fold more sensitive than Western blot (Rapley R. and Walker J.M., 
1998).
6.1.5 General Immunohistochemistry (IHC) introduction
There are two methods of antigen detection commonly used in tissue in IHC: 
direct and indirect. The direct way uses only one antibody which is quicker but 
not very sensitive. The indirect method involves two antibodies, primary and 
secondary antibodies, and results in an enhancement of the signal for antigen 
detection. Primary antibody reacts with the antigen in tissue and secondary 
antibody reacts with primary antibody. The secondary antibody is against the IgG 
of the animal species in which the primary antibody has been raised. It is also 
can be labelled with fluorescent dye which is called immunofluorescence method 
or be labelled with enzyme such as peroxidase, alkaline phosphatase or glucose 
oxidase which is called immunoenzyme method. A substrate is reacted with 
these enzymes and demonstrated presence of antigen in tissues.
Two of the commonly used indirect methods are:
•  PAP Method (peroxidase anti-peroxidase method)
•  Avidin-Biotin Complex (ABC) Method:
The PAP method amplifies the signal by using a complex composed of antibody 
to peroxidase coupled with peroxidase forming a very stable peroxidase anti­
peroxidase system. The complex acts as a magnified layer antigen binding to the 
unconjugated secondary antibody.
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The ABC method is a standard and widely used IHC method. The secondary 
antibody is biotinylated. Avidin which is a large glycopyrotein, has a very high 
affinity for biotin. It can be labelled with peroxidase or fluorescein. The amplified 
signal is a complex composed of avidin-biotin peroxidase. Biotin is a low 
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Figure6 .2  Diagrammatic representation of general IHC. This includes direct 
labelling, indirect labelling with/without labelling with amplified signal. 
Direct labelling as shown on the left of the diagram, where the primary 
antibody (Add 1°) is directly attached to the target protein. Indirect labelling 
without signal amplification is diagrammatically shown in the centre, 
depicting the target protein reacting with the primary antibody (Add 1°) and 
then with the secondary antibody (Add 2°). The final method involves 
three steps. Firstly, the primary antibody (Add 1°) reacts with the target 
protein; secondly, it reacts with secondary antibody (Add 2°, such as 
biotinylated antibody); lastly, this combination reacts with amplifying 
streptavidin to enhance the signal.
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6.2 Aims and objectives
•  To determine whether TRAIL, TRAIL-R1 and OPG are expressed in
normal tissues
• To determine whether TRAIL, TRAIL-R1 and OPG are expressed in
calcified AAA tissues
• To determine whether there are protein expression differences of TRAIL
and its receptors’ expression between normal control samples and AAA 
samples
•  To determine whether there are variations among TRAIL, TRAIL-R1 and
OPG in tissues with different level of calcification
•  To determine where TRAIL, TRAIL-R1 and OPG localisation is consistent
with the calcification deposition
6.3 Materials and methods
6.3.1 Protein expression materials and methods
6.3.1.1 Samples
Protein detection and determination was performed on normal aortae and AAA 
tissues that were sourced as described in chapter 5. The AAA samples were 
from the same 31 donors but 12 different normal aorta samples were analysed 
as there was insufficient sample remaining of the tissues used in gene 
expression study (chapter 5). The age range of normal aorta donors was from 15 
to 57 (mean age 46± 13 year old). None of them had AAA but one sample had 
visible atherosclerosis on the aortic wall. The age of this donor is 57.
6.3.1.2 Protein isolation materials and methods
•  NaCI (sodium chloride), Promega, UK
• Tris-HCL (Tris (hydroxymethyl) aminomethane) HCL (hydrochloric acid),
Sigma-Aldrich Co Ltd, Poole, UK
•  Triton X100, Promega, UK
•  Ethylene diamine tetraacetic acid (EDTA), Promega, UK
•  Leupeptin, Promega, UK
•  Aprotinin, Promega, UK
Choosing the most suitable lysis buffer for AAA protein isolation is a very 
important step for good quality protein detection. A standard Triton X100 lysis 
buffer was used containing 0.15M NaCI, 10mM Tris-HCI (pH=4), 1 % Triton X100, 
5mM EDTA (pH=8 ) and the protease inhibitors, leupeptin and aprotinin. This 
buffer is less denaturing, but gives a higher background and less likely to inhibit 
kinase activity and disrupt protein complexes. Sodium fluoride is an inhibitor of 
serine/threonine protein phosphatases. Tris-HCL functions as an inhibitor of 
phosphatases. EDTA prevents phosphorylation in the lysate. The concentration 
of the detergent Triton X100 was varied to determine the optimal conditions for 
lysis of the samples. Concentrations of 0.1%, 1% and 10% were tested and 1 % 
Triton X100 showed the best results by Bradford assay (detailed below).
Human AAA and normal aorta tissues were stored at -80°C for total protein 
isolation. Tissues were ground into powder by using liquid N2 followed by adding 
the lysis buffer (see appendix A for recipe and chapter 5 methods for isolation 
details). The solution was transferred into new Eppendorf tubes and centrifuged 
at 13,000rpm at 4°C for 1 0  minutes. Final total protein samples were stored at - 
80°C for future study (Bollag etal., 1996).
6.3.1.3 Bradford protein assay materials and methods
•  Bovine Serum Albumin (BSA), Bio-Rad, Hertfordshire, UK
•  Biorad Reagent, Bio-Rad, Hertfordshire, UK
•  96-well, flat-bottomed tissue culture test plates, Orange scientific, Belgium
For improved isolation of protein, 1% Triton X100 was used in the lysis buffer. 
The detergent in the lysis buffer concentration (1%Triton X100) is incompatible 
with Biorad reagent (Biorad being compatible with 0.1% Triton X100). This would 
interfere with the standard cun/e. Two completely different curves appeared
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when BSA was run with water and with lysis buffer. The standard curve with lysis 
buffer was very flat. This is because the Triton X100 in lysis buffer interacts with 
Biorad reagent. Thus, the lysis buffer was diluted 100 times with Milli-Q water to 
correct the interference. The total protein samples were diluted 100 times in Milli- 
Q water in the Bradford assay for accurate results.
Bovine serum albumin was used as protein standard in the Bradford assay. It 
was diluted into different dilutions for the standard curve (see Table 6.1 and 
Figure 6.3 for individual concentration and standard curve).
cuvette Buffer pi BSA pi Concentration (pg/ml).
O(Blank). 1000pl O.OpI 0
1 996.5pl 3.5pl 5
2 992.5pl 7.5pl 10
3 989.Opl 11.Opl 15
4 985.2pl 14.8pl 20
5 982.Opl 18.Opl 25






0.0 2.5 5.0 10.07.5
pg BSA
Figure 6.3 Typical standard curve for protein assay.
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Diluted sample solution (800pl) was mixed with 200pl Biorad reagent. Each 
dilution (100pl) was then added to a 96-well plate in triplicate. The well plate was 
shaken vigorously to prevent bubbles from forming. The final solution was 
incubated at room temperature for 1 0  minutes to allow colour development (no 
more than 45 minutes to avoid the effects of Biorad reagent degradation). 
Absorbance at 595 nm was measured using a multi-well plate reader (Dynex 
Technologies, MRX TC II). The concentration of sample protein was determined 
from the standard protein curve using GraphPad Prism 3.2 data analysis 
software.
6.3.1.4 Polyacrylamide gel electrophoresis (SDS-PAGE) 
materials and methods
• Acrylamide 40% or 30%, Anachem Bioscience, UK
• Ammonium Persulphate (AMPS), Sigma-Aldrich Co Ltd, Poole, UK
• Bromophenol Blue, Promega, UK
• DTT, Sigma-Aldrich Co Ltd, Poole, UK
• Glycine, Sigma-Aldrich Co Ltd, Poole, UK
• Rainbow marker (molecular weights, 250-1OKD), Amersham Life Sciences,
UK
• SDS, Sigma-Aldrich Co Ltd, Poole, UK
• TEMED, Promega, UK
• Trizma base, Promega, UK
Acrylamide gel was prepared according to Laemmli (Laemmli, 1970) on a Hoefer 
Mighty Small Dual Gel Caster (Hoefer Pharmacia Biotech Inc. USA). Five 
percent stacking gel includes 1.3ml 30% acrylamide, 2ml 4X stacking gel buffer, 
4.7ml H20 , 21.6|il 20% AMPS and 8 pl TEMED. This stacking gel buffer (1 0 0 ml) 
includes 0.4g SDS, 0.05g Trizma base (pH=6 .8 ). The composition of 1 2 % 
resolving gel includes 9.6ml 30% acrylamide, 3ml 8 X resolving gel buffer, 11.4ml 
H20 , 60|il AMPS and 12pl TEMED; the 9% resolving gel includes 7.2ml 30%  
acrylamide, 3ml 8 X resolving gel buffer, 60pl 20% AMPS and 1 2 pl TEMED. This 
resolving gel buffer (100ml) includes 0.8g SDS and 36.3g Trizma base (pH=8 .8 ). 
As detailed in the introduction, stacking gel (the upper layer) is responsible for
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sweeping up proteins in a sample between two moving boundaries so that they 
are compressed into micrometer thin layers when they reach the separating gel. 
The resolving gel (the lower layer) is designed to separate polypeptides by size. 
The gel includes SDS which is used to denature the proteins and acrylamide 
which is the material for preparing electrophoretic gels to separate proteins by 
size. A cross-linked polymer network forms when acrylamide is mixed with AMPS. 
Then AMPS produces free radicals faster in the presence of TEMED. The size of 
the pores created in the gel is inversely related to the amount of acrylamide used 
and often is used to resolve large proteins. Hence, lower % acrylamide gels will 
have larger pores. The gel limits larger molecules to slower migration than 
smaller molecules. Thus, protein can be separated by SDS-PAGE gel by 
estimating relative molecular mass.
An equal volume of reducing sample buffer was added to the protein samples 
which were prepared as detailed in 6.3.1.4. These were diluted to different 
concentrations in Eppendorf tubes and boiled for 5 minutes at 99°C, then cooled 
on ice for 5 minutes. This reducing sample buffer (pH=8 ) includes 130nM Tris- 
HCI, 20% (v/v) glycerol, 4.6% (w/v) SDS, 0 .0 2 % Bromophenyl Blue and 2 % 
dithiothreitol (DTT). Glycerol is a stabilising factor and helps with protein sample 
loading in the well. Bromophenyl blue is a dye that is functional for visualising 
protein samples in the well and tracking the progress through the gel. DTT is 
used for protein denaturation. Tris-HCL is used for adjustment of pH value. 
Rainbow marker (10pl) was mixed with an equal volume of reducing sample 
buffer. It was then centrifuged at 10,000 rpm for 30 seconds and incubated on 
ice for 5 minutes.
The gel plates were placed in the electrophoresis equipment (Hoefer Pharmacia 
Biotech Inc. USA) which was then filled with running buffer. The running buffer 
(1 L) included 3.03g Trizma base, 14g glycine and 10g SDS. An equal volume 
(1 0 pl) mixture (protein sample mixed with sample buffer) was carefully loaded 
into the gel wells, in parallel with rainbow marker mixed with sample buffer. The 
gel was then subjected to electrophoresis at a constant voltage of 100V for 
approximately 1 hour, or until the dye reached the base of the gel. If the bands 
are not sharp on the developing film after ECL, the voltage could be reduced to 
solve the problem.
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6.3.1.5 Protein blotting and immuno-detection materials 
and methods
•  Blue reagent, Sigma-Aldrich Co Ltd, Poole, UK
• Enhanced chemiluminescence detection kit, Amersham Life Sciences, UK
• Chromatography paper 17 CHR, Whatman International Pic., UK
• Kodak X-OMAT AR auto rad film, Amersham Life Sciences, UK
• Methanol, Fisher Scientific UK Ltd.
•  Nitrocellulose paper (hybond-C extra), Amersham Life Sciences, UK
• PBS, Oxoid Ltd., UK
• Ponceau S, Sigma-Aldrich Co Ltd, Poole, UK
• Primary antibody and secondary antibody (see table 6.3-2 for details)
•  Tween 20, Sigma-Aldrich Co Ltd, Poole, UK
• Western blotting tank, Hoeffer Scientific, CA
• Non fat dried milk, Marvel®, UK
Following electrophoresis, the gel was carefully removed and incubated in 
blotting buffer. Add 3.3g Trizma base and 14g Glycine with 1L Milli Q water and 
this is called BLOT A. The blotting buffer (1L) includes 800ml BLOT A and 200ml 
methanol. Then at the same time Hybond-C extra nitrocellulose paper and 
chromatography paper (17 CHR - Whatman) were cut to the size of the gel and 
soaked in the blotting buffer in order to avoid fuzzy bands occurring. A Western 
blot cassette holder (see Figure 6.4) was used, into which 3 filter papers were 
placed on top of the sponges on one side of the holder. The nitrocellulose 
membrane and the gel were placed on one set of filter papers carefully removing 
all air bubbles. A further set of 3 filter papers was then placed on top of the gel 
and the cassette was closed. This was then transferred to a Western blotting 
tank making sure that the nitrocellulose paper was nearest to the positive 
electrode (anode). Blotting buffer was added to the tank and the proteins were 
blotted for 4-5 hours at a current depending on the area of the gel (normally 6X9 
cm) determined by the equation;











Figure 6.4 A schematic diagram of the blotting apparatus used to transfer 
proteins onto nitrocellulose paper.
After this the cassette was removed from the tank and the gel was stained with 
blue reagent solution for analysis of complete transfer of protein to the 
nitrocellulose paper. The membrane was stained with 1% Ponceau S to detect 
protein expression. The positions of different molecular weight markers were 
marked on nitrocellulose paper with a pencil. The nitrocellulose was then 
incubated in blocking buffer (5% milk / PBS Tween) at 4 °C overnight or on the 
rocker at room temperature for an hour.
The nitrocellulose membrane blot was then transferred to 20 ml tube containing 
5ml of the diluted primary antibody (and
Table 6.2 for details). This was incubated on a rocking plate for 2 hours at room 
temperature then thoroughly washed in 0.5% Tween 20/ PBS ( see appendix A 
for making) 3 times, 15 minutes each. The blot was then incubated with the 
diluted secondary antibody (see
Table 6.2 for details) for 1 hour at room temperature. The blot was again 
washed in 0.5% Tween 20/ PBS 3 times, 15 minutes each. As controls the 
primary and secondary antibodies were adsorbed with the individual specific 
protein standards. Different primary antibodies were chosen and tested (see
Table 6.2 for details).
124
Equal volumes of solution A and solution B from the enhanced 
chemiluminescence detection kit (Amersham Life Sciences) were mixed and 
added to the membrane immediately making sure the whole of the membrane 
was covered. The membrane was incubated for 60 seconds and the excess 
drained off and covered in SaranWrap™ ensuring that all bubbles were 
smoothed out and placed in a film cassette, protein side up. In a dark room, a 
sheet of Kodak autoradiography film was carefully placed on top of the 
membrane and exposed initially for 5 minutes. Exposure time was adjusted for 
optimal results. This film was then developed using Fuji RG II X-ray film 
processor (Fuji Photo Film Company Ltd, Japan). Analysis of data was 
performed using Scion Imaging Software.
6.3.1.6 Optimisation of blotting procedures
troubleshooting
Many problems occurred before a successful Western blot image was obtained. 
Low protein signal could be a result of ineffective blotting; therefore it is important 
to perform the pre-detection staining of the gel and membrane as described. 
Another reason for low signal could be that the concentration of target protein is 
too low in the total protein sample. This could be solved by concentrating the 
total protein in a High Performance Centrifugal Spin Concentrator (Orbital 
Biosciences). Low affinity of primary antibody is another possible reason for low 
signal that can be remedied by increasing the incubation times and/or 
temperature and increasing the concentration of primary antibody or by trying a 
primary from a different source. The right choice of secondary antibody is 
imperative too. To confirm that the ECL system works the detection reagent A 
and B were pre-mixed and added to 1pl HRP-labelled antibody in the dark room. 
Blue light is visible if the reagent is working. Finally, it is worth checking whether 
the X-ray detection procedure works and if so enhancement can be achieved by 
exposing the film for a longer time such as in the fridge overnight.
In contrast, excessive diffuse signal occurs sometimes. A simple first fix is to load 
less protein on the gel and also check the transfer from gel to membrane stage
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were bubbles may interfere with the quality of the signal. Obviously, reducing the 
exposure time and/ or increasing washing time are potentially other solutions.
High background on the film could result from 3 main causes. These are: too 
high concentrations of primary antibody and/or secondary antibody; 
contaminated buffers or equipment; and insufficient blocking. Simply increasing 
the blocking time would be the first attempt to remedy high background and/ or 
increasing the blocking buffer from 5% milk to 10% milk in PBS Tween 20. 
Additionally, different dilution buffers could be tried for different proteins. Four 
dilution buffers for antibody were tested here, 10%, 5%, 1% and 0% milk powder 
in 0.05% PBS Tween 20. The detergent Tween 20 can reduce the background 
on the final film but high concentration of Tween 20 could reduce the affinity with 
primary antibody. Ultimately, 0.05% PBS Tween 20 was chosen. One percent 
milk /  PBS Tween 20 buffer was used as dilution the buffer for primary antibodies 
and PBS Tween 20 without milk was used as the dilution buffer for secondary 
antibodies as the possibility of biotin in the milk may cause non-specific binding.
6.3.1.7 Stripping blot materials and methods
•  2-Mecaptoethanol, Sigma-Aldrich Co Ltd, Poole, UK
•  Tris-HCL, Sigma-Aldrich Co Ltd, Poole, UK
•  SDS, Sigma-Aldrich Co Ltd, Poole, UK
Sometimes it was necessary to strip the bound antibodies from the gels to 
troubleshoot and to save time and protein samples. Stripping methods for blots 
allow the first set of protein probes (the primary antibody and the secondary 
antibody) to be removed from the target protein on the membrane in Western 
blot. Thus, the different proteins on the membrane can be detected by a second 
set of protein probes. To do this the membrane was washed in PBS Tween 20 
for 5 minutes followed by incubation in stripping buffer for 30 min at 50-60°C. 
Generally, stripping buffer is sufficiently harsh to dissociate the affinity interaction 
between protein probes and the target proteins. It is also an efficient way to 
remove protein probes without damaging the proteins on the membrane. The 
stripping buffer used comprises 62.5 mM Tris-HCI (pH 6.8), 2% SDS and a final
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concentration of 0.1 M 2-Mecaptoethanol. The membrane was shaken by hand 
every 15 minutes and finally was washed in PBS Tween 20 for 5 minutes twice. 
Empirical testing by using Ponceau S to visualise the protein band to ensure the 
stripping process was effective and the protein was still present on the 
membrane. The membrane was then ready for re-blocking followed by normal 
Western blot protocol as described.
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Table 6.2 Primary antibodies and secondary antibodies that were used in 
the Western blot.
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6.3.1.8 Dot blots materials and methods
• Enhanced chemiluminescence detection kit, Amersham Life Sciences, UK
• Chromatography paper (17 CHR), Whatman International Pic., UK
• Kodak X-OMAT AR auto rad film, Amersham Life Sciences, UK
• Hybond-C Extra Nitrocellulose paper, Amersham Life Sciences, UK
• PBS, Oxoid Ltd., UK
• Ponceau S, Sigma-Aldrich Co Ltd, Poole, UK
• Primary antibody and secondary antibody ( see table 6.2 for deatails)
• Tween 20, Sigma-Aldrich Co Ltd, Poole, UK
If primary antibodies specifically bind only the target protein, Dot blots provide a 
good alternative to the Western blot.
In a Dot blot, a nitrocellulose membrane is placed in a 96-well Dot blotter (DHM- 
96, Jencons Scientific Inc. PA) (see Figure 6.5 for details) into which the protein 
samples are applied. The sample is aspirated into the membrane which allows 
the protein to penetrate the membrane in good quantities. Dot blots allow 
comparisons of more samples at once and giving more accurate indication of 
level of expression.
Protein samples were prepared (detailed in 6.3.1.2) for loading on to the Dot blot 
according to their concentrations assessed by the Bradford assay. Two pieces of 
Whatman paper (17 CHR) were assembled underneath a piece of nitrocellulose 
membrane (Hybond-C extra) to make a Dot blot “sandwich” and then soaked in 
the running buffer. Positive control, protein samples and pure H20  which was 
used as a negative control were loaded into each well of the Dot blot apparatus. 
The suction power was kept on for 30 seconds after loading to drain excess blot 
buffer. The nitrocellulose blotting membrane was blocked in the blocking buffer 








Figure 6.5 A schematic diagram of the Dot blot apparatus. Protein is loaded 
into the well as the red arrow indicates. Membrane and filter paper were 
assembled as shown. The blue arrow indicates the flow direction.
6.3.1.9 Statistical analysis
As discussed in the introduction, a standard curve was constructed using the 
results of blotting pure protein controls (10 pg, 20 pg and 30 pg) on membrane at 
the same time as the test samples. Test protein concentrations were measured 
by reading off the standard curve after densitometric scanning. The analyses 
were carried out in duplicate. All extracted proteins were finally subjected to Dot 
blots simultaneously for more accurate results. Paired analysis between two 
groups was performed by paired t test. The linear regression test (Pearson test) 
was used to determine the correlation between protein expressions in the TRAIL- 
rTRAIL system. Significant differences were considered at *P <0.05 levels and 
confidence >95%. All error bars are ± standard error of the mean (SEM). One 
star refers to *P< 0.05 and two stars refers to **P< 0.01. Three stars refers to 
***P< 0.001.
All analyses were performed using the GraphPad Prism Instat package, Version 
3.02, GraphPad Software Inc., San Diego USA.
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6.3.2 Immunohistochemistry material and methods
6.3.2.1 Fixation and Sectioning materials and methods
Fixation is usually performed to preserve tissue architecture and cell morphology 
prior to staining. It acts to crosslink and stabilise proteins in the tissue. The 
choice of fixation, dehydration and clearing methods can impact the final result 
depending on the antigen to be detected and also the antibodies used. 
Inappropriate or prolonged fixation may dramatically reduce the target antigen 
lability. Neutral buffered formalin is a commonly used standard fixation method 
which preserves tissue structure well.
• Formol saline, BDH laboratory supplies, Poole, UK
• Xylene, Fisher Scientific UK Ltd.
Dissected tissues were fixed in 10% formalin for at least 24 hours prior to 
dehydration in a graded series of alcohol solutions and embedding in paraffin 
wax using a Shandon Hypercentre 2 automated tissue processor (programmed 
for use as follow). In brief, specimens were incubated in a series of diluted (70%, 
80%, 90%, 100%) alcohol to dehydrate tissue followed by incubation in xylene, 
then wax.
The tissue blocks were sectioned (to 4-6 pm) using a sledge microtome and 




IMS 70% 01:00 15
IMS 80% 01:00 15
IMS 90% 01:00 15
IMS 95% 01:00 15
IMS 100% 01:30 15
IMS 100% 01:30 15





Table 6.3 Embedding process procedure
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6.3.2.2 Deparaffinisation and tissue rehydration 
materials and methods
•  Xylene, Fisher Scientific UK Ltd.
• IMS, Sigma-Aldrich Co Ltd, Poole, UK
Deparaffinisation and rehydration is essentially the reverse process of 
embedding process. Generally, tissue blocks were deparaffinised in xylene, 
rehydrated in alcohol, and finally soaked in water. In detail, slides were incubated 
twice in xylene for 5 minutes each. The slides were then placed twice in IMS for 
5 minutes each to hydrate samples. Slides were lastly incubated in water for 5 
minutes.
6.3.2.3 Avidin-Biotin complex- Alkaline Phosphatase 
(ABC-AP)
• Aquamount, VWR International, Poole, UK
• Fast red, Sigma-Aldrich Co Ltd, Poole, UK
• Horse serum, (65mg/ml) Sigma-Aldrich Co Ltd, Poole, UK
• PBS (10X), VWR International, Poole, UK
• Mayer’s Haematoxylin, Sigma-Aldrich Co Ltd, Poole, UK
• Negative control Mouse lgG1, DakoCytomation Ltd, Ely, UK
• VECTA STAIN ABC Kit, Vector Laboratories Ltd, Orton Southgate,
Peterborough, UK
The ABC-AP technique was superior to PAP method for staining tissues rich in 
endogenous peroxidase (Cordell etal., 1984) such as arterial wall.
The following protocol was applied to sample slides and positive control slides 
(placenta) with the appropriate staining controls. Following the antigen retrieval 
process the slides were incubated with normal horse serum solution (65mg/ml * 
10pl per slide) for 20 minutes to block non-specific binding of immunoglobulin 
and followed by rinsing twice in PBS for 5 minutes each. Blocking solution was
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then removed and slides were incubated in diluted primary antibody in a humid 
box overnight at room temperature. Slides were then incubated with secondary 
antibody diluted in buffer (50|il biotinylated antibody in 10ml PBS) for 30 minutes 
at room temperature. At the same time, enzyme solution AB (100pl solution A in 
10ml PBS, then add 100 pi solution B, mix well) was prepared and was left for 30 
minutes at room temperature. Slides were washed twice in PBS for 5minutes 
each. Enzyme solution AB was added to each slide and left for 30 minutes at 
room temperature. Slides were washed again twice in PBS for 5 minutes each. 
Substrate solution (sigma fast-red as instruction manual) was prepared just 
before application to slides. Finally, slides were observed under LM to determine 
the end-point (when red stain appears). The reaction was eventually stopped 
with water, and counterstained with Mayer’s Haematoxylin for 1 minute. Slides 
were rinsed in running tap water for 5 minutes and covered with a coverslip on 
permanent aqueous mounting medium.
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6.4 Results
6.4.1 Presence of TRAIL, TRAIL-R1 and OPG protein in 
AAA samples
As is known, after an mRNA molecule is synthesised, many steps are required in 
order to produce a functional protein. Often, intracellular mechanisms conspire to 
alter or even destroy the mRNA or protein along the way. However, if mRNA is 
not expressed in the cell, the correlated protein cannot be transcribed. Thus, a 
further study of protein expression for TRAIL and its receptors was performed.
The investigation and analysis of mRNA expression among all three receptors 
were shown above (see chapter 5). It seems that TRAIL-R1 dominates in AAA 
formation between two death receptors. Osteoprotegerin was found to be 
significantly correlated with TRAIL and TRAIL-R1 and may play an important role 
in protection from AAA formation. However, antibodies for TRAIL-R3 and TRAIL- 
R4 were not available commercially when these experiments were carried out 
therefore only TRAIL, TRAIL-R1 and OPG protein were subjected to further 
study.
The reducing sample buffer worked well with pure control proteins but gave a 
high background when used with protein isolated from the AAA. It was 
considered that the reducing sample buffer might breakdown proteins too much 
and caused the high background, so a comparison of non-reducing sample 
buffer and reducing sample buffer was carried out. However, non-reducing 
sample buffer did not reduce the high background either. The reducing sample 
buffer was used since.
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Recombinant soluble human TRAIL protein was diluted into 30pg/ml, 20pg/ml 
and 10pg/ml and then subjected to Western blotting. The picture following shows 
the standard curve of human TRAIL. The human TRAIL was successfully 
detected by the methods detailed in chapter 6 methods and the band density of 
TRAIL protein was changed while the protein concentration changed.
TRAIL
Figure 6.6 shows the standard curve for recombinant soluble human 
TRAIL examined by Western blot as detailed in methods. Dilution for 
TRAIL was a 20pg/ml, b 30pg/ml and c 10pg/ml respectively. R indicates 
the rainbow size marker. The protein for TRAIL is in the right place 
according to the rainbow marker developed on the same film (indicated 
by red arrow).
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Recombinant human TRAIL-R1 proteins (dilution 30pg/ml, 20pg/ml and lOpg/ml) 
were detected by Western blot and developed on the film. They were shown on 
the following film though not very clear. The density of bands is still correlated 
with the concentration of the protein. TRAIL-R1 at 10pg/ml could not be detected 
on the film for two possible reasons. First, this might be because of a loading or 
dilution failure of this protein. Secondly, such a small amount of TRAIL-R1 
protein was not detectable by Western blot under the conditions used (detailed in 
methods).
TR A IL-R 1
Figure 6.7 shows the standard curve for recombinant soluble human 
TRAIL-R1 examined by Western blot (detailed in methods). Dilution for 
TRAIL-R1 was a 30pg/ml, b 20pg/ml and c 10pg/ml respectively. The 
bands of protein are not very sharp. However, the tendency still can be 
observed that band density intensifies while the protein concentration 
increases. The TRAIL protein of 10pg/ml could not be detected. R 
indicates the rainbow marker loaded on the same gel with these proteins. 
The bands were detected at the 55kDa position according to the rainbow 
size marker.
135
Human purified OPG protein was detected by Western blot as shown in figure 
6.50. The samples were diluted to 30pg/ml, 20pg/ml and 10pg/ml. The band of 
protein with dilution of 10pg/ml is not very clear. However, the standard curve 
tendency can be seen. The band density increases while protein dilution 
increases. The possible reasons for the poorly defined band at 10pg/ml protein 
may be, firstly, loading error and secondly, this small amount OPG protein can 
not be detected under the conditions of antibody dilution used.
OPG
Figure 6.8 shows the standard curve for recombinant soluble human OPG. 
The dilution range for OPG was 30|jg/ml (a), 20pg/ml (b) and 10pg/ml (c). 
Dilution for the primary antibody was 1:1000. The changes of band 
density follow the change of dilution for protein. R indicates the rainbow 
size marker on the film marked with pen from the positions on the original 
membrane. Red arrow indicates the position of the target protein.
The protein for TRAIL, TRAIL-R1 and OPG was determined by Western blot as 
shown in Figure 6.9. These samples were extracted from AAA (detailed in 
6.3.1.1) and loaded with rainbow marker (R) on each gel. The protein obtained 
from AAA were observed and shown on the film without cross reaction, for this 











Figure 6.9 shows 4 Western blot analyses performed on AAA protein to 
detect OPG expression in 12% acrylamide gel, and TRAIL, TRAIL-R1 
protein expression in 9% acrylamide gel. A rainbow marker was loaded on 
each gel for band size identification. Panel a shows a membrane loaded 
with two different AAA protein samples indicated as 1 and 2 probed with 
mouse anti-human OPG (dilution 1:1000). Panel b shows 3 AAA samples 
(1, 2 and 3) probed with polyclonal rabbit anti-human TRAIL antibody 
(dilution1:500). The continuous line underneath the protein bands here 
are the bottom of the gel. Panel c shows 6 different AAA protein samples 
labelled 1-6 probed with polyclonal rabbit anti-human TRAIL- R1 antibody 
(dilution 1:1000). Sample d here was not expressed TRAIL-R1 protein. The 
other band images are not clear, however there were no cross reactions. 
Panel d represents a Western blot of 3 AAA samples probed with anti- 
TRAIL-R1 but without a secondary antibody (2°). It clearly shows that 
TRAIL-R1 primary antibody works well in AAAs. Red arrows indicate the 
molecular weight of each protein respectively. R indicates the rainbow 
marker on each film.
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The samples from normal aortae and AAAs were subjected to Dot blot 
procedures described in the methodology section in chapter 6.
Figure 6.10 shows the representative films of TRAIL (panel a), TRAIL-R1 
(panel b) and OPG (panel c) protein expression in AAA samples 
determined by protein Dot blots. P indicates positive control (purified 
protein) for antibody used on each film. N indicates negative control 
(purified water) on each film. Two AAA samples probed for TRAIL are 
shown on panel a indicated as a and b. Three AAA proteins samples 
probed for TRAIL-R1 are shown on panel b indicated as a, b and c. 
Sample 1 did not express TRAIL-R1 protein. Two AAA protein samples 
probed for OPG are shown here on panel c indicated as 1 and 2.
138
The presence of TRAIL protein in human AAA tissue was confirmed in fresh AAA 
tissue that was paraffin-embedded and prepared as described in section 6.3.2.4 
for immunohistochemistry staining.
Figure 6.11 Immunohistochemical staining was performed for TRAIL (a and 
b). Arrows indicate positive staining. The micrograph in Panel b was taken 
using higher power microscopy than panel a originally.
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The presence of TRAIL-R2 in human AAA tissue was visualised in fresh AAA 
that was also paraffin-embedded and stained as detailed in 6.3.2.4 shown in 
figure 6.12. The panel b of the figure shows obvious cholesterol deposition.
Figure 6.12 Immunohistochemical staining for TRAIL-R2 was performed. 
Black arrows in picture a indicate positive staining on the medial layer of 
AAA (M). The open, needle-like spaces (red arrows indicated) in the picture 
b are cholesterol clefts on the intimal layer (I). L= lumen
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OPG existence in human AAA tissue was confirmed in fresh AAA tissue that was 
subjected to paraffin-embedding and immunohistochemistry staining. Figure 6.13 
shows that more OPG is expressed in the medial layer of AAA than in the tunica 
adventitia layer of AAA.
Figure 6.13 Immunohistochemical staining for OPG. Picture a shows tunica 
media (M) and picture b shows tunica adventitia (A) in cross section. 
Arrows indicate positive staining. Negative controls of staining were done 
but are not shown here.
6.4.2 Protein expression in normal aortae
Isolated protein from 12 normal aortae was subjected to dot blots. Most normal 
aortic vessel walls (90%) express TRAIL-R1, 64% express TRAIL and 54% 
express OPG. A normal aorta sample with atherosclerosis only expresses OPG. 
Both normal aortae whose ages are 15 and 24 year old respectively, express 















Figure 6.14 shows frequency distribution histogram of donor age of normal 
aortae examined. Most patients were aged from 50-60-year old including 
one with atherosclerosis. Two patients were aged younger than 30-year 
old.











AAA samples (increasing age) ►
Figure 6.15 The summary graph of protein expression in normal aortae 
(n=12) in the order of donor ages ( Figure 6.14). Every group of bar series 
represents a sample. TRAIL-R1 was expressed the most often and OPG 
was expressed half of the vessels. The last normal aorta (sample 12) was 
the one with atherosclerosis. There is no correlation was found between 
ages of AAA donor and concentration of protein expression.
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Combining the age with protein expression in normal aortae, youngest age group 
only express TRAIL, TRAIL-R1 but no OPG. Oldest age group only express 
TRAIL-R1 or OPG excluding one expressing all three proteins. The middle age 
group express all three proteins and in relatively higher abundance compared to 
the other two groups. This was shown in Figure 6.15.
6.4.3 Protein expression in AAA
Following graph shows concentrations of protein expression in normal aortae 
and AAAs. No significant difference was found. More protein was expressed in 
normal aortic walls than in AAAs.
Protein expression in AAAs
25 1 
g 20 I
AAA samples ( — ►increasing age)
■ TRAIL* TRAIL-R1 □ OPG
Figure 6.16 This diagram indicates the level of normalised total protein 
expression for TRAIL (blue), TRAIL-R1 (pink) and OPG (green) in 42 AAA 
samples. The sample was arranged according to the order of the age of 
donors for AAA. No certain pattern was found. However, the diagram 
shows clearly that significantly more TRAIL-R1 protein was expressed 
than OPG protein in AAAs (**p<0.01, paired t test, confidence >95%). 
TRAIL was expressed at a similar level to TRAIL-R1. They were weakly 
correlated (r=0.35). In contrast, TRAIL was expressed at a significantly 
higher than OPG (***p<0.001, by two tailed t test).
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6.4.4 Protein expression correlated with the diameters of 
AAA size
Abdominal aortic aneurysms were subclassified into two categories according to 
their diameters. This classification is based on three stages of AAA progression: 
development, growth and rupture. These three stages correlate with the diameter 
of AAA (Maeda T, 1996). Since all the AAA specimens were obtained from 
elective surgeries, the diameter is above 50mm. The average AAA size of 
patients is 6.7 cm from 01/1990-06/2001 in Royal United Hospital, Bath. The 
diameters of sample AAAs were between 5cm and 8.3cm (mean diameter 6.5 ±1 
cm). Thus, the samples are representative.
Accordingly, AAA diameters smaller than 69mm and greater than 50mm were 
considered as AAA at the growth stage. Aneurysm diameters greater than 69mm 
were considered as AAA at the final stage.







TRAIL TRAIL-R1 OPG 
<69mm
Figure 6.17 TRAIL, TRAIL-R1 and OPG protein expression in AAA. Panel a 
indicates their expression in the group whose diameter is greater than 
69mm (n=7) and panel b indicates their expression in the group whose 
diameter is less than 69mm (n=19). The same trend was found in both 
groups that TRAIL was expressed the most and OPG was expressed the 
least. TRAIL was expressed significantly higher than OPG in the group with 
a diameter of less than 69mm. The top of the bar represents standard error.
AAA <69mm AAA >69mm
TRAIL
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Figure 6.18 These graphs illustrate protein expression levels in AAA. Graph 
a shows the protein expression for TRAIL in both AAA groups. Graph b 
shows protein expression for TRAIL-R1 in both AAA groups. Graph c 
shows the protein expression for OPG in both AAA groups. No significant 
difference in expression of these 3 proteins in either AAA groups. There is 
a tendency that all three of them increase as the diameters increase. The 
top of the bar represents standard error.
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6.4.5 Comparison of protein expression between normal 
aortae and AAA
6.4.5.1 Frequency of protein expression in normal aortae 
and AAAs
Comparing protein expression in normal aortae and AAA, more AAA vessels 
expressed TRAIL than normal aortic vessels. Fewer AAA vessels expressed 
TRAIL-R1 and OPG than normal aortic vessels.
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Figure 6.19 The graph illustrates the frequency of protein expression in 11 
normal aortae and in 42 AAA vessel walls. TRAIL was expressed more 
often in AAAs than in normal aortae, and TRAIL-R1 and OPG were 
expressed in fewer AAA than normal aortae. There is, however, no 
significant difference between the frequencies of expression of protein.
Proteins for TRAIL and TRAIL-R1 were widely expressed in the AAAs and 
normal aortae while mRNA for both of them was only detected in approximately 
50% of vessel walls.
As was suggested in the last chapter, TRAIL-R1 dominated initially in AAA 
formation and the mRNA expression for TRAIL and OPG is perfectly correlated. 
Hence, the concentration of proteins for OPG could represent the effect of 
apoptosis inhibition. Comparing proteins expression for TRAIL, TRAIL-R1 and
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OPG in normal aortae (n=11) and AAAs (n=42), significant differences were 
found between normal and abnormal aortae (*p<0.05, using a one-way ANOVA 
test, confidence >95%). The normal aorta with atherosclerosis was not included 



















Figure 6.20 Summary box and whisk graphs of protein expression in 
normal aortae and aneurysm. More TRAIL, TRAIL-R1 and OPG were 
expressed in normal aortae than in AAAs.
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6.4.5.2 Concentration of protein expression in normal
aortae and AAA
The expression of TRAIL protein was greater in the AAA but less TRAIL-R1 and 
OPG were expressed in the AAA compared to normal aortae. This is compatible 
with the mRNA results that TRAIL is upregulated in the AAA tissue and its 
receptors are downregulated.
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Figure 6.21 The graph shows that TRAIL, TRAIL-R1 and OPG were 
expressed in the normal aortae and AAAs. The same tendency was 
observed here as TRAIL was expressed the most and OPG was expressed 
the least in both normal aortae and AAA. More TRAIL was expressed in the 
AAA but TRAIL-R1 and OPG were expressed less in the AAA compare to in 
the normal aortae. Significant difference was found of OPG protein 
between normal aorta and AAA. OPG was found to be significantly 
expressed higher in the normal aortae. NA refers to normal aortae. (*P< 
0.001, one-way ANOVA test, confidence> 95%). The top of the bar 
represents standard error.
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6.4.6 The correlation between Calcification Score and 
protein
As shown in chapter 5, CT scans demonstrate that the proximal is the least 
calcified area and the distal is the most calcified area in AAA. Figure 6.22 
demonstrates that this is irrespective of AAA diameter.








Figure 6.22 AC score correlation with proximal, body and distal AAA area 
in different AAA diameters’ groups. Figure a shows AC score in AAA 
whose diameter is greater than 69mm (n=7) and figure b shows AC score in 
AAA whose diameter is smaller than 69mm (n=19). These graphs clearly 
show that distal is the most calcified area and proximal is the least 
calcified area irrespective of diameter. (*p<0.05) The top of the bar 
represents standard error.
150
Sufficient evidence exists showing that OPG is expressed in calcified vessel 
walls (Dhore et al., 2001) but there is no study about TRAIL and TRAIL-R1 
protein expression in the vessel wall. Thus it is worth exploring their expression 
in the three areas under examination (proximal, body and distal) to draw a better 
conclusion.




Figure 6.23 AC score of outer and inner layer of AAAs. Inner layer of AAA 
is significantly less calcified than outer layer of AAAs (***p<0.0001, paired t 
test, confidence >95%). The top of the bar represents standard error.
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Percentage of AAA vessel walls expressing protein 




















Figure 6.24 This graph shows the frequency of protein expression in 
proximal, body, distal AAAs (n=42). More vessels in the AAA express 
TRAIL-R1 and OPG protein as the area becomes more calcified (body and 
distal region), while the body area expresses the most TRAIL and the 
distal area expresses the least TRAIL. This is consistent with mRNA 
expression findings.
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6.4.7 Concentration of protein expression in different 
areas of AAA walls















Figure 6.25 show TRAIL, TRAIL-R1 and OPG protein expression in proximal 
(n=9), body (n=11) and distal area (n=12) in AAA. Graph a shows their 
expression in proximal AAA. TRAIL was expressed the most and 
significantly higher than TRAIL-R1. TRAIL-R1 was expressed the least. 
Graph b shows their expression in body AAA. TRAIL was expressed the 
most and OPG was expressed the least. Graph c shows their expression in 
distal AAA. They were expressed very similarly. The top of the bar 
represents standard error.
The expression of proteins was compared in each AAA region individually. 
TRAIL, TRAIL-R1 and OPG were spread fairly equally in the distal region. 
Significant differences were found in proximal and body AAAs, which are 
considered as processes of ongoing calcification.











Figure 6.26 TRAIL, TRAIL-R1 and OPG protein expression in proximal, 
body and distal AAA. Panel a indicates TRAIL expression in these regions. 
TRAIL was expressed very similarly in all three regions. Panel b indicates 
TRAIL-R1 expression in these regions. TRAIL-R1 was expressed the most 
in the distal AAA and the least in the proximal AAA. Panel c indicates OPG 
expression in distal AAA. OPG was expressed the least in the body AAA 
and most in the distal AAA. The top of the bar represents standard error.
A similar protein expression for TRAIL was observed in these three regions. 
Thus, the capacity of the TRAIL-rTRAIL system to induce or inhibit apoptosis 
depends on TRAIL receptors. TRAIL death receptor (TRAIL-R1) was expressed 
the most abundantly in the most calcified area (distal AAA). This implies that the 
potential to induce apoptosis increases in the more calcified AAA. TRAIL decoy 
receptor (OPG) was expressed the least in the body AAA (enlargement of AAA) 
and the most profusely in the distal AAA. This entails that OPG was counter­
regulated in the most calcified area. Also this suggests that OPG might be 
competing with death receptors of TRAIL in the body AAA to inhibit apoptosis 
induced by TRAIL.
The ratios of TRAIL to TRAIL-R1 and TRAIL to OPG were compared with AC 
score in figure 6.27. There is not any linear regression between the ratios and 
AC score. This indicates AAA formation is not simply related to the calcification 
level of vessel walls. It implies a more complex situation that is influenced by the 
position within the vessel wall.
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Figure 6.27 Non-linear regression between TRAIL to TRAIL-R1 and AC 
score; and TRAIL/ OPG and AC score. Panel a indicates non-linear 
regression between TRAIL to TRAIL-R1 and AC score; and graph b 
indicates non-linear regression between TRAIL/ OPG and AC score. TRAIL 
was expressed very similarly in all areas of AAA (see Figure 6.26), thus TRAIL 
to TRAIL-R1 indicates the possibility of TRAIL to induce apoptosis. The 
ratio of TRAIL to OPG indicates the potential of TRAIL to inhibit apoptosis. 
This indicates that the possibility of intervention by inhibition or induction 
of apoptosis is reduced when the AC score elevated.
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6.5 Discussion
6.5.1 Protein expression for TRAIL, TRAIL-R1 and OPG 
in normal aortae
All normal aortae were obtained with informed consent from Bristol Southmead 
Hospital. Considering the age difference of the specimen donors, no OPG was 
expressed in younger age group (<25 year old) and in 70% vessel walls of older 
age group (>40 year old). This agrees with the finding of higher OPG expression 
in the old than in the young (Hak et al., 2000; Jono et al., 2002). Very 
imbalanced distribution of the three proteins was found in the age above 50. This 
might imply that more apoptosis occurs in the elderly.
6.5.2 Protein expression for TRAIL, TRAIL-R1 and OPG 
in AAA
Osteoprotegerin (OPG), a decoy receptor of TRAIL discovered in 1997, can 
inhibit osteoclast maturation to protect from osteoclast remodelling (Simonet et 
al., 1997). Increasingly evidence suggests the involvement of OPG in vascular 
disease. It has been identified in human carotid stenosis (Golledge et al., 2004), 
and serum levels of OPG have been found to be positively correlated with the 
onset and severity of atherosclerotic artery disease (Erdogan et al., 2004b; Jono 
et al., 2002; Nitta et al., 2003). It was also found to be distributed around 
calcification areas associated with inflammatory cells and vascular SMC (Moran 
eta!., 2005).
When TRAIL, TRAIL-R1 and OPG expression was compared on AAA walls, 
TRAIL and TRAIL-R1 were expressed at very similar levels (weak positively 
correlated), but OPG is expressed significantly less than either (weak negatively 
correlated). A recent study suggests that OPG protein maybe down-regulated in 
calcified arteries, whereas the expression of transcription factors that regulate 
mineralisation and osseous differentiation programs, and the up-regulation of 
osteogenic genes such as alkaline phosphatase, bone sialoprotein, or boneGLA 
protein in vascular smooth muscle cells in the course of medial calcification has
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been demonstrated (Dhore et al., 2001). This is compatible with the finding that 
OPG expression is less than TRAIL and TRAIL-R1 in the AAA.
The potential morbidity of an aneurysm increases with increasing size. Larger 
aneurysms are more prone to rupture and cause life-threatening complications. 
Serum OPG was found to be correlated weakly with aneurysm growth rate 
(Moran et al., 2005). Aneurysms were analysed after sub-classification into two 
groups according to AAA diameter. TRAIL-R1 protein was expressed more often 
in the AAA group with bigger AAA than in the other group. This implies that 
TRAIL might influence the disorder of elastin metabolism and participate in both 
stages of AAA formation. Osteoprotegerin protein was expressed along with 
TRAIL-R1. Overall, TRAIL and its receptors show greatest expression in the 
larger aneurysm group (diameter greater than 69mm, see Figure 6.17). This 
suggests a possible correlation between TRAIL and its receptors with aneurysm 
size that warrants further investigation.
6.5.3 The comparison of protein expression between 
normal aortae and AAA
The reason for analysing the frequency of protein expression is to ascertain the 
difference between their absence and presence. More TRAIL was expressed 
than OPG in AAAs. Interestingly, TRAIL-R1 and OPG were expressed on fewer 
AAA vessel walls than normal aortae. This finding is consistent with mRNA 
expression. However, only 50% of AAA vessels expressed TRAIL-R1 mRNA but 
more AAA vessels expressed TRAIL-R1 protein. Firstly, this could be because 
protein dot blot used is more sensitive for detecting TRAIL-R1 protein than RT- 
PCR used for mRNA detection. Secondly, protein might last longer than mRNA 
post mortem even though the tissue was strictly snap-frozen after being 
transferred to the laboratory to minimise destruction by proteinase inhibitors. 
Finally, it could be because mRNA was already transcribed into protein at the 
analysis stage. Therefore, less mRNA was found than protein for TRAIL-R1 in 
AAA.
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6.5.3.1 Concentrations of protein expression in normal 
aortae and AAAs
There are differences in TRAIL, TRAIL-R1 and OPG levels between normal 
aortae and AAAs. According to Figure 6.21, TRAIL was expressed higher in 
AAA and TRAIL was expressed less in AAA than normal aorta. OPG was 
significantly higher in the normal aorta compare to AAA. This is consistent with 
discoveries of mRNA detection and demonstrates that TRAIL, TRAIL-R1 and 
OPG contribute to AAA formation.
Osteoprotegerin was found to be expressed higher in the age-matched AAA 
tissue (n=5) than in aortic occlusive disease (n=10), thoracic aorta (n=10) 
undergoing coronary artery bypass graft (CABG) and normal aorta (n=5) (Moran 
et al., 2005). The findings in this project do not agree with this. More OPG was 
expressed in normal aortae (n=11) than in AAA (n=42). Three factors could be 
responsible for this. Firstly, a much smaller number of AAA was examined in the 
Moran et al. studies than in this study. Secondly, thoracic aorta begins at the 
lower border of the fourth thoracic vertebra and ends in front of the lower border 
of the twelfth at the aortic hiatus. Abdominal aorta follows it and ends on the 
body of the fourth lumbar vertebra dividing into the two common iliac arteries 
(Gray H., 1918). Anatomically, the normal aorta sample used in this project is 
closer to AAA. Previous finding in chapter 5 between umbilical artery and normal 
aorta suggests that different vascular bed may express the TRAIL system 
differently. Finally, greater age difference of normal aorta samples and AAA in 
this project could be a reason of these opposite findings. The average age of 
normal aorta donors in this project was 46±13 and that of AAA was 76±7 while 
the age was matched in Moran et al. study (65±6). Taken together, these 
findings may imply that OPG is upregulated from the young to the older (around 
60-year old) and downregulated after seven to eight decades of life. It may also 
imply that OPG is downregulated while the AAA diameter gets bigger and 
reaches the certain point (average 6.5±1 cm) since AAA is an increasing dilation 
of the abdominal aorta.
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6.5.4 Protein expression in different AAA areas
The observations in comparison of three AAA regions as described in chapter 5 
not only indicate that TRAIL, TRAIL-R1 and OPG proteins were expressed in the 
atherosclerotic lesion of human aorta but also, more importantly, show that the 
magnitude of TRAIL-R1 expression increases in proportion to the stage of 
atherosclerosis. TRAIL-R1 was expressed the most in distal AAA and the least in 
proximal AAA. TRAIL was expressed similarly in all areas. This confirms the 
hypothesis that as a death receptor, TRAIL-R1 induces apoptosis to initiate 
calcification in AAAs. As a decoy receptor, OPG was expressed the least in body 
AAA and the most in distal AAA, suggesting that OPG might protect cells from 
apoptosis in a protective manner in body AAA and reactive manner in distal AAA. 
In addition, the weak negative correlation between calcification level (determined 
by AC score) and the ratios of TRAIL to OPG and TRAIL to TRAIL-R1 indicated 
TRAIL-R1 and OPG increase when calcification level increases. This is partly 
consistent with serum OPG correlation with AAA growth rate.
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7.
Chapter 7 Apoptosis in AAAs
7.1 Introduction
7.1.1 Apoptosis in aneurysm smooth muscle cells
Apoptosis has been observed in rat SMCs in vitro (Bennett e ta l., 1994), cultured 
human SMCs (Bjorkerud et al., 1994) and in remodelling of sheep arterial walls 
(Cho et al., 1995). Smooth muscle cell disappearance and extensive apoptosis 
were also found to co-localise in the medial layer of advanced saccular cerebral 
aneurysms in rats. In addition, apoptosis-affected SMCs frequently appear in the 
medial layer of pre-aneurysms or early aneurysms in the rat model of saccular 
cerebral aneurysms (Kondo etal., 1998). Particularly, these changes were at the 
distal site of the aorta where the aneurysmal changes started. More apoptotic 
cells were detected while apoptosis was at an early stage rather than at a later 
stage. The aneurysm body develops from the early stages of aneurysm 
formation often the late stages of aneurysm established the proximal area of the 
aneurysms. In another words, this indicates that apoptosis primarily occurs in the 
body of aneurysms before they enlarged.
Furthermore, since SMCs have been found going through all the stages of 
apoptosis, this demonstrates that they undergo apoptosis during the complete 
formation of aneurysm (Thompson etal., 1997). The role of apoptosis in SMCs in 
tunica media of aneurysm has not been clearly elucidated but the above 
evidence provides support for apoptosis involvement in the formation of 
aneurysm in animal models.
7.1.2 Apoptosis within the human abdominal aortic 
aneurysms
Human aneurysm, similarly to animal aneurysm, is a progressive weakening of 
the aortic wall. Aorta dilates gradually to form AAA and normally it is 
asymptomatic until the aneurysm eventually ruptures. Important pathological 
features of AAA include calcification of the vessel wall (Halloran and Baxter, 
1995), medial lamellae degeneration (Zatina et al., 1984), accelerated collagen 
turnover (Satta et al., 1995) and decreased medial SMC density (Zhang et al., 
2003; Lopez-Candales etal., 1997).
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As mentioned in chapter 3, elastic content and elastic fibre structure and 
production of elastin-degrading proteinases contribute to altered human aortic 
wall tone. The tensile strength, resiliency and completeness of the vessel wall 
normally depend on the elastin and collagen on the arterial wall and these two 
components’ failure will cause aneurysm rupture (Thompson et al., 1997). 
Therefore, aneurysm could be a consequence of endothelial cells in the 
aneurysm acting as a mechanosensor perceiving increased wall shear stress. 
Internal elastic lamina degeneration. Smooth muscle cells are reported to 
synthesise and secrete connective tissue matrix, including elastic tissues (Ross, 
1971). Thus, a reduction in SMCs number would result in medial layer vessel 
wall thinning. Both changes could contribute to increasing aortic wall stress.
Apoptotic cells were also observed in the human AAA and display all stages of 
apoptosis characterisation. Especially these cells were SMCs in the medial layer 
of AAA. Therefore, apoptosis might participate to the degeneration of AAA.
Molecular apoptotic marker (P21) was also documented to be observed between 
AAA and normal aorta (Thompson et al., 1997). Medial SMCs were found to 
express FAS in aneurysm tissue. This confirms apoptosis might alter SMC to 
precipitate the AAA formation. TRAIL, like FASL is a member of TNF family and 
capable of inducing apoptosis. Significant difference of TRAIL and its death 
receptors were discovered between normal aorta and AAA in the last chapter. It 
is highly likely that TRAIL and its death receptors might also participate in AAA 
formation. However, the question of co-localisation of TRAIL and apoptosis in the 
aneurysm wall has not been elucidated, further investigation is therefore needed.
7.1.3 Smooth muscle cells in AAA
The vascular SMC is the most abundant cell type in the medial layer of human 
aortae. The SMC layer confers the strength and elasticity of the aortic wall. They 
are important in controlling vascular tone and the disruption of their integrity is a 
factor in the formation of aneurysms. They also can synthesise proteins such as 
collagen, elastin and laminin, which compose the extracellular matrices of the 
tunica media (Cheuk and Cheng, 2005).
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The vascular SMCs fail to protect and repair injury to critical load bearing matrix 
structures in the aortic wall. The elastic lamina is broken down and the SMC 
layer appears disorganised (Cheuk and Cheng, 2005) which might respond to 
the products of atherosclerosis (Cohen et al., 1992). Ultimately these processes 
result in the instability of the aortic wall and subsequent formation of AAA.
It is well documented that SMC migrate from the tunica media to the tunica 
intima in the early AAA. This could be a key process of atherosclerosis. Also 
apoptosis occurring in the SMC could result in the weakness of atherosclerotic 
plaque (Chan et al., 2005). In addition, those cells with osteoblastic 
characteristics, producing all the major components of osteoid, have been 
isolated from the vascular media (Bostrom, 2001).
Thus it is imperative to understand the characterisation of SMC in the AAA wall 
and interaction of TRAIL in the SMC.
7.1.4 Terminal deoxynucleotidyl transferase biotin-dUTP 
nick end labelling (TUNEL) assay introduction
Numerous histological methods are used to detect apoptosis of different stages. 
Typical assays include Annexin-V binding, caspase enzyme activity, TUNEL 
assay and DNA gel electrophoresis. Annexin-V binding assay can separate 
necrotic cells from those undergoing apoptosis. Caspase enzyme assay can 
determine which stage of apoptosis may be occurring in cells. As mentioned in 
chapter 3, DNA becomes fragmented in pieces of 200bp or less length in the 
process of apoptosis at final stage. These DNA fragmentations are very easy to 
be visualised by agarose gel or TUNEL assay.
TUNEL assay uses terminal deoxynucleotidyl transferase (TDT) to transfer 
biotin-dUTP to those strand breaks of cleaved DNA to detect apoptotic cells. It is 
one of the commonly used methods to detect the late stage cells undergoing 
apoptosis. Also it is the most popular method which can be used in tissue 
sections (Hawkins etal., 1997). TRAIL induces apoptosis by caspase-dependent 
pathways, which involve late dissipation of the mitochondrial membrane potential
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and cytochrome c release that follows activation of caspase-8 and caspase-3 
and induction of DNA fragmentation (Thomas et al., 2000). The AAA samples 
obtained from selective surgeries were considered to be at a mature stage. They 
were theorised to be at the late stage of apoptosis if there was any expression. 
In addition, they were preserved in the form of paraffin sections. According to the 
limitation of AAA samples and storage of specimens, TUNEL assay was used to 
identify apoptosis. In another words, the most reliable technique in detecting the 
extent of apoptosis in tissue sections would most likely be combining the two 
techniques based on apoptotic morphology and specific labelling of apoptotic 
DNA and TUNEL assay is the most appropriate assay for this study (Anna-Kaisa 
Eerola, 2000).
Large numbers of DNA fragments appearing in apoptotic cells results in a 
multitude of 3'-hydroxyl termini in the DNA. It can be used to identify apoptotic 
cells by labelling the 3'-hydroxyl ends with directly conjugated fluorescent- 
deoxyuridine triphosphate nucleotides (FITC-dUTP). TDT catalyses a template 
independent addition of deoxyribonucleoside triphosphates to the 3'-hydroxyl 
ends of double- or single-stranded DNA with either blunt, recessed or 
overhanging ends. Non-apoptotic cells do not incorporate significant amounts of 
the FITC-dUTP owing to the lack of exposed 3'-hydroxyl DNA ends. The 
apoptotic cells in tissue sections can be identified by the biotin-labelled cleavage 
sites which are detected by reaction with HRP conjugated streptavidin and 
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Figure 7.1 Diagrammatic representation of the addition of FITC-dUTP 
catalysed TDT to the 3’-OH sites of DNA breaks. The DNA strand breaks are 
detected by enzymatically labelling the free 3'-0H termini with modified 
nucleotides. The new DNA ends that are generated upon DNA 
fragmentation are typically localised in morphologically identifiable nuclei 
and apoptotic bodies.
7.1.5 Alternative apoptosis cellular marker introduction
Human FLIP, known as an inhibitor of caspase 8 (FLICE), caspase 10 or FADD, 
is an inhibitor of extrinsic apoptosis pathway. FLIP has four splice variants, a, p, 
y and k . They contain two death effector domains and one caspase domain and 
compete with mediating apoptosis caspase to inhibit apoptosis (Hu et al., 1997). 
Molecular weights of these four splices are variable from 28 kDa to 58 kDa. To 
confirm apoptosis is involved in AAA formation it would be interesting to 
investigate the presence of FLIP.
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7.1.6 Indicator of smooth muscle cells and 
atherosclerosis
Smooth muscle actin, a-actin, is one of few gene which is strictly expressed in 
vascular smooth muscle cells. It is altered by cell proliferation, and pathological 
conditions such as atherosclerosis (Reddy etal., 1990).
Smooth muscle heavy chain (SMHC) isoform has two types of clones, SMMS-1 
and SMMS-2 which were first isolated by Nagai et al. (1989). It has been found 
that SMMS-1 was expressed more selectively in aorta than SMMS-2 during early 
normal vascular development and in experimental arteriosclerosis and 
atherosclerosis development (Kuro-o M et al., 1989). Intimal smooth muscles 
diminished the expression of both isoforms of SMHC, whereas a-actin was well 
preserved during the progression of atherosclerosis. Hence, SMMS-1 and 
SMMS-2 are important molecular markers for studying human vascular smooth 
muscle cell differentiation as well as the cellular mechanisms of atherosclerosis. 
Furthermore SMMS-1 is an important cell marker for the study of development of 
atherosclerosis in aortae (Aikawa etal., 1993).
7.2 Aims and objectives
•  To determine whether apoptosis is in the AAA tissue
•  To determine how much apoptosis occurs in AAA
• To determine whether the TRAIL-rTRAIL system expresses in the human
cultured SMC
• To determine whether atherosclerosis is localised in the AAA tissue
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7.3 Materials and methods
7.3.1 Terminal deoxynucleotidyl transferase biotin-dUTP 
nick end labelling (TUNEL) assay materials and 
methods
•  Aqueous mounting medium for fluorescence with DAPI, Vector Laboratories
Ltd, Orton Southgate, Peterborough, UK
• Protease K, Sigma-Aldrich Co Ltd, Poole, UK,
•  Internal apoptosis positive control, ApopTag kits, CHEMICON Europe, Ltd.,
UK
• Zeiss fluorescence microscope, Carl Zeiss Inc., USA
Normal aorta and AAA tissue samples were stored in 10% formalin for 24 hours 
and then deparaffinised. The tissue sections were cut into 4-5 pm slides and pre­
treated with Protease K for 15 minutes at room temperature. The slides were 
washed twice in PBS for 2 minutes each followed by applying 75pl/ 5cm2 
equilibration buffers for at least 10 seconds at room temperature. Then 55pl/ 
5cm2 working strength TDT enzyme was applied on each slide and incubated in 
a humid incubator at 37°C for 1 hour. These slides were then immersed into the 
working strength stop buffer to end the reaction. After agitation for 15 seconds, 
slides were incubated for 10 minutes at room temperature. They were washed 
three times in PBS for 1 minute each. Subsequently, 65pl/ 5cm2 warm working 
strength antidigoxigenin conjugate was applied to the slides. The slides again 
were incubated in a humid incubator for 30 minutes at room temperature. Final 
wash was carried out by rinsing with PBS four times for 2 minutes each. An 
aqueous mounting medium containing DAPI mount (2 drops) was used and 
slides were finally visualised under a microscope by DAPI (wavelength 350- 
400nm) (Chemicon international., 2006).
Internal positive control, AAA samples and internal negative controls (AAA slides 
without exposing to TDT enzyme) were performed according to the above 
protocol. Samples sizes were around 5mm2 since TUNEL was proved to be very
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sensitive to small size sample fixation (Labat-Moleur et al., 1998). Images were 
viewed using a FITC filter in Zeiss fluorescence microscope or LM. The desired 
area of analysis is located visually by using the camera on the Zeiss microscopy. 
Scan area are set and the scan initiated using 10X and 40X objective 
magnification. Negative control tissue was used to define the false-colour 
assignments. Ten contiguous fields per slide were chosen randomly and the 
number of apoptotic cells was manually counted because the background colour 
of slides made automated counting problematic. Apoptotic index (Al) was 
determined.
Al= (number of TUNEL-positive cell nuclei/ total number of cell nuclei) %
7.3.2 Calcification detection
Various techniques are used to characterise biological mineralisation in intact 
tissues and cell cultures including the von Kossa staining method, CT scan and 
fourier transformed infrared spectroscopes (FTIR). A study demonstrated that 
Von Kossa staining alone is not an appropriate way to identify and quantify bone­
like mineral (Bonewald et al., 2003), therefore, this was used to verify the 
presence and location of calcium deposition.
7.3.3 Von Kossa staining materials and methods
•  Aqueous safranin O, Sigma-Aldrich Co Ltd, Poole, UK
• IMS, Sigma-Aldrich Co Ltd, Poole, UK
•  Silver nitrate, Sigma-Aldrich Co Ltd, Poole, UK
•  Sodium thiosulphate, Sigma-Aldrich Co Ltd, Poole, UK
• DePeX mounting medium (DPX), BDH laboratory supplies, Poole, UK
Paraffin-embedded sections were cut into 4-5pm thickness slices. These slides 
were soaked with water, and then treated with a 5% silver nitrate solution (25mg 
silver nitrate in 500ml distilled water). The slides were exposed to strong light for 
45-60 minutes to let the silver deposit by replacing the calcium. Then they were 
washed with distilled water and treated with 3% sodium thiosulphate for 5
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minutes followed by washing with water. Counterstain in 0.5% aqueous safranin 
O for 60 seconds. Finally dehydrate slides with 95% and 100% IMS in the order 
and amount slides in DPX. Slides were ready to be visualised as metallic silver 
under the LM. The calcium deposition was shown in black, cytoplasm was shown 
in pink and nuclei were shown in red.
Normal aorta tissue, negative control for each AAA slides (staining without sliver 
nitrate) and AAA sample were followed above protocol.
7.3.4 Haematoxylin and Eosin (H&E) staining
• Acid Alcohol 1%: 70% Alcohol 99ml + conc. Hydrochloric Acid 1ml
•  Eosin powder: Sigma-Aldrich Co Ltd, Poole, UK
• Mayer’s Haemotoxylin, Sigma-Aldrich Co Ltd, Poole, UK
• DePeX mounting medium, BDH laboratory supplies, Poole, UK
Deparaffinsed sections were placed in haematoxylin for 5 minutes followed by 
washing in running water for 5 minutes. Then slides were placed in 1% acid 
alcohol for 60 seconds. Slides were washed in running water again for 5 minutes 
and thereafter were immersed in eosin (eosin Y (Yellowish): 1.0g + Distilled 
Water 100ml) for 5 minutes. After washing in water for another 5 minutes, slides 
were dehydrated and mounted in DPX.
Slides were viewed under LM to identify blue nuclei, pink cytoplasm, dark pink 
fibres to distinguish the sections structure.
7.3.5 Smooth muscle cell culture materials and methods
• 6 well plate, Orange Scientific, Belgium
• Acutase, TCS CellWorks Ltd, Botolph Claydon, UK
• Cell dissociation solution, Sigma-Aldrich Co Ltd, Poole, UK
• Dulbecco’s Modified Eagle Medium (DMEM), Gibco, Life Tech, Paisley, UK
• Foetal calf serum (FCS), Globepharm, UK
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•  Hank’s Balanced Salt Solution (HBSS), Gibco, Life Tech, Paisley, UK
•  L-Glutamine 200 mM, Gibco Life Tech, Paisley, UK
•  Penicillin/Streptomycin 10,000 units ml'1 Penicillin and 10,000 pg ml'1
Streptomycin, Gibco Life Tech, Paisley, UK
•  Trypsin EDTA x10 solution, Sigma-Aldrich Co Ltd, Poole, UK
As a consequence, SMCs have been cultured as an in vitro model of vascular 
calcification. They were cultured from abnormal tissue e.g. AAA and normal 
tissue e.g. umbilical artery and normal aortae as control samples.
It is relatively difficult to extract cells from the tunica media in the AAA than in the 
normal artery because the atherosclerosis plaque composed the majority of the 
tissue. However, by increasing the foetal calf serum (FCS) concentration to 20%, 
the cells grow much easier.
Fresh human artery vessel wall tissues were placed into sterile specimen pots 
containing Hank’s Balanced Salt Solution (HBSS) at 4°C immediately for 
transport and short-term storage. Sterile forceps were used to strip the medial 
layer of the vessel wall from the intima and adventitia. This was then minced 
using crossed scalpels and placed in 6-well plates and covered with 1.0 ml of 
medium (DMEM with 10%-20% (FBS), 1% Penicillin and streptomycin, 1% 
glutamine). The plate was stored in the humidified 5% C 02 incubator at 37°C. 
The medium was changed twice a week while the cells attached firmly to the 
wells. Cells migrated from tissue and were harvested when they had grown to 
semi-confluence.
The tissue pieces were removed carefully and cells were retrieved with 0.1%  
trypsin once growth was seen. The trypsinised cells were suspended, then 
centrifuged for 10 minutes at 1,200 rpm. The supernatant was removed carefully 
and the cell pellet plus remaining liquid was transferred to 250ml culture dishes 
with sufficient medium to cover the bottom of the flask. Flasks were incubated at 
37°C about half an hour to allow cells to attach to the bottom firmly. Finally, flask 
were stored in the incubator at 37°C (Rebecca R.Pauly etal., 1998).
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7.3.6 Smooth muscle cells staining materials and
methods
•  Acetone, VWR International, Poole, UK
•  Aquamount, VWR International, Poole, UK
•  Fast Red, Sigma-Aldrich Co Ltd, Poole, UK
• PBS (10X), VWR International, Poole, UK
• Lab-tek chamber slide, 8 well on glass, Sigma-Aldrich Co Ltd, Poole, UK
Mayer’s Haemotoxylin, Sigma-Aldrich Co Ltd, Poole, UK
• Methanol, VWR International, Poole, UK
• Negative control Mouse lgG1, DakoCytomation Ltd, Ely, UK
• Smooth muscle cells primary antibody (Mouse Anti-human a-actin
antobody), DakoCytomation Ltd, Ely, UK
• VECTA STAIN ABC Kit (Alkaline Phosphatase Mouse IgG), Vector
Laboratories Ltd, Orton Southgate, Peterborough, UK
To confirm appropriate SMCs have been cultured, a-actin as a specific antibody 
for SMCs has been used (Jerareungrattan etal., 2005).
The cells were passaged into chamber slices when cells became confluent. 
When the cells attached to the bottom of the chamber and became confluent 
again, staining was performed following the procedure below.
Slices were fixed in ice-cold acetone for 5 minutes then washed with washing 
buffer (PBS) 3x3minutes. Then they were incubated at room temperature with 
normal horse serum solution for 20 minutes to block non-specific binding of 
immunoglobulin. Primary antibody a-actin was incubated with cells at dilution of 
1:200, 1:100 and 1:50 for 1.5 hours or overnight at room temperature in the wet 
box. Chamber slides were rinsed in PBS for 3x3 minutes. Then these slides were 
incubated with diluted secondary antibody buffer (1 drop in 50pl biotinylated in 
10ml PBS) for 30 minutes at room temperature. At the same time, enzyme 
solution AB (100pl, (2 drops solution A in 10ml PBS, add 2 drops solution B, mix 
well)) was prepared and left for 30 minutes at the room temperature. The slides 
were then washed in PBS for 3x3minutes and enzyme solution AB was added to
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each slide and incubated for 30 minutes at room temperature. Slides were then 
washed in PBS again 3x3 minutes. Substrate solution (Sigma fast-red prepared 
according to manufacturer’s instruction manual) was prepared just before 
incubating slides. Finally, slides were observed under LM to determine end-point 
(when red stain appears). The reaction was stopped with water, and 
counterstained with Meyer’s Haematoxylin for 2 minutes. Chamber slides were 
rinsed under running tap water for 10 minutes and covered by coverslip with 
permanent aqueous mounting medium.
7.3.7 Horseradish peroxidase (HRP) staining materials 
and methods
•  DAB detection kit, Vector Laboratories Ltd, Orton Southgate, Peterborough,
UK
• DePeX mounting medium, BDH laboratory supplies, Poole, UK
•  Fast red, Sigma-Aldrich Co Ltd, Poole, UK
•  Hydrogen peroxidase, Sigma-Aldrich Co Ltd, Poole, UK
•  PBS (10X), VWR International, Poole, UK
•  Mayer’s Haematoxylin, Sigma-Aldrich Co Ltd, Poole, UK
•  Negative control Mouse lgG1, DakoCytomation Ltd, Ely, UK
•  VECTA Elite STAIN ABC Kit , Vector Laboratories Ltd, Orton Southgate,
Peterborough, UK
Sample slides were deparaffinised and rehydrated according to this protocol
aligned with negative control and positive control slides. Slides were firstly
rehydrated twice in PBS 5 minutes each. They were then incubated with block
solution (BSA) for 60 minutes to block non-specific binding of immunoglobulin.
The blocking solution was then removed and slides were incubated in diluted
primary antibody in the wet box overnight at room temperature. The slides were
incubated with hydrogen peroxidase buffer (3% H2O2 in PBS) for half an hour at
4°C followed by rinsing twice in PBS for 5 minutes each. These slides were
incubated in diluted secondary antibody buffer (1drop in 10ml PBS) after primary
antibody for 30 minutes at room temperature. At the same time, enzyme solution
AB (100pl, (2 drops solution A in 10ml PBS, add 2 drops solution B, mix well))
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were prepared and remained for 30 minutes at the room temperature. Slides 
were washed twice in PBS for 5minutes each. Enzyme solution AB was added to 
each slide and left for 30 minutes at room temperature. Slides were washed 
again twice in PBS for 5 minutes each. Substrate solution (DAB detection kit as 
instruction manual) was prepared just before incubating on the slides. Finally, 
slides were observed under LM to determine end-point (when brown stain 
appears). The reaction was eventually stopped with water. Slides were rinsed 
with running water and mounted with coverslips with DPX mounting medium.
7.3.8 Apoptosis cellular markers detection
FLIP expression in AAAs
• Rabbit polyclonal anti-FLIP, Abeam pic., Cambridge, UK
FLIP detection was established by immunohistochemistry analysis. Parallel 
slides of each AAA samples were tested. Normal SMCs were used as a positive 
control. Rabbit anti-FLIP antibody was used at dilution of 1:50. HRP method was 
used and DAB was demonstrated as chromogen. These sections were lightly 
counterstained with haematoxylin and mounted with DPX mounting medium.
7.3.9 Indicator of smooth muscle cells and 
atherosclerosis (Smooth muscle actin (a-actin) 
and smooth muscle myosin heavy chain -1 
(SMMS-1) expression in AAAs)
•  Mouse anti-human smooth muscle myosin heavy chain (SMMS-1)
DakoCytomation Ltd, Ely, UK
•  Smooth muscle cells primary antibody (Mouse Anti-human a-actin antibody),
DakoCytomation Ltd, Ely, UK
The combination of a-actin and SMMS is a good marker of calcification of AAA at 
the histological level. It is ideal to compare both of their expression in normal
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aorta and AAA. However, the difficulty of obtaining fresh normal aortae made this 
comparison impossible.
The detection of SMC markers was also carried out by immunohistochemistry. 
Negative control, normal SMCs (a positive control) and parallel slides of each 
AAA sample were performed. Primary antibodies were diluted of 1:50. Slides 
were incubated overnight in the wet box. HRP method was used and DAB was 
demonstrated as chromogen. These sections were lightly counterstained with 
haematoxylin and mounted with DPX mounting medium.
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7.4 Results
7.4.1 Normal and abnormal aorta structure
The H&E stained normal aorta paraffin section showed normal histological 
structure of vessel wall. As previous detailed in chapter 2, tunica intima, tunica 
media and tunica adventitia compose the artery wall. The tunica intima is mainly 
composed of a single layer of endothelial cells, forming the lining of the vessel. 
The tunica media is the middle layer of a blood vessel. It consists of smooth 
muscle cells and elastic tissue. A continuous layer of elastic tissue forms the 
boundary between tunica media and tunica intima, called elastic lamina. Tunica 
adventitia is mostly composed by fibrous connective tissue.
Figure 7.2 Human normal aorta stained by H&E. The slide depicts the 
typical appearance of normal aorta in cross-section. It has a thick wall and 
a narrower lumen. Because of the large amount of muscle in the wall, it 
appears round in cross-section. Note the uniformity of the SMCs in the
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tunica media (M). L refers to lumen, I refers to tunica intima and A refers to 
tunica adventitia.
Endothelial cytoplasm is inconspicuous even under high power microscopy, but 
the nuclei are visible at the boundary between the lumen and the wall of a vessel. 
Smooth muscle cells are well organised into layers.
Figure 7.3 Light microscopic appearance of normal aorta by H&E staining 
under high power microscopy. Picture a shows tunica adventitia (A) and 
tunica media (M). Blue arrow indicates elastic fibre. Picture b shows tunica 
media (M) and tunica intima (I). Green arrow indicates SMC in the medial 
layer. Yellow arrow indicates elastic lamina. L refers to lumen
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In contrast, cells in AAA sections are disordered as shown in Figure 7.4.
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Figure 7.4 Representative photos of AAA paraffin section stained by H&E 
staining. Smooth muscle cells in tunica media (M) display irregular 
orientation.
High-power photomicrographs of AAA sections stained by H&E clearly 





Figure 7.5 Light microscopic appearance of AAA by H&E staining under the 
high power microscopy. Panel a shows tunica media (M). Green arrow 
indicates SMC as patchy cells crowded together. Panel b shows tunica 
adventitia. Blue arrow indicates elastic fibres. L refers to lumen
Figure 7.6 Inflammatory AAA sections stained by H&E. Panel a shows 
smooth muscle cells in the tunica media of AAA. Figure b shows dark blue 
inflammatory cells are scattered within the tunica media (M).
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7.4.2 Apoptosis in the AAA
Apoptotic cells were confirmed by TUNEL assay shown in Figure 7.2. The 
unstained slide was purchased as normal control for TUNEL assay. The positive 
staining shows that apoptotic cells were capable of detection by TUNEL assay.
40pm
Figure 7.7 External normal control section for TUNEL assay. Five pm-thick 
section of normal control of TUNEL assay (female rodent mammary gland, 
purchased from Chemicon), is showing an apoptotic body (red arrows by 
TUNEL under fluorescence. Panel b depicts the identical field shown in A 
by higher microscopic power. Apoptotic body (red arrow) is positive 
stained. As detailed in the Chemicon Apop-tag protocol, 1-2% apoptosis 
appear in the normal control slides as indicated.
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Human normal aortic slides were used as normal aortic control for apoptosis 
detection in human AAA tissue sections.
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Figure 7.8 Normal aorta section stained by TUNEL assay. Fluorescence 
microscopic pictures showing normal aorta section stained by TUNEL 
assay. Picture a was taken under DAPI (wave range 350-400nm) and picture 
b taken under FITR (wave range 450-500nm). An arrow in picture a 
indicates smooth muscle cells in tunica media of AAA (M). An arrow in 
picture b indicates elastic lamina in intimal layer of AAA. L= lumen.
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Human AAA sections were subjected to TUNEL assay. Figure 7.9 clearly shows 
thickened intimal wall and disorganised cells in the arterial wall of AAA.
Figure 7.9 AAA section stained by TUNEL assay (low-power). Fluorescence 
microscopic pictures showing AAA section stained by TUNEL assay. Panel 
a shows the medial layer of AAA. Panel b shows the tunica adventitia layer 
of AAA. Note the intimal layer is thicker than that observed in normal aorta 
(Fig 7.3). The red arrow indicates red blood cells without nuclei and having 
the shape of a biconcave disc.
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Positive staining for apoptotic bodies was observed in human AAA tissue section 
by TUNEL assay in Figure 7.10. More apoptotic cells were detected in the tunica 
media than in the tunica adventitia.
Figure 7.10 Aneurysm tissue stained by TUNEL assay (positive staining). 
Panel a shows a low-power magnification of tunica adventitia (TA). Panel b 
shows a low-power magnification of tunica adventitia (TA) displaying 
apoptosis (arrows indicate). Panel c shows a low-power magnification of 
tunica media of AAA (TM). Arrows indicate apoptosis. Overall impression 
from slides reading that more apoptosis is observed in TM than in TA 
(panel b). Panel d shows a high-power magnification of tunica media of 
AAA. Green arrows indicate apoptotic bodies, showing the greenish 
particles around the adjacent nucleus. L= lumen
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Percentage of apoptotic cells in proximal, body and distal AAA area. More cells 
can be seen undergoing apoptosis in the body of AAA than in either the proximal 
or distal regions of AAA. The least number of apoptotic cells were found in the 
distal area (the most calcified AAA area according to CT scan AC score.
Areas of AAA AI score (%)
Proximal (n=5) 27%±0.1 %
Body (n=10) 37%±2.9%
Distal (n=7) 20%±2.2%
Table 7.1 Percentage of apoptotic cells by region. Twenty to forty percent 
cells were found going through apoptosis in these areas. The most 
affected area is the body AAA and the least affected is the distal AAA.
Figure 7.11 reveals the vaso vasorum of the AAA vessel walls. The cells in these 
micrographs are disorganised and their orientation is lost compared with the 
uniform alignment of cells in the normal aorta wall (Figure 7.8).
Figure 7.11 Vaso vasorum of aortic wall in AAA section. Consecutive 
sections of AAA were stained by H&E (a) and TUNEL (b) displaying part of 
the vaso vasorum inside the AAA wall. No apoptosis was observed. Arrows 
indicate disrupted structure of the tunica media.
184
Figure 7.12 shows extensive cell loss in the tunica adventitia in human AAA 
section.
Figure 7.12 Tunica adventitia of AAA stained by H&E and TUNEL. Panel a 
shows H&E stained section demonstrating tissue destruction and cell loss. 
Panel b depicts a TUNEL stained section showing completely destroyed 
structure of AAA and very few nuclei.
The structure of AAA veseel wall was destroyed. The number of cells reduced 
dramatically comparing to normal aorta.
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7.4.3 Apoptosis cellular marker
Human FLIP was found in AAA by Vries C. et al. (2000), and this backs up the 
evidence that apoptosis is localised in human AAA.
Human FLIP as another cellular marker of apoptosis was used to confirm the 
extent of apoptosis involvement in human AAA formation as shown in figure 7.8.
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Figure 7.13 Human FLIP positive staining in AAA section. Brownish 
immunoperoxidase staining FLIP positive cells in AAA from formalin saline 
fixed tissue counterstained with haematoxylin. a. High-power magnification 
of medial layer of AAA. Note positive cells were indicated by a white arrow, 
b. Low-power magnification of media layer of AAA. Negative controls for 
staining were done but are not shown here.
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7.4.4 Atheroclerosis cell marker
Smooth muscle actin and SMMS-1 was found in human AAA sections. Figure 7.9 
demonstrates a loss of SMC. It also shows that atherosclerosis is localised within 
human AAA tissue. Normal aortic samples were not able to be obtained for the 
paraffin staining.
Figure 7.14 Actin and SMMS-1 staining of AAA tissue. Panel a is stained for 
actin, an indicator of smooth muscle cells (white arrows). Panel b depicts 
AAA tissue stained for SMMS-1 to differentiate areas of atherosclerosis as 
indicated by black arrows.
The number of SMCs was reduced in AAA comparing to that in normal aorta 
section. Atherosclerosis in AAA is not only be confirmed by pre-operative CT 
scan but also it was verified here by atherosclerosis marker SMMS-1.
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7.4.5 The location of calcium deposition
Von Kossa staining revealed the location of calcification in AAA according to 
paralleled H&E staining. Not surprisingly, calcium deposited in the AAA vessel 
wall constantly and no calcification was detected in the normal aortae.
Calcium tends to be deposited in the neointimal part of atherosclerotic artery as it 
is verified by Schoppet at at. (Schoppet et al., 2004). It is also proved by 
preoperative CT scan, calcium deposit in the outer side of AAA vessel wall.
Normal aorta was stained by Von Kossa methods as normal control for AAA 
sections. No calcium was found in figure 7.15.
Figure 7.15 Normal aorta section stained by Von Kossa. L refers to lumen, I 
refers to tunica intima, M refers to tunica media and A refers to tunica 
adventitia. The tissue was counterstained with safranin O (in red). No 
calcium was detected by vonKossa.
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Von Kossa staining was performed on human AAA sections as shown in figure 
7.16. More calcification was found in medial layer than in tunica adventitia.
ItfOpm 100pm
Figure 7.16 Aneurysm tissue stained with von Kossa and H&E (low-power). 
Light microscopic appearance of representative human AAA tissue: (a) 
Histological staining of AAA sections to demonstrate the distribution of 
disrupted architecture in the medial layer (M) of atherosclerotic aneurysm 
compare to normal aorta (see Figure 7.15). The haematoxylin-stained 
clusters of infiltrates are located on the edge of tissue facing lumen (L). (b) 
Von Kossa staining of consecutive section of AAA in panel a to 
demonstrate the calcium deposition which is found to be on the medial 
layer of AAA as green arrow indicates, (c) Von Kossa staining shows 
tunica adventitia (A) of AAA. No calcium was found in this AAA. (d) H&E 
staining section paralleled section of tunica adventitia in panel c.
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Calcium deposits were more visible under high-power microscopy as shown in 
figure 7.17.
Figure 7.17 Aneurysm section stained by Von Kossa and H&E (hig-power). 
Panel a shows tunica media (M) of AAA. SMC cell number is reduced 
compared to normal aorta in Figure 7.16 and elastic fibres appear 
increased. The alignment of SMC is non-uniform. Panel b shows severe 
calcification of the tunica media (M) of AAA stained by Von Kossa. Yellow 
arrows indicate black lamellar deposits and black granular deposits.
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7.4.6 Protein expression in the inner layer and outer
layer of AAA
Since it is thought that aneurysms occur by the gradual thinning of the vessel 
wall through the degradation of its medial layer, the samples were dissected into 
two layers, outer and inner, to study TRAIL, TRAIL-R1 and OPG protein 
expression (figure 1c). Outer layer represents tunica adventitia and inner layer 
represents tunica media and tunic intimal. Protein expression for TRAIL and 
TRAIL-R1 is much higher in inner layer and OPG is absent. Previous finding by 
Von Kossa staining and H&E staining show that calcium mainly locates in the 
medial layer of AAA. The structure in AAA is disrupted. Smooth muscle cells are 
reduced compare to normal aorta and the orientation is not uniform. The elastic 
fibres in tunica media increased compare to normal aorta.
Protein expression in outer and inner layer of AAAs
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Figure 7.18 Protein expression in outer and inner layer of AAAs. Graph 
shows TRAIL, TRAIL-R1 and OPG protein expression in outer (OU) and 
inner (IN) layer of AAA vessel walls, examined by protein dot blots (n=6). 
TRAIL and its death receptor TRAIL-R1 were expressed more in the inner 
layer consisting of the tunica media and tunica intima, but the decoy 
receptor OPG was absent in the inner layer. TRAIL was significantly higher 
in the inner layers than the outer.
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Figure 7.19 Protein expression in outer and inner layers of AAAs. The 
graph show protein expression in the outer (n=6) and inner (n=6) layers of 
AAA samples. Panel a indicates protein expression in the outer layer of 
AAAs and panel b indicates protein expression in the inner layer of AAAs. 
There is a significant difference between TRAIL, TRAIL-R1 and OPG in the 
inner layers of vessel walls (**p<0.01, by one-way ANOVA). The top of the 
bar represents standard error.
OPG was not present in the inner layer of AAA vessel walls among any of the 
AAA tested. TRAIL and TRAIL-R1 were expressed more often in the inner layer 
than in the outer layer. The Inner layer of AAA vessel walls contained much less 
calcification (even zero) than the outer layer, which was proved by CT scan and
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morphology. The fact that OPG was increasingly expressed and TRAIL and 
TRAIL-R1 decreased in the more calcified areas is consistent with the finding of 
their mRNA expression.
7.4.7 Messenger RNA expression for TRAIL-rTRAIL 
system in cultured SMCs
Cells were cultured from an umbilical artery, the intimal and medial layers of 
normal aortae and AAA specimens. To detect mRNA expression for the TRAIL- 
rTRAIL system, PCR was carried out on cultured cells.
As mentioned in chapter 2, the SMCs failed to protect and repair injury to arterial 
wall and ultimately results in instability of the arterial wall in the AAA formation. 
Utilising in vitro VSMC tissue culture, the role of the VSMC in aneurysmal 
degeneration could be clarified.
Figure 7.20 Smooth muscle cell culture. Panel a shows cultured SMCs 
from a normal umbilical artery. Panel b shows cultured SMCs from AAA. 
SMCs from AAA retained a narrow spindle-shape with a centrally located 
nucleus, similar to normal SMCs but grew more slowly.
193
The cultured cells were transferred to chamber slides for a-actin staining when 
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Figure 7.21 Both Panels a and b show cultured SMCs from AAA with a- 
actin staining under LM. Smooth muscle cells were observed in a rosy-pink 
colour, as indicated by the black arrows. They appear spindle-shaped with 
a single nucleus in the middle. This confirmed the existence of SMCs.
SMCs which were obtained from an umbilical artery and the media of normal 
aorta specimens were subjected to RT-PCR to study mRNA expression of TRAIL 
and its receptors. Firstly, a comparison of mRNA was carried out on SMCs from 
umbilical artery, cells from medial normal aortae and cells from intimal normal 
aortae. Then, normal aorta cells were arrested for 48 hours and followed by RT- 
PCR. Surprisingly, cells from the same normal aorta showed a very great 
difference after being arrested, as detailed below. No further study has been 
carried out in SMC cells from AAAs.
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Figure 7.22 PCR gel images for cells isolated from normal artery. These 
gel images demonstrate the mRNA expression of SMCs from an umbilical 
artery and cells from intimal and medial layers of normal aortae. UM 
indicates SMCs from an umbilical artery; INT represents cells from intimal 
normal aortae and MED represents cells from medial normal aortae. PCR 
products from these cells were loaded and run on a 1.2% agarose/TBE 
analytical gel and stained with ethidium bromide. The PCR products were 
then compared with the standard loaded in the same gel, to identify their 
size. Red arrows indicate the size of the samples on the DNA ladder. 
Panel a indicates the PCR products of GAPDH, all three samples show 
very similar levels of GAPDH expression. Panel b indicates the PCR 
products of TRAIL; panel c indicates the PCR products of TRAIL-R1; 
panel d indicates the PCR products for TRAIL-R2; panel e indicates the 
PCR products for TRAIL-R3; panel f indicates the PCR products for 






Figure 7.23 PCR gel image for cells isolated from normal aorta (arrested). 
These gel images show the mRNA expression of cells from intimal and 
medial layers of normal aortae after being arrested for 48 hours. INT 
represents cells from intimal normal aortae and MED represents cells 
from medial normal aortae. The PCR products from these cells were 
loaded and run in the 1.2% agarose/TBE analytical gel and stained with 
ethidium bromide. The PCR products were then compared with the DNA 
ladder, loaded in the same gel. Red arrows indicate the size of the 
samples on the DNA size ladder. Panel a indicates the PCR products for 
GAPDH, both samples show very similar levels of GAPDH expression. 
Panel b indicates the PCR products for TRAIL; panel c indicates the PCR 
products for TRAIL-R1; panel d indicates the PCR products for TRAIL-R2; 
panel e indicates the PCR products for TRAIL-R3; and panel f indicates 
the PCR products for TRAIL-R4. Panel g indicates PCR products for OPG 
and there was a missing band for intimal cells.
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Figure 7.24 Comparsion graph of cells from normal aorta. These graphs 
compare the mRNA expression (normalised to GAPDH) of TRAIL and its 
receptors in cells from normal arteries. Panel a shows the expression of 
cells from intimal normal aortae. Panel b illustrates the expression of cells 
from medial normal aortae and SMCs from umbilical arteries. The graphs 
show the changes in the mRNA expression of TRAIL and its receptors in 
cells before and after being arrested.
197
Cells from medial normal aorta are mainly SMCs, which are cells thought to be 
involved in vascular calcification (Bostrom, 2001).They were confirmed by a-actin 
staining and showed a similar mRNA expression pattern to SMCs from umbilical 
arteries (shown in Figure 7.24b). Interestingly, when those cells were arrested 
for 48 hours, the mRNA levels for TRAIL and its receptors were observed to 
change considerably. TRAIL increased dramatically in medial cells after being 
arrested, while TRAIL-R2 decreased. Among decoy receptors, TRAIL-R4 also 
showed a considerable decrease. In the other three receptors, the mRNA 
expression remained similar to previous levels. When cells from intimal normal 
aortae were arrested for 48 hours, the mRNA expression of the TRAIL-rTRAIL 
system showed a similar trend to that in medial cells. TRAIL increased and both 
TRAIL-R1 and OPG reduced greatly, as did TRAIL-R4. It is also noteworthy that 
OPG was not found in the intimal cells after 48 hours arrest. However, this is a 
very preliminary result which has not been repeated. It indicates that further 
investigation should be made into the behaviour of cells, especially in the 
behaviour of SMCs from AAA.
Thus far, the results suggest that intimal and medial aortic cells secret TRAIL 
and all five receptors. TRAIL increased over the course of the cell culture in both 
cell types from normal aortae with variable expression for its receptors.
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7.5 Discussion
7.5.1 Apoptosis in the aneurysm
Cells were found to be undergoing apoptosis in different areas of AAA vessel 
wall. However, only a very small proportion of apoptotic cells were visualised in 
the tissue sections. Relatively, the least apoptotic cells were found in the distal 
AAA (most calcified region). As mentioned in chapter 3 the apoptotic cells are 
available to be observed under LM for only a few minutes and apoptotic bodies 
only can be visualised for only a few hours before they undergo phagocytosis 
under ultrasound (Kerr, 1971). This could explain why a much smaller 
percentage of cells were found in apoptosis. It has been suggested that even the 
presence of a small detected percentage can still represent a considerable 
magnitude of cell loss (Arends et a!., 1994). Also comparatively less apoptosis 
detected in the distal area may imply that apoptosis occurred early and 
frequently in this area.
Combining the findings of highest calcification in the distal AAA, the theory of the 
blood flow dynamics (detailed in chapter 5) and the apoptotic index of the 
different areas, the following possibilities can be suggested. Apoptosis that 
occurs in the distal area (where aneurysm occurred firstly, early stage) might be 
involved in the arterial wall remodelling. Blood flow dynamics increases aortic 
wall stress causing injury of the arterial wall leading to atherosclerosis. In 
addition, the histological features of thinning of the tunica media and the 
disappearance in the elastic lamina are contributory to aneurismal changes. After 
formation of an aneurysm apoptosis continues to occur frequently in the neck of 
AAA (proximal area), which might explain why more apoptosis was found in the 
proximal than in the distal area in the AAA samples examined. The AAA samples 
used here were all under the established stage.
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7.5.2 Smooth muscle cells atherosclerosis cell marker 
and difference of normal and abnormal aortic 
structure
The thinning of the tunica media is a feature specific to AAA in this study. The 
internal elastic lamina was clearly defined in normal aorta but fragmented or 
missing in aneurysm sections. In the medial wall, the number of medial SMCs is 
decreased with variable size displaying a disorderly fashion. Some SMCs 
showed distorted cell shape by a-actin. The normal characteristics of the tunica 
media, including well defined connective tissue and medial SMCs, were missing 
in AAA. This study identifies a reduction in SMC number in AAA. Sometimes, 
inflammatory cells accumulated in the AAA wall. This is consistent with the 
finding from the medical records that 10-15% of patients who underwent AAA 
repair developed inflammation.
7.5.3 The correlation of calcium deposition with TRAIL- 
rTRAIL system
It is interesting to note that OPG protein was not expressed on the inner layer of 
the AAA wall (tunica intima and inner tunica media), an area of less calcification 
compared to the outer layer (seeFigure 7.19). TRAIL and TRAIL-R1 protein were 
also expressed more on the inner layer of AAA walls. As detailed in chapter 2, 
AAA are characterised by destruction of elastin and collagen in the media and 
adventitia (Crawford et al., 2003; Ernst, 1993). It is often associated with 
atherosclerosis (Jorgensen et al., 2004).Taken together, this indicates that 
TRAIL and TRAIL-R1 involvements in AAAs are associated more with the 
progression of AAA than the calcification level of the AAA wall. This suggests 
that TRAIL and TRAIL-R1 may interplay in the tunica media of AAA. These 
features of the inner layer of the AAA wall may result in the expansion and 
degradation of AAAs. In addition, the imbalance of OPG in the tunica media and 
intima may be a result of OPG post-binding relationships with TRAIL, protecting 
cells from apoptosis, or this may be one reason why apoptosis is found in AAA 
wall. Furthermore, OPG protein was co-expressed with TRAIL-R1 in AAA. This 
verifies again that OPG protection is a reaction of TRAIL-R1 initiation.
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Another explanation for the results in Figure 7.19 would be that TRAIL and 
TRAIL-R1 play a role in the AAA medial wall thickening and neointimal formation. 
As discussed in chapter 2, SMCs in the medial layer of the aorta vessel wall 
migrate from their original location toward the intimal layer. The higher level of 
TRAIL-R1 expression in the inner layer of AAA walls indicates that it is an 
influencing factor of SMCs.
7.5.4 Messenger RNA expression of TRAIL and its 
receptors in vascular cells
TRAIL has been found to be expressed in human and animal atherosclerotic 
plaques and in cultured human smooth muscle cells (Stocker and Keaney, Jr., 
2004).The primary data from Figure 7.22 showed that TRAIL death receptors, 
TRAIL-R1 and TRAIL-R2 were both expressed by intimal cells and medial cells 
isolated from normal aortae. TRAIL selectively induces apoptosis in tumourgenic 
cells or transformed cells but not normal cells (Willey et. al, 1995). Thus, normal 
vascular cells are assumed to be cells which are susceptible to TRAIL-induced 
cell death; this might be due to the high expression of decoy receptors.
Of particular interest, TRAIL was reported as being induced in a P53-dependent 
manner or P53-independent manner by DNA damage (Meng and El-Deiry, 2001). 
This might suggest that TRAIL is expressed in a similar manner to the p53 gene 
in vascular cells. As mentioned in chapter 3, the tumour suppressor gene P53 is 
known to block the cell cycle at the S phase, eventually inducing apoptosis 
(Kulesz-Martin et al., 2005). The P53 protein has been found to be over­
expressed in 30 per cent of human angioplasty restenosis sites and only induces 
apoptosis of cells infected with dominant proto-oncogenes but not normal cells 
(Bennett et al., 1995). The fact that expressions of TRAIL increase and TRAIL 
death receptors decrease in both intimal cells and medial cells after being 
arrested suggests that down-regulation of death receptors may be a response to 
an increase in TRAIL. This also confirms the above finding that there are 
negative correlations among TRAIL and its decoy receptors after being arrested.
The above results could not be repeated because of the difficulties of obtaining 
fresh normal aorta tissue and growing SMCs from end-stage AAAs. It would be
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very interesting to test apoptosis induced by TRAIL and mRNA and protein 
change in itself and its receptors in normal and abnormal vascular cells if the 
fresh tissue storage and transport problems could be solved.
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Section III
GENERAL DISCUSSION AND FUTURE
WORKS
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Chapter 8 General discussions
8.1 General Discussions
This project has evaluated the presence of the TRAIL-rTRAIL system and its 
possible effects in human AAA. The early part of the study confirmed that 
apoptosis and atherosclerosis (vascular calcification) was associated with human 
AAA. The study demonstrated for the first time that gene expression for TRAIL 
and its receptors and protein expression for TRAIL, TRAIL-R1 were present in 
the in human AAA and confirmed previous reports of their presence in normal 
aorta.
Human AAA has been documented to be associated with atherosclerosis 
(vascular calcification). Abdominal aortic aneurysm occurs in 7.5% of the male 
population over 65 years old but is rare under the age of 50 years old. It causes 
2% of all deaths in men over 65 years old. There were 6800 AAA-related deaths 
in 2004 in England and Wales alone (Quick C., 2004). The prevalence is still 
increasing (Quick C., 2004) and small AAA increase in diameter by 0.26cm per 
year in a study of small AAA in England (Powell J., 2004). Only 10% of patients 
living with AAA are alive 8 years after being diagnosed compared with 65%  
survival rate in unaffected subjects in a similar population (Wilmink T., 2004). 
The only effective way to treat AAA is surgery (ref). The mean hospital costs over 
four years per patient undergoing endovascular abdominal aortic aneurysm 
repair (EVAR) was £13,632 compared to £4983 in the no intervention group, 
therefore the mean difference is £8649 in England (Greenhalgh et al., 2006). 
Thus far, there is no evidence to show that altered blood pressure, weight or 
serum lipid affects AAA growth (Powell J., 2004). Hence, it is necessary to find 
an effective way to slow AAA growth before the surgical intervention is necessary.
Recently, human calcification has been proved to be a regulated process with 
similarities to bone modelling and remodelling (Shanahan et al., 2000; Bostrom, 
2000; Shanahan et al., 1994). Osteoprotegerin is an inhibitor of osteoclast 
formation which was found to be in bone cells and endothelial cells (Aubin and 
Bonnelye, 2000). Mice deficient in OPG often exhibit extensive bone fractures 
and medial calcification of the aorta and the renal arteries (Schinke and 
Karsenty, 2000). This is compatible with findings of coexisting bone fractures and 
vascular calcification in humans (Pennisi et al., 2004; Sattler et al., 2004; Schulz
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et al., 2004). These studies indicated that OPG might play a role in osteoporosis 
and vascular calcification. Additionally, apoptosis and its cellular marker were 
found to be expressed in the human AAA. The TRAIL-rTRAIL system is capable 
of regulating apoptosis and OPG is a decoy receptor of TRAIL.
To confirm that apoptosis and vascular calcification is associated with human 
AAA, TUNEL assay, Von kossa staining and other immuno-chemical stains were 
used (chapter 8). Atherosclerosis cellular maker (SMMS) was performed to prove 
that human AAA is association with atherosclerosis. Human FLIP staining, as an 
apoptosis cellular marker, was also performed. On the molecular lever, mRNA 
and protein expressions were examined by RT-PCR and protein blot respectively. 
To explore these factors, comparisons were carried out between human normal 
aorta and AAA. TRAIL and its receptors mRNA and protein were found to be 
expressed which is in agreement with the ubiquitous expression of TRAIL- 
rTRAIL system in various human tissues. Because both normal aorta and AAA 
express TRAIL and its receptors, it implies a possible function of inducing or 
inhibiting apoptosis in the vessel wall. The significant difference of mRNA (p< 
0.05) and protein (p<0.01) for TRAIL -rTRAIL system between normal aorta and 
AAA suggests that it may be involved in the initiation of vascular calcification. 
The fact that TRAIL death receptors were lower in the more calcified specimens 
than more calcified AAAs is consistent with this idea. However, the study had 
some unavoidable shortcomings. To compare the TRAIL-rTRAIL system 
expression in human normal and abnormal tissue more precisely, it would be 
ideal to choose age-matched normal and abnormal specimens. They both should 
have had a CT-scan on normal and abnormal specimens prior to 
experimentation. This would establish that the normal specimens were, in fact, 
healthy and free of calcification. However, normal aorta sample were obtained 
from kidney transplant donors and it could not be ruled out that some 
calcification may have been present on normal vessel wall. The samples 
obtained from open AAA repair mostly had pre-operative CT scan while there 
was no access of CT scan for normal aorta samples. Also, age-matched 
sampling was technically impossible because the criteria governing AAA open 
surgery and kidney transplant donors (normal aortae resource).
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The limitations of human AAA specimens restrict the age and the AAA 
development level. Thus, AAA specimens were separated to three body parts 
according to location as well as calcification level: proximal, body and distal to 
imitate three AAA development stages. Also the blood flow systematic theory 
supports this separation. Apoptosis-inhibiting receptors; TRAIL-R3, TRAIL-R4 
and OPG were expressed in all areas of AAA walls examined. This is consistent 
with bone-related inhibitors of calcification which were found to be exhibited at all 
stages of human atherosclerosis (Dhore et al., 2001). Correspondingly, 
apoptosis-inducing receptors; TRAIL-R1 and TRAIL-R2 were expressed mainly 
on the more calcified AAA walls than the less calcified ones. This is also 
consistent with the results of bone-related activators of calcification which were 
found restricted to lesions with advanced calcification. In a similar manner, Dhore 
et al. suggested that vascular calcification is the result of time and plaque-stage- 
restricted activation and continuous inhibition. The fact that TRAIL death 
receptors decreased in the more calcified specimens compared to the more 
calcified AAAs is also consistent with this idea. However, there are questions that 
remain to be addressed. There are two further ways of exploring these questions. 
Firstly serum levels of the TRAIL-rTRAIL system could be measured in patients 
who are diagnosed with small AAA on a regular basis (such as monthly) in 
addition CT scans or ultrasound scans could be performed about twice per year. 
This is a possibility for the future as it is reported that small AAA increases 
0.26cm per year in a study of small AAA in England (Powell J., 2004). It is 
possible that AAA screening will be launched in the near future. This would 
provide a huge databank of information in a short time that may help in future 
research. The second possibility is to further develop AAA in animal models. 
Several researchers have already successfully generated AAA in rat (Kaito et al., 
2003) and swine (Ruiz et al., 1997). A recent study successfully created AAA in 
pigs by performing a double-layered peritoneal patch. The aneurysm was proven 
to have a similar morphology to human aneurysms and also to have the potential 
for further growth leading to rupture (Maynar et al., 2003). However, it cannot 
completely represent human AAA because there no atherosclerosis occurs in 
AAA of animal models.
The pattern of expression for TRAIL in the AAA is remarkably similar to that in 
the normal aortae, where TRAIL was widespread in both vessel walls. This
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indicated that the ratio of TRAIL to its receptors is crucial in determining the 
potential influence on apoptotic events. The affinities of TRAIL with its five 
receptors are still unclear making it difficult to determine which receptors are 
more important in the process of vascular calcification.
The very high positive correlation beyween TRAIL-R2 mRNA with TRAIL-R3, 
TRAIL-R4 and OPG mRNA and the negative correlation between TRAIL-R1 
mRNA with TRAIL, TRAIL-R2, TRAIL-R4, OPG mRNA in AAA indicate that 
TRAIL-R1 may be the dominant force in vascular calcification out of the 2 death 
receptors.
Is it only coincidence that TRAIL-rTRAIL system shares similarity with inhibitors 
and activators of bone calcification in calcified arterial walls? Or are they 
correlated to a certain extent? OPG is a favourite link between TRAIL-rTRAIL 
system and bone-related proteins. OPG has been found in bone marrow stromal 
cells, osteoblast-like cells, and osteosarcoma cells (Dhore et al., 2001) as well as 
being found in the vascular wall, endothelial cells and vascular smooth muscle 
cells (Schoppet et al., 2004). This study reveals that TRAIL receptor protein is 
up-regulated in the more calcified regions compared with less calcified regions. 
Taken together, these factors suggest that decoy receptors continuously prevent 
calcification whereas death receptors are restricted to the active calcification 
area similar to the behaviour of bone calcification proteins (Dhore e ta /., 2001).
Further protein study of OPG and TRAIL-R1 confirmed the involvement of the 
TRAIL-rTRAIL system in vascular calcification. TRAIL-R1 proteins were 
expressed more than OPG proteins in AAA and specifically in the most calcified 
areas of AAA. OPG protein was up-regulated in the less calcified area and down- 
regulated in severely calcified areas. This might indicate that a counter- 
regulatory mechanism exists for OPG that limits apoptosis in the less calcified 
area and thereby delaying the onset of calcification. OPG has been found to 
play a role in the process of vascular calcification in an animal model, this 
strongly implies that OPG may also play a role in human vascular calcification. 
Serum OPG levels significantly increased as the severity of coronary artery 
disease increased. Increased OPG level might be a compensatory self-defensive 
response to the progression of atherosclerosis (Jono etal., 2002)
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It has been reported using western blot analysis that OPG associated with 
endothelial cells is likely to be native dimeric OPG. Whereas the OPG 
predominantly found in the synovial lining is not a native dimer but possibly a 
breakdown product or monomer of OPG (Jono etal., 2002).
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8.2 Future works
To explore the possible function of the entire TRAIL-rTRAIL system in human 
AAA, more studies need to be carried out. Firstly, the protein expression for 
TRAIL-R3 and TRAIL-R4 in human AAA needs to be confirmed. The antibodies 
for these analyses were not commercially available at the time of this study. The 
antibodies, anti-TRAIL-R3 and anti-TRAIL-R4 are now both available from 
Biolegend, San Diego, USA for use as primary antibodies in Western blot 
analysis. If the presence and level of expression of TRAIL-R3 and TRAIL-R4 is in 
agreement with their mRNA expression in human normal and abnormal aortic 
tissue, a full characterisation of death receptors and decoy receptors in human 
aortic wall will be possible.
Secondly, further study can be carried out in testing TRAIL and OPG serum level 
in AAA patients. Recording OPG and TRAIL serum level in follow-up AAA 
patients with their CT scan AC score could be very useful. It is well known that 
AAA diameter increases as patient age increases. However, the question has 
not been addressed whether calcification level increases followed with the 
increasing of AAA size. It will be very interesting if there are correlations between 
OPG serum levels, TRAIL serum levels, AAA diameter and AAA calcification 
levels. As mentioned in chapter 7, OPG serum levels have been found to be 
weakly correlated with AAA growth rate (Moran et al., 2005). There does not 
appear to be any technical difficulties in carrying out this study.
Thirdly, further studies could be performed in vitro to investigate the biological 
activity of cells isolated from normal aorta and AAA. It would be interesting to 
expose normal aorta cells to TRAIL and its death receptors and then examine 
the change in the number of apoptotic cells. Cells have been successfully 
explanted from AAA and normal aortic tissue in this study. Careful arrangement 
of the collection, transport and storage conditions for specimens will ensure a 
good source of material for the isolation and culture of cells for such studies.
Fourthly, animal studies can be carried out to strengthen the evidences of the 
TRAIL-rTRAIL system function in human AAA. As mentioned in chapter 8, AAA 
animal models were effectively created on rats and swine. It might be possible to
210
test the potential therapeutic effect of the TRAIL-rTRAIL system by looking at the 
aneurysm development rate after subjecting animal models to decoy receptors 
and/or blocking TRAIL death receptors. It is also worth increasing TRAIL and 
TRAIL death receptor level in animals with AAA to observe the correlation of 
AAA growth rate and TRAIL and its death receptors serum concentrations.
Ultimately, because the human body and prevalent living conditions are very 
different from any likely animal model, a clinical trial of TRAIL and OPG could be 




To recapitulate, this project investigates and demonstrates the presence of the 
TRAIL-rTRAIL system and possible biological interaction in human AAA. It 
demonstrates that significant difference of the TRAIL-rTRAIL system in human 
normal and abnormal aortic tissue and differences in all different areas of human 
AAA vessel walls. This is associated with vascular calcification levels examined 
by pre-operative CT scan and apoptosis areas determined by TUNEL assay. 
These suggest that the possible biological function of the TRAIL-rTRAIL system 
in human AAA that may participate in the AAA development. Interference of this 
system could influence human AAA development in its early stage. 
Optimistically, this also implies a possible medical treatment to be used to slow 
human AAA expansion, an alternative to surgical treatment.
A very recent study has suggested that OPG serum level can be a predictive 
biological marker for sub-clinical disease and near-term cardiovascular events in 
diabetic II patients (Xiang et al., 2006). In addition, 78% patients in this study 
have more than one cardiovascular disease. This may suggest that TRAIL- 
rTRAIL system could also have biological interference in the other vascular 























8X resolving gel buffer: 100ml
0.8g SDS (add last).
36.3g Trizma base(=3M).
Adjust pH to 8.8 with concentrated HCI
4X stacking gel buffer: 100ml
0.4g SDS (add last).
6.05g Trizma Base(=0.5M).
Adjust pH to 6.8
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running buffer: 1L




3.3g Trizma Base (=0.25M).
14g Glycine(=1.92M).
pH should be 8.3 ,










3ml 8X Resovling gel buffer
13.8ml water
12plTEMED (add last).
60pl 20% ammonium persulfate
12% Resovling gel
9.6 ml 30% acrylamide
3ml 8X Resovling gel buffer
11.4ml water





2ml 4X stacking gel buffer
4.7ml water
8pl TEMED (add last).
21.6pl 20% AMPS
5%blocking buffer
5%marvel milk /0.05%PBS tween
Stripping buffer 0.5L
(sterile filter solution and keep at 4C). 0.2M Glycine pH=2.5
0.05% Tween 20





making up to 1L
1.2% agarose gel
1.2% agarose in 50ml 0.5X TBE buffer is dissolved by heating in the microwave. 
Add 10pl ethdium bromide per 50 ml solution; cool the solution down with tap 
water. Pour the mixture into gel tank with combs. After gel set, loading 
appropriate volume sample into each well, running gel at 50V for about 40 
minutes ( when the dye reach the end of gel)..
DEPC treatments
Soak equipment in 10ml DEPC in 1L DDH for 2 hours at room temperature. Dry 
them on the oven followed by autoclave.
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The Laemmli system
The most widely used system for electrophoresis of proteins is probably that 
described by Laemmli, 1970. It is a discontinuous system for resolving proteins 
denatured with SDS. The leading ion in the Laemmli buffer system is chloride, 
and the trailing ion is glycine. Accordingly, the resolving gel and the stacking gel 
are made up in Tris-HCI buffers (of different concentration and pH), while the 
tank buffer is Tris-glycine. All buffers contain 0.1% SDS.
Membrane for western blot
Nitrocellulose and reinforced PVDF membranes are generally used in Western 
blotting. For larger molecular weight proteins both types of filters works well. 
However, if your protein is less than 10 kb nitrocellulose should be used because 
it has a much higher binding capacity. The PVDF membranes will not work well 
under these circumstances.
Automated Autorad Developer
Kodak X-OMAT AR auto rad film was cut into appropriate size and placed on the 
nitrocellulose membrane for 30 seconds, 1 minutes and 5 minutes or even 
overnight at 4°C. Then the film was developed in the Fuji RG II X-ray film 
processor.
Scion Imaging Software
http://www.scioncorp.com accessed. Scion Image is an image processing and 
analysis program which is based in NIH Image on the Macintosh platform. To 
analyse the mean density of protein bands after enhanced chemiluminescence 
dectection.
• Open the saved file (.TIFF format) of interest and select the rectangular
selection tool and outline the area of interest.
•  Select ‘measure’ from the ‘Analyse’ menu. This computes the area and
mean gray value of the selection.
•  Move the outline selection box to the next area of interest and repeat the
measurement.
•  Continue until all areas of interest have been analysed.
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Enzyme solution A and B ( from Alkaline Phospahtase kits, Vectastain. UK)
Enzyme solution A: AvidinDH 
Enzyme solution B: Biotinylated Enzyme
PCR image gel for RANK and RANKL
f  \
Image of RANK and RANKL in normal aorta
R3 R4 OPG RANK RANKTRAIL R1 R2
The representative gel image here shows eight PCR reactions that were set up 
on the isolated RNA for in normal aorta. The reactions amplified TRAIL, TRAIL- 
R1, TRAIL-R2, TRAIL-R3, TRAIL-R4, OPG , RANK and RANKL gene, as shown 
here. A 10pl aliquot of each product was loaded and run in the same 1.2% 
agarose/ TBE gel and stained with ethidium bromide. The PCR products were 
then compared with the standard, loaded in the same gel. The red arrows 
indicate the size of the samples on the DNA ladder.
VIII Appendix B
Apoptosis Necrosis




Cell size Shrinkage Swelling
Fragmentation




Mitochondria Increased membrane 
permeability
Swelling
















DNA appears in cytoplasm
Cell degradation Phagocytosis Inflammation
No inflammation Macrophage
invasion




Specific stimuli Growth factor deprivation: 
NGF; IL-2
Toxic












Oxidants in cell: Increased
DNA damage



















Protease inhibitors IAP-1, 2 
& 3, p35 etc.




Bcl-2 family (Some). Bax, 
Bcl-xS etc.
Table 8.1 The diagram shows that the basic morphological changes 
happen when cells undergo apoptosis or necrosis.
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This piece of work has been presented in the scientific conference of society of 
Vascular Medicine and Biology in California, USA in June 2004. It also has been 
nominated as one of 6 finalists for the Young Scientist of the Year Award.
This updated results of this work have been presented in the scientific session of 
South West Vascular Surgeons’ conference in Oxford in March 2005.
This work is submitted to journals for publishing.
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